A human race
# INTRODUCTION

<table>
<thead>
<tr>
<th>Section</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction</td>
<td>3-6</td>
</tr>
<tr>
<td>Corporate responsibility at GSK</td>
<td>7-17</td>
</tr>
<tr>
<td>Access to medicine</td>
<td>18-25</td>
</tr>
<tr>
<td>Research</td>
<td>26-33</td>
</tr>
<tr>
<td>Ethical conduct</td>
<td>34-39</td>
</tr>
<tr>
<td>Employment practices</td>
<td>40-49</td>
</tr>
<tr>
<td>Supply Chain</td>
<td>50-51</td>
</tr>
<tr>
<td>Environmental management</td>
<td>52-74</td>
</tr>
<tr>
<td>Our work with communities</td>
<td>75-80</td>
</tr>
<tr>
<td>Data summary</td>
<td>81</td>
</tr>
</tbody>
</table>
Introduction

Welcome to GlaxoSmithKline’s Corporate Responsibility Report 2006. This report explains our approach to the wide range of social, ethical and environmental issues associated with our business and our performance in 2006.

About GSK

We are a research-based pharmaceutical company. Our mission is to improve the quality of human life by enabling people to do more, feel better and live longer. Our business employs over 100,000 people in 116 countries. Our consumer healthcare business includes dental health products, over-the-counter medicines and nutritional drinks.

About our report


Data relate to the calendar year 2006, except where stated.

The environmental data cover the calendar year 2006. Data are collected from all of our 80 pharmaceutical and consumer manufacturing sites, 11 of our 13 biologicals manufacturing sites that are in operation, 18 of 22 pharmaceutical and consumer research and development sites and 6 of 8 major office locations. We include available data for sites that were in operation for all or part of the year. We do not require environmental data from small offices and distribution centres. Notes attached to the charts explain the scope and data collection process for each parameter in more detail.

Unless specified as being per unit of sales, figures are absolute numbers, i.e. total consumption of energy, water etc. Data in the environment, health and safety sections of this report are externally verified, see Verification.

The scope of other data relate to our worldwide operations except where indicated.

We use external guidelines and frameworks to inform our reporting where relevant. We do not base our report on the Global Reporting Initiative guidelines but we have produced a GRI index to show which elements of the guidelines we cover and to aid comparison with other company reports.

More background information on our policies and approach to CR is available on our website: www.gsk.com/responsibility.

We also publish a Corporate Responsibility Review which provides an overview of our approach to corporate responsibility. It is available in print and on our website.

Our 2005 CR report was one of the top 50 reports (ranked 17th) in the 2006 SustainAbility, United Nations Environment Programme and Standard & Poor’s Global Reporters Survey – an international benchmark survey of non-financial reporting.

Medicines

Our key pharmaceutical products target serious diseases including:

- Asthma and chronic obstructive pulmonary disease
- Epilepsy, depression and other diseases of the central nervous system
- HIV/AIDS, herpes and other viral diseases
- Infections
- Diabetes
- Cancer
- Heart disease and other cardiovascular diseases
- Urogenital diseases

Vaccines

GSK makes vaccines that protect against diseases including:

- Hepatitis A and B
- Diphtheria
- Influenza
- Polio
- Rotavirus
- Tetanus
- Typhoid
- Whooping cough

Consumer healthcare brands

Our brands include:

- Over-the-counter medicines – Beechams, Contac, Nicorette/Niquitin, Panadol, Tums, Zovirax
- Dental health – Aquafresh, Macleans, Polident, Sensodyne
- Nutritional drinks – Horlicks, Lucozade, Ribena
We believe that a healthcare company isn’t sustainable if it is only concerned about the 20 percent of the world’s population lucky enough to have the resources to pay for new treatments. We believe that Access to medicines is essential to our vision for GSK. Improving people’s health is what drives us and what makes talented scientists want to work here.

Our commitment to the poorest countries is integral to this. These countries may not represent a viable commercial market for some new medicines but there is still a need for people to have medicines they cannot afford. Yet pure philanthropy is not the right solution either – the needs are too great.

We look for new ways to tackle these problems. GSK is involved in over ten public private partnership projects – researching new medicines and vaccines for diseases disproportionately affecting developing countries, including HIV/AIDS, malaria and TB. We are also making key medicines and vaccines more accessible through discounted prices and have negotiated eight licences for third-party manufacturers to produce generic versions of our key HIV medicines.

As this Report shows, our efforts are starting to bear fruit. Preferential pricing and voluntary licences are helping to increase the supply of HIV/AIDS medicines to sub-Saharan Africa. In 2006, seven countries completed their five-year programmes to eliminate lymphatic filariasis using our albendazole treatment. We will continue donating our tablets until this disabling and incurable disease is completely wiped out.

Vaccines are another exciting area. In 2006, 75 percent of all the vaccine doses we produced were sold at preferential prices for immunisation campaigns in the developing world. These will save millions of lives. We expect to launch our vaccine for cervical cancer in 2007. This disease affects women in all countries but has the greatest impact in the developing world where there are few screening programmes to catch early cases.

There is no room for complacency – much more effort is needed from all stakeholders to resolve the healthcare problems of developing countries. But we are proud of the contribution we are making.

We know that our efforts on access to medicine must be based on a solid foundation. Our industry is high profile and often the subject of criticism. Good medicines can make a big difference to the quality and length of life for all of us and it is rightly expected that we should meet the highest standards of integrity in all aspects of our work.

This Report gives a snapshot of our approach to embedding an ethical culture across GSK. This includes applying the highest standards of behaviour and transparency in our R&D and promotion of medicines, treating our people well, and minimising the impact of our business on the environment. We also need to play our part in tackling major global issues such as climate change.

We value the input of our stakeholders and would welcome your views on this Report or any aspects of corporate responsibility at GSK.

Sir Christopher Gent
Chairman

JP Garnier
Chief Executive Officer
What is your vision for CR at GSK?
There are three elements. We want to achieve high standards of behaviour in everything that we do, in all parts of the company. And we want to be known for that. We’ve adopted the theme ‘performance with integrity’ which has been very successful in engaging our employees. Secondly, we need to bring the outside world into our decision making. Only through a full understanding of stakeholder views will we make the best decisions. The third element is our desire to be a real member of the local community everywhere that we operate. That includes playing our part in the wider global community by contributing to better healthcare.

Where do you think GSK is doing well?
We are very engaged on issues of the developing world – and in my experience this is quite unusual for a public company. I believe that we lead our industry on R&D for neglected diseases, preferential pricing and voluntary licensing and are well ahead of most other sectors. We take a long-term approach and our programmes involve a high degree of partnership and dialogue with NGOs, governments, and organisations such as the World Health Organisation and the Gates Foundation.

Where should GSK be doing more?
Sales and marketing practices are always a hot topic for the pharmaceutical industry. We need to ensure that we keep up with public and regulatory expectations of how we market our products, and ensure GSK policies meet or exceed these changing expectations. However, being the first to change commercial practices runs the risk of reducing our competitiveness, so we must also be proactive in encouraging others in our industry to follow suit.

What is the biggest challenge?
The most difficult task is finding a balance between the needs of different stakeholders. Our investors are concerned primarily with profit. CR is important to them because it affects the long-term success of the company but the next quarter’s earnings are often a more pressing priority. On the other hand, NGOs and others in society would like us to be more concerned with solving society’s healthcare problems.

Are GSK’s programmes for the developing world philanthropy or are they part of your business?
There’s no doubt that they are part of the business. The need for our medicines will not go away so we need to make sure that our programmes are sustainable, and the best way to do this is make sure they are part of our day-to-day business. A great example of this is our long-term commitment to providing not-for-profit HIV medicines in the world’s poorest countries. There is also such immense stakeholder pressure on this subject that it would be impossible to turn a blind eye. But it’s not just about responding to pressure from the outside. Our 100,000 employees want to work for a company that is addressing these challenges. We have a duty to use our scientific know-how and human capital to make a difference where we can – it’s essential to our own sense of integrity.

Why haven’t you reduced the price of your products in all markets?
To be a sustainable business we have to make an adequate return or we won’t be able to discover new medicines. We’re under immense pressure from competitors and investors. Nevertheless we are looking at the issue of pricing beyond the world’s poorest countries.

Are you researching new medicines that are really needed or just looking for ‘me-too’ drugs?
In many cases the drugs that are really needed will be the most profitable because that’s where the demand is. New drugs for cancer or Alzheimer’s will be meeting a huge unmet medical need and will be profitable too. The problem is that these diseases tend to present extreme scientific challenges and require novel scientific approaches which carry a greater risk of failure. Diseases of the developing world present a different problem – there is great need but no viable commercial market for new products. We get round this problem by working through public private partnerships and are very active on R&D for neglected tropical diseases. I think the debate about me-too drugs has been taken too far. If a new drug enables patients to take fewer doses each day or reduces side effects then it may seem like only a small improvement but it can make a very big difference to the treatment outcome.
The pharmaceutical industry has been criticised for lack of transparency over clinical trial results. Are you doing anything to address this concern?

There is a perception that the pharmaceutical industry is less than transparent and I think this is partly because we haven’t done a very good job of communicating the challenges we face. I believe that our online Clinical Trial Register has gone some way to addressing these concerns. But the communication of data from clinical trials is a tough area. Weighing up the balance of risks and benefits from a medicine is rarely straightforward. Data isn’t black and white – it requires interpretation and judgement. This inevitably means that people will have different views and that our knowledge will change over time as new drugs are tested and used. So actually talking about medicines to doctors is not straightforward. This communication is very important but very challenging.

Is the pharmaceutical industry sustainable?

We have a ‘contract with society’ – in return for investing in new drugs we generally have around ten years of intellectual property protection on our products before generics can be made. R&D is uncertain and unpredictable so in some periods we are more successful at this than in others. But I believe that the basic model is still a good one because it fosters a high level of innovation. Of course there are challenges and the industry must continually look for ways to improve R&D productivity. We have a unique type of product that plays a very personal role in people’s lives. Nowadays good health is seen as a right but it’s also a business and for some people this is uncomfortable. Generally, though, I believe people accept the need for a trade-off – they may not like us making a profit from health but they accept it because it’s the best way to encourage the discovery of new medicines.

What role is GSK playing in addressing climate change?

We have targets for reducing energy usage. I believe we’ve adopted a sustainable approach that is linked to our business. Because of our position as a company that addresses healthcare needs, and the relatively small footprint we have compared to other sectors, there are other issues that are a higher priority to address. Nevertheless climate change is an important issue for GSK and for our stakeholders and we need to play our part in tackling it.
**Corporate responsibility at GSK**

**Why is CR important to GSK?**

Corporate responsibility is about how we achieve our goals and implement our business strategy. We aim to operate in a way that reflects our values, while understanding and responding to stakeholder views and connecting business decisions to ethical, social and environmental concerns.

Corporate responsibility helps to achieve our business goals by:

- Supporting our relationships with key stakeholders including patients and consumers, doctors and governments
- Protecting and enhancing our reputation and therefore trust in our products
- Improving our ability to attract, retain and motivate the best people
- Strengthening our risk management processes

We believe that our business makes a valuable contribution to society by developing and marketing medicines which improve people’s lives. However we know that the research, development, manufacture and sale of medicines raise ethical issues. We seek to minimise the negative impacts of our business and maximise the positive benefits of our products and operations.

**Our strategy**

GSK is committed to addressing two key challenges facing the pharmaceutical industry and society as a whole. These are:

- Improving productivity in research and development
- Doing our part to support patient access to new medicines

To do this we focus on four business strategies. We have structured this report around these strategies to show how corporate responsibility is integrated into our business.

<table>
<thead>
<tr>
<th>Build the best product pipeline in the industry for the benefit of patients, consumers and society</th>
<th>Maximise the potential of our current product portfolio</th>
</tr>
</thead>
<tbody>
<tr>
<td>Relevant responsibility issues include:</td>
<td>Relevant responsibility issues include:</td>
</tr>
<tr>
<td>- Animal research</td>
<td>- Ethical conduct</td>
</tr>
<tr>
<td>- Conduct of clinical trials</td>
<td>- Standards in our supply chain</td>
</tr>
<tr>
<td>- Patient safety</td>
<td>- Environmental impact</td>
</tr>
<tr>
<td>- Interactions with patient groups</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Improve access to medicines in the developed and developing world</th>
<th>Be the best place for the best people to do their best work</th>
</tr>
</thead>
<tbody>
<tr>
<td>Relevant responsibility issues include:</td>
<td>Relevant responsibility issues include:</td>
</tr>
<tr>
<td>- R&amp;D for diseases of the developing world</td>
<td>- Employment practices</td>
</tr>
<tr>
<td>- Preferential pricing</td>
<td>- Diversity</td>
</tr>
<tr>
<td>- Voluntary licensing</td>
<td>- Human rights of employees and in our supply chain</td>
</tr>
<tr>
<td>- Access to medicines in middle income and developed countries</td>
<td>- Health and safety</td>
</tr>
<tr>
<td>- Community investment</td>
<td>- Resilience and well being</td>
</tr>
</tbody>
</table>
Our most important corporate responsibility issues
Corporate responsibility is a broad subject which covers a very wide range of issues. We need to prioritise these issues in order to manage them effectively and report clearly on our performance.

We identify the most important (material) issues for GSK through engagement with stakeholders, our risk management processes and our knowledge of our business and the pharmaceutical industry.

These inputs have led us to identify four CR issues that are particularly relevant and significant for GSK. These are:

- Research and innovation – contributing to healthcare by developing medicines and vaccines that meet the needs of patients
- Access to medicines in developed and developing countries
- Ethical conduct including sales and marketing practices
- Environment, including climate change and the impact of pharmaceuticals in the environment

MANAGING CR
Our Corporate Responsibility Statement and Principles define our approach to our key CR issues and provide guidance for employees on the standards to which the company is committed. You can view the Principles in the background section of our website.

CR governance
We have a Corporate Responsibility Committee (CRC) of non-executive board directors that provides high-level guidance on our approach to CR. The CEO and members of the corporate executive team are actively involved in CR and participate in CRC meetings.

The committee members are Sir Christopher Gent (Chair), Sir Ian Prosser, Dr Daniel Podolsky and Tom de Swaan. You can find more information on the CRC members and Terms of Reference in the background section of our website.

The Committee meets four times a year to review our policies and progress on our CR Principles. Four Principles – access to medicines, standards of ethical conduct, research and innovation and global community partnerships – are reviewed annually. Other Principles are discussed at least once every two years. The Committee’s findings are reported to the Board.

During 2006 the Committee reviewed our activity in a number of areas including:

- Access to medicines
- Community investment
- Reputation management
- Caring for the environment
- Standards of ethical conduct
- DTC advertising
- Consistency of commercial practices codes

The Committee also reviews and signs off our annual CR report.

CR risks
Management of significant business risks is coordinated by the Risk Oversight and Compliance Council (ROCC). The ROCC also considers reputational and corporate responsibility risks.

For more background information on the ROCC, see Risk management and compliance on gsk.com.

Management structure
Duncan Learmouth, Senior Vice President Corporate Communications and Community Partnerships, and Rupert Bondy, General Counsel, are our executive team members with responsibility for CR.

We believe that day-to-day management of CR issues is done most effectively within our business operations, where experts on all our CR issues work. Coordination is provided by a cross-functional team, made up of representatives from key business areas. These representatives are senior managers and have direct access to the appropriate executive team member. Their role is to oversee development, implementation and communication of CR policy across GSK. This ensures a comprehensive and consistent approach is taken throughout the organisation.

We also have a small CR team that co-ordinates policy development, reporting and communication with socially responsible investment analysts.

For details of our environment health and safety management see EHS management.

Assurance
The environment, health and safety sections of this report are externally verified by environmental assurance consultancy, SGS. The purpose of their assessment is to:

- check that the EHS data presented are accurate and that they represent GSK’s performance fairly
- critically review the completeness and relevance of the information presented
- assess the effectiveness of GSK’s data management and reporting systems

You can find SGS’s verification statement and our response on page 70.

Other sections of the report are not externally verified. However GSK has an extensive internal audit programme that covers all aspects of our business.

Internal communication and awareness
We keep employees informed about corporate responsibility. During 2006, 34,000 copies of our CR Overview brochure were distributed to employees directly and through Spirit, our internal magazine. Spirit also features regular articles on CR related topics.
We also surveyed a random selection of 1000 employees on their awareness of corporate responsibility and which issues they consider the most important. 369 employees from across the world and in all the different areas of the business responded to the survey.

- 80 percent have heard of corporate responsibility
- 78 percent recognised it was the responsibility of themselves and other employees
- Ethical business conduct, access to medicines and health and safety were the three areas identified as most important
- These are also the areas that employees believe that the company is doing most to address

STAKEHOLDER ENGAGEMENT

Stakeholder engagement is an important component of our approach to managing our business responsibly. It helps us to identify the important CR issues for our business, understand stakeholder views and expectations and to build trust with key audiences. We also engage with our stakeholders to tell them about our work and to learn from their expertise. GSK interacts with a wide range of stakeholders including:

- Patients
- Doctors
- Governments and regulators
- Public and private health providers
- NGOs
- Multilateral organisations
- Employees
- Investors
- Local communities
- Suppliers
- The scientific community
- Peer companies

Most of this discussion takes place in the normal course of business. For example our scientists meet regularly with academics, researchers and other pharmaceutical companies.

It is difficult to quantify the extent of our engagements, since this activity is embedded in our business operations, but we have included examples in this section and throughout this report. These are some of the ways we engaged with our stakeholders in 2006.

Investors and benchmarking organisations

We held 18 meetings with investors in 2006, to discuss CR issues.

These included one-to-one meetings to discuss key issues as well as educational visits and meetings. In January we hosted a meeting for 17 investors at our vaccines facility in Belgium. Investors were shown a presentation on the science of vaccines and visited the site's research and production areas. In October, eight investors visited our manufacturing plant in Dartford, England. Investors were shown the process for making the active ingredients in our products and the environmental management facilities at the plant. On both occasions investors had the opportunity to meet and question senior GSK staff.

In December, GSK and Dresdner Bank ran an educational seminar on patient safety for 16 investors. Our senior physician in charge of global patient safety explained our current drug safety monitoring procedures and how GSK plans to further develop these, and answered questions from investors.

Investors raise questions and issues throughout the year. In 2006, the main issues raised related to sales and marketing practices, climate change, access to medicines and clinical trials ethics, particularly in the developing world. Our approach to all these issues can be found in this report.
GSK received the following ratings from agencies:

<table>
<thead>
<tr>
<th>Organisation</th>
<th>Rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Association of British Insurers</td>
<td>GSK was given a ‘full’ rating for its disclosure of Board responsibilities and policies relating to social, ethical and environmental issues. This is the highest possible rating.</td>
</tr>
<tr>
<td>Dow Jones Sustainability Index</td>
<td>GSK was included in this year’s index. Individual company scores and rankings are no longer published.</td>
</tr>
<tr>
<td>FTSE4Good Index</td>
<td>GSK was included in the FTSE4Good Index.</td>
</tr>
<tr>
<td>Innovest Strategic Value Advisors</td>
<td>We were rated 3rd out of 44 companies in Innovest’s Global Pharmaceutical Sector Report. GSK was rated particularly highly in the area of strategic governance.</td>
</tr>
<tr>
<td>Claremont McKenna</td>
<td>GSK received a B+ in a rating of pharmaceutical sustainability reporting, carried out by Claremont-McKenna, a US college that evaluates companies on corporate responsibility issues. GSK was 7th out of the 25 companies evaluated</td>
</tr>
</tbody>
</table>

GSK reported its greenhouse gas emissions through the Carbon Disclosure Project (CDP). You can read our response on the CDP website at www.cdp-project.net.

**CR benchmark studies**
We co-sponsored a benchmarking study by the consultancy and think-tank SustainAbility into non-financial reporting in the pharmaceutical industry. GSK was rated highest overall compared to 12 other companies in the sector.

We were also ranked 17th out of the top 50 companies in the SustainAbility/UNEP Global Reporters study of best practice in sustainability reporting. GSK was one of only two pharmaceutical companies in the top 50.

We retained our position in the Premier League (companies scoring above 95 percent) of Business in the Community’s Environment index.

**EHS**
We have established a stakeholder panel to inform our approach to EHS management. This is made up of ten external stakeholders representing customers, suppliers, regulators, public interest groups and investors, as well as four senior GSK EHS representatives.

**Opinion leaders**
Opinion leaders are influential individuals or organisations with expertise in corporate responsibility. These include NGOs, government representatives, investors, journalists, academics and consumer and industry organisations.

We held two discussions, one each in the US and UK, to gather feedback from 18 opinion leaders on our CR performance and reporting.

**Performance**
Participants mostly agreed that GSK’s approach to corporate responsibility is comprehensive, well thought-out and well managed. We were rated most highly for our programmes to increase access to medicines in the developing world.

Opinion leaders made suggestions for how we should improve in a number of areas. These included:

- GSK should demonstrate its commitment to improving health globally beyond selling pharmaceuticals (e.g. through disease prevention)
- We should do more to embed CR throughout the company and should set targets to improve our performance
- GSK should spend more time listening to stakeholders
- We should develop a strategy for reducing our impact on climate change
- We should focus on improving access to medicines in middle-income countries

**Reporting**
The opinion leaders felt GSK’s CR report covered the right issues, but the report was too long overall, reducing readability. GSK scored points for improving the transparency of its reporting over the last three years. But stakeholders expected further disclosure on GSK’s work with patient advocacy groups, ethics, management of the supply chain and our approach to human rights issues.

**Other stakeholders**
The following table summarises our interaction with other groups and shows where further information can be found.
<table>
<thead>
<tr>
<th>Stakeholder</th>
<th>Engagement</th>
</tr>
</thead>
<tbody>
<tr>
<td>NGOs</td>
<td>We engage with international and community NGOs through our access, education and public health programmes. Read more in Investment in Public Health Initiatives on page 76 and Community Investment on page 75. We also engage regularly with animal welfare organisations. Read more in Animal Research on page 26.</td>
</tr>
<tr>
<td>Employees</td>
<td>We seek feedback from our employees through regular employee surveys. See Employment on page 40 for a summary of the results from our latest survey. We also consult employees on changes that affect them and discuss business developments through our Works Councils and European Employee Forum. For more information see Internal Communications on page 44.</td>
</tr>
<tr>
<td>Governments and regulators</td>
<td>We engage in debate on legislation and seek to influence policy decisions that affect GSK. We also engage with governments to advance our corporate responsibility objectives. See Government and External Affairs on page 12.</td>
</tr>
<tr>
<td>Multi-lateral agencies</td>
<td>We engage with multi-lateral agencies through our access and public health initiatives. See Access to Medicines on page 18.</td>
</tr>
<tr>
<td>Doctors</td>
<td>We engage with doctors in many ways including through our medical representatives and when running clinical trials. See Research and Ethical Conduct for information on how we manage the issues this engagement raises.</td>
</tr>
<tr>
<td>Patients</td>
<td>GSK researchers and scientists meet with patients as part of our Focus on the Patient initiative. This engagement influences our understanding of diseases and our research priorities. We also engage with patient groups directly and through Patient Advocacy Leaders’ Summits. Read more in Patient Advocacy. We also conduct market research via third parties to understand patient needs.</td>
</tr>
<tr>
<td>Local communities</td>
<td>Our interactions with local communities are managed by individual GSK sites. See Working with Communities for examples of our initiatives.</td>
</tr>
<tr>
<td>Suppliers</td>
<td>We hold global and regional supplier review meetings where senior GSK managers address and interact with suppliers on key issues. For more information see Supply Chain on page 50.</td>
</tr>
<tr>
<td>The scientific community and academic partnerships</td>
<td>It is important for GSK to be part of scientific and academic debates. This report contains examples of some of these interactions. For a discussion of how we manage such relationships see Research.</td>
</tr>
</tbody>
</table>
GOVERNMENT AND EXTERNAL AFFAIRS

The pharmaceutical industry is highly regulated and these regulations can have a significant impact on our business. So it is essential that we engage in debate on legislation and seek to influence policy decisions that affect GSK. In fact, as a major multinational corporation we are often approached by governments to give our views, along with other stakeholders such as NGOs.

Our size and global reach give us access to governments and policy makers. We need to use this access responsibly to benefit patients and our business. We believe that by being transparent about our lobbying and public policy work we can increase stakeholder trust and confidence in GSK.

We have policies governing our interactions with important stakeholders. This section covers our interaction with governments and other external groups, including patient advocacy groups. Information on our approach to working with doctors and healthcare professionals is available in the Research section of this report.

More background information on our approach to public policy is available in the external affairs section of gsk.com.

Our approach to external affairs

GSK’s external affairs teams monitor changes and proposed reforms to legislation and meet regularly with government officials to explain our views on a range of public policy issues. Lobbying on issues affecting the whole pharmaceutical industry is sometimes conducted through trade associations. We may also hire professional lobbyists to support our public policy work.

Our public policy work is governed by our External Affairs Code of Conduct, and is backed up by factual research and analysis. See policy on background site.

GSK believes that, where legally and culturally appropriate, political donations are a legitimate way of supporting the political process. Information on donations is given both in this report and in the Annual Report and Accounts. We have a Political Donations Policy governing our contributions to political candidates.

Public policy activity in 2006

In 2006 we engaged with governments on a wide range of issues that affect our industry. In particular we advocated for policies that will deliver:

- Strong intellectual property rights and data exclusivity protection to encourage the research and development of new medicines and vaccines
- Pricing and reimbursement systems that support innovative medicines and provide greater predictability and transparency. We believe there should be greater liberalisation in pharmaceutical pricing, especially for medicines that are not paid for by governments
- A common European regulatory system that offers rapid approval of new products
- Intellectual property incentives to promote research on orphan medicines, paediatric medicines and medicines for the developing world
- Implementation of clinical trial regulations that promote safety and good clinical practice
- Appropriate use of health technology assessments (HTAs). We believe HTAs should be independent, transparent and scientifically robust – they should be a means of ensuring the right medicines reach the right people, rather than be used as a rationing tool
- Increased individual involvement and responsibility for personal healthcare, including improved access to information about medicines from pharmaceutical companies
- An environment which promotes research and development, and encourages informed debate on the benefits and challenges of new research technologies

Advocacy on CR issues in 2006

We engage with governments and other stakeholders to advance our corporate responsibility objectives. For example, in 2006 GSK:

- Advocated for improvements to healthcare in the developing world through discussions with the UK and US governments, multilateral agencies and NGOs, see Access to medicines
- Participated in the World AIDS conference held in Toronto, Canada. See Access to medicines
- Supported Mobilising for Malaria, an advocacy initiative to generate political commitment and sustained funding to combat malaria, see Community Investment
- Worked with regulators to encourage acceptance of alternatives to animal testing, see Animal research
- Participated in developing the World Health Organization's International Clinical Trials Registry Platform, an initiative to standardise the way information on medical studies is made available to the public
- Encouraged more consistent approaches to patient safety and the reporting of side effects, see Patient Safety
- Led efforts to develop industry codes of conduct for marketing ethics in several Asian countries. See Marketing Codes of Practice
Our position on key issues
We publish our position on many key issues in the background section of our website. We are happy to discuss our position on these or any other issues with legitimate parties. Contact our corporate responsibility team at csr.contact@gsk.com

The current position statements published on www.gsk.com/responsibility include:

- Clinical trials in developing countries
- Counterfeit medicines
- Developing world challenges and access to medicines
- Importation of medicines
- Intellectual property and the TRIPS agreement
- Product diversion
- Preparations for a flu pandemic

Membership of trade associations
GSK is a member of trade organisations including:

- Association of the British Pharmaceutical Industry (ABPI)
- Biotechnology Industry Organization (BIO)
- European Federation of Pharmaceutical Industries (EFPIA)
- Intellectual Property Owners Association (IPO)
- Japan Pharmaceutical Manufacturers Association (JMPA)
- The Swedish Association of the Pharmaceutical Industry (LIF)
- Organization For International Investment (OFII)
- Pharmaceutical Research and Manufacturers of America (PhRMA)
- International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)

US lobbying expenditures
GSK spent $5.14m on federal lobbying activities in the US during 2006. This information is reported to the US Congress in accordance with the Lobbying Disclosure Act of 1995. It includes the costs of salaries and benefits for all employees registered to lobby the US government; hiring outside lobbying consultants; support for lobbying contacts such as planning activities, research and other background; running the GSK Washington DC government affairs office; support staff; and the portion of trade association fees associated with federal lobbying.

In other countries we do not collect separate data on lobbying expenditure.

Political donations
GSK makes political donations with corporate funds where these are authorised by law and are culturally appropriate.

In 2006 we contributed £319,000 to political organisations in the US, Canada and Australia. All donations are covered by the GSK policy on political donations.

GSK does not make donations to political parties or other political organisations in the European Union. See our Annual Report for more information.

Contributions in the United States
In the US, candidates are financed primarily by contributions from companies, individuals, NGOs and other parties. Corporate contributions are an accepted and important way for companies to engage in the political debate.

Corporate contributions to national political parties and candidates running for federal office are prohibited by US law.

Contributions to state candidates
GSK corporate funds are only given to candidates at state level, in states where this is permitted by law. In 2006, we donated $536,000 (approximately £290,000) to candidates for state-held offices. This was split between Republicans (approx 55 percent) and Democrats (approx 45 percent).

Our contributions are not made on the basis of political party. GSK supports candidates who seek an environment that appropriately rewards high-risk, high-investment industries and believes in free market principles and intellectual property rights. All states publish information about political donations.

Political Action Committee contributions
In accordance with the Federal Election Campaign Act, there is a GSK Political Action Committee (PAC) that facilitates voluntary political contributions by eligible employees. The PAC is not controlled by GSK but by our participating employees, who have the legal right to make contributions to candidates and political parties at the federal and state levels. All PAC contributions are voluntary and donations are subject to strict limitations. For example, the GSK PAC may not contribute in excess of $5,000 to a candidate for federal office per election.

PAC contributions are determined by a governing board of PAC-participating GSK employees from across the company. As required by law, PAC contributions are reported to the Federal Elections Commission (FEC). In 2006, the second half of the two-year federal election cycle, the GSK employees’ PAC contributed $1.36m to candidates for state and federal offices.

Contributions in Canada
In 2006, GSK donated $CAD 56,000 (approximately £27,000) in Canada to political candidates in those provinces where it is legal.

Contributions in other countries
In 2006, GSK donated $AUS6,000 (approx £2,000) in Australia.

Patient advocacy
Patient advocacy groups provide their members with support and information on how to live with their condition, represent patient views and advocate on issues affecting patients’ interests. They are an important stakeholder for GSK and we engage with them as part of our aim to be a patient-focused company.
Across the world we work with a wide range of patient groups in a variety of different disease areas such as cancer, asthma, diabetes and HIV/AIDS. Our interest in patient advocacy is about understanding patient needs and their illness. Our aim is to support the voice of patients and thus encourage a constructive healthcare debate for all stakeholders. We believe that patient groups are playing an increasingly valuable role in improving healthcare. To protect their independence and credibility patient groups should be encouraged to obtain support, financial and non-financial, from diverse multiple sources – private, public and through individual donations.

Our approach
We are committed to ensuring that we work with patient groups at the highest levels of ethical standards and transparency, and have established strong global principles.

As part of GSK's commitment to working ethically with patient groups, all employees involved receive formal training on our global principles and work within a framework set by our Standard Operating Procedures. In addition employees have access to a patient advocacy resource intranet site.

In the UK GSK's advocacy work is governed by the Association of the British Pharmaceutical Industry (ABPI) Code of Practice. This states that there must be a written agreement between the company and the patient group, and that companies must publish a list of all patient groups that they fund.

We list all UK patient groups receiving funding from GSK. In 2007 we have gone further towards greater transparency and extended the list to include all patient groups in Europe that receive funding from GSK and have given full details of that funding.

In Europe GSK developed a Standard Operating Procedure (SOP) for working with patient groups. This initiative is being extended to the other GSK regions in 2007. The SOP covers a variety of areas concerning GSK’s work with patient groups. It states that GSK will not seek a patient group's endorsement of any medicine, and that we will not provide more than 50 percent of a patient group's overall funding. In 2007 this will become no more than 25 percent funding. In the vast majority of instances the actual percentage is much lower. Additionally all activities are accompanied by a written agreement.

GSK is working with many pharmaceutical company representative bodies to encourage industry-wide transparent and ethical approaches to working with patient groups.

Work with patient groups in 2006
Patient Advocacy Leaders’ Summits (PALS) are one of the ways we engage with patient groups. In 2006 we held summits in the US, Japan and in many European countries including Poland, Netherlands, Romania and Latvia. These meetings give patient groups the opportunity to learn about GSK, tell the company how it can better support their work, and discuss and debate key issues relating to patient advocacy and healthcare policy. There is typically a range of workshops for attendees, including sessions on media training and sharing best practice.

We have a European patient group advisory board that we consult on GSK policies and thus work with to make the company as patient-centric as possible. The board has an independent chair, and is made up of representatives from a series of European groups, many from disease areas where GSK has no direct therapeutic interest.

CONTRIBUTION TO SOCIETY
We believe that our business adds social and economic values to society through the contribution our products make to healthcare and through the jobs and wealth we generate.

Contribution to healthcare
Our medicines and vaccines enable people to live longer and enjoy a better quality of life.

Healthcare is expensive – especially when patients need to make frequent visits to the doctor or spend time in hospital. For example in the US, $3 of every $4 spent on healthcare goes to treating people with chronic diseases. Healthcare costs are also likely to rise further in many countries as the population ages. Vaccines and medicines reduce the burden on healthcare systems by preventing diseases, enabling people with chronic diseases to work and helping patients to control their symptoms and make fewer visits to hospital.

GSK contributes to healthcare in three ways:

- Disease prevention
- Effective intervention – medicines to treat diseases
- Innovation – investment in R&D to discover new medicines and vaccines to meet future healthcare needs

GSK Corporate Responsibility Report 2006

14
Disease prevention
Preventing disease is better for the potential patient, who avoids illness, pain and suffering, and better for society because it reduces healthcare costs. We support disease prevention efforts in several ways:

Vaccines
We make vaccines that protect against crippling and fatal diseases including hepatitis A and B, diphtheria, seasonal flu, polio, tetanus and whooping cough. We currently supply 22 vaccines against 17 diseases.

Global immunisation efforts have led to the eradication of smallpox, the potential eradication of polio, and are estimated to save the lives of up to three million people worldwide each year. Vaccination has a longer term benefit and is more cost-effective than treating people after they become sick. It can also reduce healthcare costs by:
- preventing disease outbreaks
- reducing the need for expensive treatments and hospitalisations
- reducing permanent disabilities and the long-term effects of disease
- preventing loss of productivity from illness

GSK Vaccines
We distributed 1.1 billion vaccine doses in 2006 to 169 countries in both the developed and the developing world—an average of 3 million doses a day. We invested £348 million in vaccine research in 2006 and had 1,500 scientists working at our vaccine research centres.

We make our vaccines available in developing countries through an innovative tiered pricing model. In 2006, 75 percent of the 1.1 billion vaccines we produced went to the developing world. We are currently researching new vaccines for more than 15 diseases including several that are particularly relevant for developing countries. See Access to medicines, page 18.

Patient education – We support patient education and disease prevention initiatives. These include working with patient advocacy groups, producing patient information leaflets for medicine packs and doctors’ surgeries and publishing information on disease prevention on our website.

Anti-smoking – It is estimated that around five million people die prematurely each year as a result of smoking. This makes smoking cessation one of the most effective ways to improve health. GSK’s nicotine replacement therapy brands such as NicoDerm and Nicorette have helped more than five million smokers quit since 1996, making a significant contribution to public health.

Community investment – We support several major disease prevention programmes in developing countries through our community investment. These include:
- the Global Alliance that plans to completely eliminate LF (a disfiguring disease that is one of the world’s leading causes of permanent disability) by 2020. See Community Investment, page 75.
- PHASE, our programme to reduce diarrhoea-related disease by encouraging school children in developing countries to wash their hands. See Community Investment, page 75.

Intervention
Our key pharmaceutical products target serious diseases including:
- Asthma and chronic obstructive pulmonary disease
- Epilepsy, depression and other diseases of the central nervous system
- HIV/AIDS, herpes and other viral diseases
- Infections
- Diabetes
- Cancer
- Heart disease and other cardiovascular diseases
- Urogenital diseases

These make a major contribution to healthcare in several ways:
- Prolonging life – GSK is a pioneer in treatments for HIV/AIDS. Our antiretrovirals (ARVs) such as Combivir help patients to control the effects of HIV infection for many years. We sell our ARVs to countries in sub-Saharan Africa at not-for-profit prices. See Access to Medicines.
- Preventing complications – Many diseases such as diabetes are progressive – if patients don’t receive the right treatment they can suffer severe side effects. Every day in the US diabetes is the cause of an estimated 225 amputations, around 50 cases of blindness, and 117 people experiencing kidney failure. Avandia, our diabetes treatment, helps patients to control their symptoms, delays the progression of the disease and prevents complications. Avandia has now been used by more than seven million people worldwide.
- Improving quality of life – Many of our medicines such as those for asthma and diabetes help patients with chronic diseases live full and productive lives. GSK preventative treatments for asthma such as Seretide/Advair control the symptoms of asthma and prevent asthma attacks.
- Curing infection – We produce antibiotics that treat respiratory tract and other infections. In 2006, we donated antibiotics to help relief efforts in disaster areas. See community on page 75.
**Value to UK economy**

In 2006, the British Pharma Group (comprising the two UK-based companies, GSK and AstraZeneca) commissioned a report by the Office of Health Economics (OHE), an independent research organisation, into the companies’ value to the UK economy.

The report used the concept of ‘economic rent’ – the net additional income and wealth brought to the UK by a company, in excess of the income that would be generated if the labour and capital were put to the next best alternative use.

The OHE stated that the estimated net economic rent earned by many enterprises in any economy can be expected to be close to zero i.e. they yield as much economic value as, but not significantly more than, the next best alternative uses of the capital and labour they employ.

GSK and AstraZeneca’s economic rent from manufacturing, R&D and other activities in the UK was estimated to be at least £1 billion annually, and possibly much higher.

GSK contributes approximately 6% percent of this figure.

You can read a copy of the report in the background section of our website.

Other studies have also ranked GSK’s value to the UK economy highly:

The UK Government Department of Trade and Industry (DTI) 2006 Value Added Scoreboard lists the companies making the largest contributions to value added in the UK and in Europe. GSK was ranked 6th in the UK and 19th in Europe (the highest pharmaceutical company). Our value added was calculated as £11.8 billion or £118,500 per employee.

Investment in R&D stimulates economic growth. GSK is ranked 10th in the UK DTI’s R&D Scoreboard which ranks the top global companies by the value of their R&D investment. We are the highest ranked UK company. See www.dti.gov.uk/innovation

**Innovation**

Despite revolutionary advances in healthcare there are still many diseases for which there is no cure or for which treatments could be improved. So continued research and innovation is essential.

We believe that R&D into new medicines is the most important element of corporate responsibility for our company. GSK invested £3.46 billion and employed over 15,000 people in R&D in 2006.

**Our pipeline**

We have 159 prescription medicines and vaccines in clinical development. Current projects include research into asthma, cancer, depression, diabetes, epilepsy, heart disease, HIV/AIDS, influenza, irritable bowel syndrome, osteoporosis, schizophrenia, stroke and TB.

We expect to launch five major new vaccines within the next five years:

- a human papilloma virus vaccine preventing cervical cancer
- the USA launch of a vaccine against rotavirus induced gastroenteritis and the strengthening of rotavirus vaccine uptake in Europe and in the international markets
- a vaccine against pneumococcal disease and non-typeable Haemophilus influenzae infections causing otitis media
- a number of vaccines against both seasonal and avian flu based on GSK’s unique expertise in adjuvant technology including, a new generation adjuvanted seasonal flu vaccine for elderly people
- vaccine combinations against meningitis

Experts are predicting there may be a major flu pandemic in the next decade caused by the H5N1 strain of bird flu. GSK is actively preparing for this potential crisis. In a pivotal clinical trial of GSK’s new generation H5N1 influenza vaccine carried out in 2006 in Belgium, it was shown that very low doses of antigen (3.8µg) combined with GSK’s novel adjuvant system elicited a strong seroprotective response. As GSK’s vaccine is also believed to have the potential to offer a protection against ‘drifted’ variants of the H5N1 virus, it could be used as part of a proactive pre-pandemic vaccination campaign.

In addition we also increased production of Relenza, our treatment for influenza. For a full review of our pipeline please see our Annual Report.

We have an extensive R&D programme into diseases disproportionately affecting developing countries. We believe GSK is the only company researching both new vaccines and treatments for HIV/AIDS, TB and malaria – the World Health Organization’s three priority diseases.

**Research into the causes of disease**

As well as researching potential new medicines we also invest in research to increase understanding of the human body and the causes of disease.

For example, in 2006 we launched ECLIPSE, a non-drug study to improve understanding of chronic obstructive pulmonary disease (COPD). The World Health Organization has predicted that COPD will be the third leading cause of death by 2020. The GSK study will involve more than 2,000 patients over three years and identify relevant markers that may help predict disease progression.

Many diseases are caused by genetic factors which makes them difficult to cure or prevent. Our research into the body’s immune system will also enable us to develop safer, more effective and more targeted vaccines to protect against a greater number of diseases.

**Economic value**

We contribute to the countries in which we operate through creating wealth and employment, paying taxes and purchasing products and services. As well as these direct financial contributions our products also contribute indirectly to economic growth by preventing and treating disease.

Detailed financial information is available in our Annual Report. However, some of the key figures for our global business are:

<table>
<thead>
<tr>
<th></th>
<th>2004</th>
<th>2005</th>
<th>2006</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sales</strong></td>
<td>19,986</td>
<td>21,660</td>
<td>23,225</td>
</tr>
<tr>
<td><strong>R&amp;D investment</strong></td>
<td>2,904</td>
<td>3,136</td>
<td>3,457</td>
</tr>
<tr>
<td><strong>Payments to:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Employees</td>
<td>5,054</td>
<td>5,254</td>
<td>5,495</td>
</tr>
<tr>
<td>Suppliers</td>
<td>n/a</td>
<td>n/a</td>
<td>8,107</td>
</tr>
<tr>
<td>Government (taxation)</td>
<td>1,757</td>
<td>1,916</td>
<td>2,301</td>
</tr>
<tr>
<td>Community investment</td>
<td>328</td>
<td>380</td>
<td>302</td>
</tr>
</tbody>
</table>

n/a = not available

**HUMAN RIGHTS**

Human rights is a broad subject that is relevant to GSK in a number of different contexts.

We are committed to upholding human rights in our sphere of influence. We have greater control over human rights in our own operations but can also influence human rights among our suppliers and wider society.

**GSK’s sphere of influence**

There are several reasons why we take human rights seriously:

- Achieving high standards on human rights supports our reputation and our goal of operational excellence
- It helps us to get the best from our employees
- By working with suppliers that match our standards, we help ensure the smooth operation of supplier contracts and therefore a reliable supply of high quality products
- It supports good relationships with the communities near our sites

GSK Corporate Responsibility Report 2006 16
Our approach to human rights is guided by the UN Universal Declaration of Human Rights, the OECD Guidelines for Multinational Enterprises and the core labour standards set out by the International Labour Organisation.

**Our employees**
Most of our direct employees are well educated and skilled people so the risk of human rights issues occurring is relatively low. We believe that our employment standards on issues such as diversity, equal opportunities and health and safety provide adequate safeguards on human rights for our employees. For more information see Employment Practices on page 40.

**Suppliers**
We expect our suppliers, contractors and business partners to meet the same standards on human rights as GSK but we recognise that some suppliers may not. We seek to influence our suppliers to adopt high standards on human rights by adding human rights clauses to our contracts and auditing suppliers. For more information see Supply Chain on page 50.

**Communities**
Human rights are relevant to our relationships with a wider community of stakeholders. Here are a few examples:

- **Countries with poor human rights records**
  Some of our stakeholders are concerned about our presence in countries which have a poor human rights record such as Sudan, North Korea and Burma. While we respect these concerns, our medicines and vaccines are needed by local populations. Our products need to be registered with governments before they can be sold, which almost always requires interaction with some aspect of government. We believe, along with the UN, that people should not be denied access to medicines because of the regime operating in their country. See UN document.

- **Local communities**
  We seek to reduce the environmental impacts of our sites, operate them safely and foster good relationships with local communities.

- **Indigenous material and traditional knowledge**
  As one of the world’s leading pharmaceutical companies, GSK fully supports the Convention on Biological Diversity’s role in providing a framework for the conservation of biological diversity, the sustainable use of its components and respect for traditional knowledge. We also support the CBD objective “to provide fair and equitable sharing of the benefits arising from the use of genetic resources”.

A wide variety of biological materials is used in biomedical research. These include human materials, non-human materials found in humans (such as bacteria and viruses), animals and plants. They are obtained from various sources. Sometimes they will be indigenous and unique to a country or community. More commonly, they will be cultivated or bred as staple commercial products and obtained through ordinary commercial channels.

Today most of GSK’s pharmaceutical research is based on screening of large numbers of synthetic chemical compounds, rather than natural resources. We do not currently have any access and benefit sharing agreements in place. However, if GSK were to undertake development work using indigenous genetic resources and associated traditional knowledge arising from any GSK natural product collection programmes, access to those resources would be obtained in accordance with local laws. Contracts would be negotiated as required with the appropriate authority and we would thereby ensure that a clear benefit was returned to the country of origin, for example through royalties or a share of net profits. See our policy on Biodiversity.

**Society**
Improving healthcare, particularly in the developing world, is one of the greatest challenges the world faces. GSK is committed to playing its part in improving access to medicines. We contribute to healthcare in the developing world through our research into new treatments and vaccines, by making our medicines available at affordable preferential prices, by negotiating voluntary licences with generic manufacturers and through our community investment. For more information see Access to Medicines on page 18 and Community Investment on page 75.

We engage with governments, multilateral agencies and NGOs to help improve access to medicines. We have developed a seven point plan for use in our advocacy efforts. For more information see page 19.
We are supporting efforts to improve access to medicines. This section explains our:

- Contribution to the developing world through research, preferential pricing, partnerships and voluntary licences, and community investment in important public health initiatives
- Pricing arrangements and discount cards for middle-income countries
- Patient Assistance Programs and discount cards to help uninsured patients in the US

We believe that our response is not only the right thing to do but makes good business sense. Companies that adapt their business practices to address such challenges will be the leaders of the future. In the competitive market for talented people this also helps us to attract and retain the best people.

Differential pricing increases affordability for patients whilst maintaining support for the intellectual property system. Intellectual property rights are essential to the pharmaceutical industry because without them we would not be able to invest in R&D for new medicines and vaccines.

By finding innovative ways to help poor people in developed and developing countries access our medicines, we are addressing ethical, reputational and commercial imperatives. For these reasons access to medicines is a strategic business driver of GSK.

We also support under-served communities worldwide through donations, funding and practical support. See community investment.

Developing world

Poverty has caused a healthcare crisis in many parts of the developing world. Millions of people do not have access to reliable food and clean water, never mind adequate healthcare. Despite unprecedented resources being made available for public health, many governments are unable to fund the clinics and staff needed to deliver basic healthcare.

The World Bank estimates that $14 per person per year is needed to provide the most basic health services. Yet the average spend in sub-Saharan Africa is just $6. The African Region of the WHO suffers more than 24 percent of the global burden of disease, but has only 3 percent of the world’s health workers. Migration of African health workers to wealthier markets is exacerbating this situation.

Globally, there is a shortage of well over 4 million healthcare workers. The AIDS pandemic is making the situation even worse, depriving communities of their greatest asset – healthy and productive people.

Tackling this crisis is a complex challenge, requiring visionary leadership. Poverty is a huge barrier to progress. Significant political will and extra resources are needed to aid development and build healthcare infrastructure. Disease programmes need to be well co-ordinated to ensure that health systems as a whole benefit.

We believe that it is the responsibility of governments and intergovernmental agencies, supplemented by the work of NGOs, to deliver healthcare in these countries. However, the pharmaceutical industry can play a significant role in supporting their efforts.

We make an important contribution through:

- Research and development into diseases disproportionately affecting developing countries. We believe GSK is currently the only company researching both new vaccines and treatments for HIV/AIDS, TB and malaria – the World Health Organization’s three priority diseases. Much of this research is conducted through public private partnerships
- Preferential pricing; specially reduced prices for anti-retrovirals (ARVs), anti-malarials and vaccines. In 2006, we shipped more than 86 million Combivir and Epivir tablets at not-for-profit prices for the treatment of HIV/AIDS to the poorest countries of the world
- Seeking innovative partnerships; GSK has granted eight voluntary licences for the manufacture and supply of generic versions of our leading ARVs for treating HIV/AIDS in Africa, and is active in other partnerships such as Roll Back Malaria and Stop TB
- Community investment in public health initiatives and partnerships that foster effective healthcare including major programmes to tackle lymphatic filariasis, malaria, HIV/AIDS and diarrhoeal disease. See community investment.

Research and development

The research and development (R&D) of new drugs and vaccines is an essential element in improving health in the developing world. There are still no effective treatments for some widespread and life-threatening diseases. Many existing treatments for diseases such as malaria are becoming less effective due to drug resistance.
For HIV/AIDS which affects both developed and developing countries, there is a commercial market for new treatments. This encourages investment into the required R&D. GSK is an industry leader in research into HIV/AIDS treatment and prevention.

However, for many diseases that disproportionately affect the developing world, the lack of resources for healthcare means there is often no viable commercial market for new treatments. Public private partnerships (PPPs) are helping to address this problem.

GSK collaborates with several PPPs including the Medicines for Malaria Venture (MMV), the Global Alliance for TB Drug Development (TB Alliance), the Aeras Global TB Vaccine Foundation (Aeras), the Alliance for TB Drug Development (TB Alliance), the Medicines for Malaria Venture (MMV), the Global AIDS Vaccine Initiative (IAVI).

GSK has created a dedicated group in our pharmaceutical R&D organisation to focus on diseases of the developing world (DDW). This includes a DDW drug discovery centre at our Tres Cantos R&D site in Spain where over 100 scientists are based, and clinical development experts in the UK and US. DDW projects are prioritised according to their social and public health benefits rather than their commercial returns. A similar group exists in our vaccines organisation based in Belgium.

In total GSK is conducting R&D into 11 diseases of particular relevance to developing world — new treatments are urgently needed. Seven of these projects are for diseases that disproportionately affect developing countries. Some of these are summarised below.

1 HIV/AIDS, malaria, leishmaniasis, dengue fever, hepatitis C, hepatitis E, N. meningitis, cervical cancer, TB, chlamydia and pneumococcal disease

### Development pipeline at end of 2006 for diseases relevant to the developing world*

<table>
<thead>
<tr>
<th>Focus</th>
<th>Pre-clinical activity</th>
<th>Phase I</th>
<th>Phase II</th>
<th>Phase III</th>
<th>Marketed</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV</td>
<td>HIV-1 entry inhibitor</td>
<td>NNRTI</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>integrate inhibitor</td>
<td></td>
<td>Retrovir, Epivir, Combivir, Zidovudine (AZT), Truvir, Agenerase, Kivexa, Telzir</td>
</tr>
<tr>
<td>Vaccines</td>
<td>Malaria (P. vivax)</td>
<td>HIV (DNA-antiviral vaccine)</td>
<td>Malaria (P. falciparum)</td>
<td>Synflorix (pneumococcal disease)</td>
<td>Rotarix – (rotavirus)</td>
</tr>
<tr>
<td></td>
<td>HIV</td>
<td>TB</td>
<td>Tuberculosis (TB)</td>
<td>Cervarix (Cervical cancer)</td>
<td>Havrix – (Hepatitis A)</td>
</tr>
<tr>
<td></td>
<td>Chlamydia</td>
<td>Hepatitis E</td>
<td>Dengue Fever</td>
<td>N.meningitis combinations</td>
<td>Engerix-B – (Hepatitis B)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Tasvirix – (Hep A&amp;B)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Infanrix/Trinrix – DPT family</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(Diptheria, Tetanus, Pertussis)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Boostrix – (DTP acellular)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Polio Sabin – (Polio)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Priorix – (Mumps, Mumps and Rubella)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Typhrix – (Typhoid)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Hibrix – (Haemophilus influenzae type b)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Mencevax ACW – (meningitis)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Malaria</th>
<th>✓</th>
<th>tefenoquine</th>
<th>CDA</th>
<th>Lapdap, Halfan, Malarone</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>TB</th>
<th>✓</th>
<th>sitamaquine (visceral leishmaniasis)</th>
<th>Zentel (de-worming agent)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Other</td>
<td>✓</td>
<td>Hepatitis C</td>
<td>Penstotan (visceral leishmaniasis)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Banocide (lymphatic filariasis – GSK India)</td>
</tr>
</tbody>
</table>

* more detailed information on our product pipeline can be found in the Annual Report

---

**Access to healthcare – whose responsibility?**

Access to healthcare in the developing world remains a complex issue. We believe that only a holistic approach embracing prevention and treatment will work. All stakeholders have a role to play.

Pharmaceutical companies must make their medicines affordable to developing countries and invest in research into diseases of the developing world – new treatments are urgently needed.

Wealthy nations must give more. Welcome new funding is coming through from the Global Fund to Fight AIDS, TB and Malaria, the Gates Foundation, PEPFAR (The US President’s Emergency Plan for AIDS Relief) and others – but funds are still inadequate. Resources are needed to fund research, purchase medicines and to discourage the export of trained healthcare workers from developing countries.

Developing countries must show genuine political commitment to addressing stigma, removing import tariffs and prioritising healthcare in national budgets.

Middle-income countries must accept their responsibilities and not seek the lowest prices offered to the world’s poorest countries.

We have developed a **Seven Point Plan** for a sustainable approach to improving healthcare in the developing world, which we use in our advocacy efforts. In 2006 these included:

- Submissions to the UK Department for International Development’s (DfID) consultations on its White Paper ‘Eliminating world poverty: Making governance work for the poor’, and also to health strategy
- Submissions to the G8 governments ahead of the St Petersburg summit
- Face-to-face meetings with Hilary Benn, UK International Development Secretary, UN Secretary General Kofi Annan, UK Government officials, White House officials, EU officials and NGO representatives
- Interactions with UNAIDS, UNITAID (the new international drug purchase facility) and the World Health Organization
What’s different about R&D for medicines for the developing world?
GSK scientists working on treatment projects for diseases disproportionately affecting developing countries make access to medicines a priority right from the start of the R&D process.

When researching new treatments we produce a Target Product Profile (TPP) – outlining the characteristics we are looking for in any new molecule. As well as safety and efficacy, a TPP for a new DOW treatment emphasises factors such as:

• Heat and humidity resistance – the product must be able to survive in a hot climate where there may not be refrigeration facilities
• Ease of use – it must be easy to use in settings where there are limited healthcare facilities. For example once-a-day tablets that can be taken at home are preferable to an injectable medicine that must be administered in a hospital or clinic
• Affordability – price is one of the most important factors. We look for molecules and formulations that are straightforward to manufacture and therefore inexpensive to produce

PROGRESS IN 2006

Malaria Vaccines
GSK has been working on a malaria vaccine for over 20 years. In 2005 clinical trials of our malaria vaccine for children showed that the vaccine remained efficacious over 18 months in reducing severe malaria by 49 percent in children. Several more years of clinical investigation are needed but these results indicate it has the potential to help save millions of children’s lives. In 2006 additional phase II clinical trials of the vaccine were initiated in Mozambique, Kenya, Tanzania, Gabon and Ghana. These are supported by a grant from the Malaria Vaccine Initiative at PATH funded by the Bill & Melinda Gates Foundation, and will further evaluate the vaccine in different settings and with younger children. If these trials are successful, the partners will initiate a large-scale phase III clinical trial. If the results continue to be positive the vaccine could be submitted for regulatory approval as early as 2010.

Treatments
We are working closely with the Medicines for Malaria Venture, which subsidises 30 scientists at our Tres Cantos facility, the World Health Organization (WHO) and academic partners to develop CDA, an affordable fixed-dose artemisinin combination treatment for drug-resistant malaria in Africa. In 2006 phase III clinical trials were initiated at several sites across Africa. An additional phase III study is planned for 2007 involving infants between the ages of three months and one year. We aim to submit CDA for regulatory approval in early 2008.

In March 2006, we identified a lead candidate (GW308678) to take forward into development from our pyridones project, along with a backup candidate (GW308121). These drugs have the potential to be highly active against drug-resistant strains of malaria and show none of the toxicity issues that affected a previous candidate in this class.

Significant chemical and pharmaceutical development was undertaken on the anti-malarial drug GSK369796 (n-tert butyl isoquine) and we plan to start clinical studies in humans when partner funding becomes available. The drug is relatively straightforward to synthesise and manufacture, and therefore has the potential to be relatively inexpensive.

Clinical data for tafenoquine, a new antimalarial being developed in partnership with the US Military, have shown that a tafenoquine-containing combination regimen may work faster than existing therapies in the treatment of P. vivax malaria and may also help to address concerns about emerging resistance to existing treatments. We are in discussions regarding the funding of additional development work for the treatment of P. vivax malaria and we plan to proceed with clinical development in 2007.

HIV/AIDS Vaccines
GSK is a leader in the global effort to develop an AIDS vaccine. We have been involved in AIDS vaccine research for more than two decades and today we are pursuing four separate vaccine technologies. A successful AIDS vaccine might need to combine several of these approaches.

GSK and the Institut Pasteur are working together to develop an AIDS vaccine by fusing genes from the HIV virus onto an existing measles vaccine. The project is being supported by a Euro 5.5 million (£3.7 million) grant from the European Union.

We are part of a public private partnership with the International AIDS Vaccine Initiative (IAVI) to develop an AIDS vaccine using nonhuman primate adenovirus vector technology. The collaboration – the first ever in AIDS vaccine research between IAVI and a major vaccine company – will facilitate research into vaccines against types of HIV that circulate predominantly in Africa.

GSK Biologicals also has an in-house AIDS vaccine development project using the company’s proprietary adjuvant system technology. Two phase I clinical trials have been conducted with this vaccine, in the United States in partnership with the US National Institutes of Health’s HIV Vaccine Trials Network, and the other in Belgium at Ghent University. These trials, completed in 2003 and 2005 respectively, demonstrated that the vaccine is safe and produces a strong immune response. A third phase I trial in 20 HIV-infected volunteers was initiated in late 2005 in collaboration with the Partners AIDS Research Center at Massachusetts General Hospital in Boston, and the results are currently being analysed. A follow-up approach explores a similar strategy using a new antigen named F4. A phase I clinical trial of the F4 vaccine candidate is scheduled to begin in the near future in Belgium.

Our fourth approach aims to develop an improved adjuvanted envelope (Env) protein vaccine able to produce neutralising antibodies that will provide lasting protection against infection with HIV. This approach is currently under preclinical evaluation.

Treatments
In December 2006 we discontinued the clinical development of brencanavir, our protease inhibitor for patients with multi-drug resistant HIV infection. We were unable to develop an oral dosage formulation that could consistently deliver the correct dosage of brencanavir to the patient.

Our scientists are working on new HIV medicines in several different drug classes. Our integrase inhibitor discovery programme is very active and the lead candidate 364735C, which is being developed in partnership with Shionogi, is currently in phase II development. New HIV-1 entry inhibitor and non-nucleoside reverse transcriptase inhibitor (NNRTI) candidates are entering the pipeline.
Experts at WHO and UNICEF have stated that access to appropriate ARV tablets (as opposed to ARV liquid formulations) would facilitate the treatment of children old enough to be able to swallow tablets. We are developing scored tablets for our key ARVs (Epivir, Ziagen, and Combivir) so they can be broken into two smaller doses suitable for the treatment of children. This will simplify treatment and help physicians and carers administer the right dose efficiently and safely to children. We expect to submit the scored tablets for registration in 2007.

We want to continue to play an important role in the treatment of HIV in children and we support four paediatric clinical studies involving 2,400 children in five resource-poor countries.

We provide ARVs through our international HIV Collaborative Research Trial programme to support clinical studies run by third parties. We are currently supporting 21 clinical studies involving 19,500 patients, of which 16 studies are taking place in sub-Saharan Africa. These include eight studies on prevention of mother-to-child transmission, one on prophylactic properties, the four studies on children mentioned above, four on HIV-TB co-infection, and four on adult treatment strategies. These studies are intended to advance knowledge about the use of ARVs in resource-poor settings and also help to increase access to ARVs.

**Tuberculosis (TB)**

TB kills two million people a year and is a leading cause of death among people with AIDS in the developing world. But no new drugs against TB have been discovered in more than 40 years.

**Vaccines**

GSK and the Aeras Global TB Vaccine Foundation are developing GSK’s TB candidate vaccine. Early-stage clinical trials in the US and Belgium showed that the vaccine is safe and well-tolerated and produces a strong immune response. In 2006 we began additional trials involving adults previously infected with TB or vaccinated with Bacillus Calmette-Guérin (BCG). We plan to conduct further studies in Africa and other locations to test the safety and efficacy of the vaccine candidate in populations highly affected by TB.

**Treatments**

In 2005 we launched a joint drug discovery partnership with the Global Alliance for TB Drug Development (TB Alliance). The TB Alliance aims to accelerate the development of affordable drugs that will shorten treatment and be effective against multi-drug-resistant strains of TB. All compounds will be screened to ensure they can be taken with HIV treatments. The TB Alliance is supporting 25 full-time scientists working exclusively on the TB drug programme at Tres Cantos. GSK is contributing a matching number of staff and all remaining overhead costs. Around 1.5 million compounds have now been tested for anti-TB activity and we have four pre-clinical TB projects underway.

In partnership with Stellenbosch University in South Africa, GSK is supporting grant applications to fund a programme to identify “biomarkers” in people who may respond to specific treatments. Such biomarkers can be used to predict whether or not patients will respond quickly to treatment or if TB is likely to recur.

**Rotavirus**

Rotavirus infection is the leading cause of severe diarrhoea and vomiting (gastroenteritis) in children under two and kills around 600,000 children each year – one child every minute – mostly in developing countries. Our vaccine, Rotarix, for the prevention of rotavirus induced gastroenteritis, was launched in Mexico in January 2005 and has now been approved in 89 countries and is being registered in a further 26. Most registrations have been in the developing world. The vaccine is now part of national immunisation programmes for all newborn babies in eight developing countries including Brazil, El Salvador, Mexico, Panama and Venezuela. We have distributed 12.5 million doses since launch. Early in 2007, GSK received prequalification status for its rotavirus vaccine from the World Health Organization (WHO). This is required before UN organisations and GAVI (formerly known as the Global Alliance for Vaccines and Immunisation) can purchase a vaccine. This was timely as it complemented the decision by GAVI in late 2006 to provide funding to support the introduction of rotavirus vaccines in developing countries.

**Cervical cancer**

Cervical cancer is the most common cause of cancer deaths in women in the developing world. Current published data suggest that our Cervarix vaccine could reduce by 70 percent a woman’s lifetime risk of developing cervical cancer. We applied for registration of the vaccine in Europe as well as 28 countries in our International region during 2006. We are on track to file for regulatory approval in the US by April 2007. We are committed to making Cervarix widely available, and will make it available to low-income countries at preferential prices through GSK’s tiered pricing model for vaccines.

We are conducting clinical studies on the use of the vaccine in low income settings.

**Leishmaniasis**

Sitamaquine is our potential new once-a-day oral treatment for visceral leishmaniasis. This disease affects half a million people a year in the developing world and is usually fatal if untreated. GSK is providing all the funding for this project. A new treatment for visceral leishmaniasis is urgently needed, since current medicines are either impractical or becoming ineffective due to drug resistance or are simply unaffordable. Sitamaquine has shown good efficacy in phase II trials. The trials also suggest that a shorter treatment period can be achieved – perhaps up to half of the four weeks needed for current treatments. The low cost suggests that sitamaquine could be the first truly accessible treatment for visceral leishmaniasis which affects the poorest of the poor.
Public private partnerships (PPPs)

What is a PPP?

In a PPP, companies such as GSK provide the R&D, technology, manufacturing and distribution expertise. Academic institutions may also provide research and disease area knowledge. Public sector partners, governments, or organisations such as the Gates Foundation, help fund the development and delivery costs and ensure that medicines get to the people who need them. Funds are usually channelled through organisations such as the Medicines for Malaria Venture.

Why are PPPs needed?

GSK wants to invest in research to tackle diseases that blight the developing world. However, there is a dilemma. We must be profitable to sustain our business and to continue to develop new medicines. This business model does not work in cases where there is no prospect of a commercial return.

Unfortunately, lack of resources means there is limited market for new treatments for diseases that disproportionately affect developing countries. The PPP model, in which business and the public sector work together, offers a solution.

How does the partnership work in practice?

Drug discovery takes place at our dedicated diseases of the developing world Discovery Centre at Tres Cantos. GSK provides the facilities and meets all the running costs. There are over 100 GSK scientists at Tres Cantos, half of whom are subsidised by our partner organisations – the Medicines for Malaria Venture (MMV) and the Global Alliance for TB Drug Development (TB Alliance).

As compounds move into clinical development, GSK provides the clinical, regulatory and manufacturing expertise and resources through our global R&D and supply network. Partners help fund the cost of running clinical trials and address issues of access and distribution. This reduces the costs of development and gets new products to patients faster. Research programmes are overseen by joint steering committees with representatives from GSK and our partners.

Does this affect the price of new treatments?

Importantly, under the terms of our agreement, we are committed to make any new treatments resulting from PPPs accessible to the developing world at affordable prices.

PREFERENTIAL PRICING

Poverty, lack of political will and insufficient medical infrastructure (hospitals, clinics and health workers) are the biggest barriers to accessing healthcare in developing countries.

The affordability of medicines is also important and there are two elements to this:

- The ability of governments or patients to pay for medicines. Governments and inter-governmental agencies must make significant additional financial resources available to solve this problem.
- The price at which medicines are sold – an area GSK can help to address.

We are making ARVs and anti-malarials available to developing countries at more affordable prices. This is a major commitment that we call ‘preferential pricing’. It includes not-for-profit (nfp) prices for the world’s poorest countries, and discounted prices for wealthier developing and middle-income countries, see page 23.

Other factors in the supply chain such as taxes, tariffs and distributor mark-ups can significantly increase the price of medicines. These factors are out of our control and should be addressed by governments.

For middle-income developing countries we continue to negotiate public sector prices on a case-by-case basis to improve affordability, see page 23.

GSK vaccines are also available at preferential prices. We use a tiered pricing structure for vaccines – prices for the developing world can be as little as a tenth of those for developed countries. We work with multinational organisations such as UNICEF, the World Health Organization and the Pan American Health Organisation, governments and non-governmental organisations, to provide low-cost and affordable vaccines for developing countries. This includes basic polo vaccines as well as specially developed combination vaccines that target several diseases. In 2006, of the 1.1 billion vaccines we shipped, around 75 percent went to the developing world. This is lower than in previous years due to the timing of some significant tenders.

Progress in 2006

We shipped 27 million tablets of nfp Combivir and 59 million tablets of nfp Epivir to the developing world compared with 45 million and 81 million tablets respectively in 2004 and 2005.

This decrease was expected and is primarily due to more customers purchasing ARVs from generic manufacturers including those licensed by GSK. This is a positive indication that our licensing policy is working.

In the last year generic manufacturers licensed by GSK have significantly increased their manufacturing capacity and ability to supply larger quantities of ARVs at lower prices. We welcome this trend as it gives customers in sub-Saharan Africa greater choice and contributes to better security of supply. In 2006 our licensees supplied over 120 million tablets of their versions of Epivir and Combivir to Africa.

We will continue to look for new customers for our nfp ARVs in these countries and to regularly review our nfp prices. However, it may well be that our licensees are able to produce first-line ARVs at lower costs and will increase their share of the business.

A massive scale-up in treatment for HIV/AIDS is planned by the global community in the next five years. We are negotiating agreements with contract manufacturers to ensure we have the capacity to contribute to meeting this demand.

The WHO published new treatment guidelines for patients with HIV. Our ARV abacavir is now recommended as a first-line treatment option. In May we reduced the nfp price of abacavir-containing ARVs by 30 percent and made our two new ARVs — Kivexa and Telzir — available at nfp prices.

There have been concerns that pharmaceutical companies are not doing enough to register essential medicines in developing countries and that this prevents these countries from taking advantage of preferential pricing offers. We continue to review the registration needs for our key ARVs in our 64 target developing countries to ensure that Epivir, Retrovir and Combivir are available as widely as necessary and possible.

A current focus is to also make abacavir and abacavir-containing ARVs available in these locations. We will prioritise our efforts where there is the greatest medical need – in particular the 15 PEPFAR countries and other developing countries with a significant HIV burden where high-quality alternatives to abacavir are not available.

Product diversion, where not-for-profit medicines are illegally shipped back for sale in wealthier countries, denies treatment to patients in poorer countries. Our anti-diversion measures include access packs (such as red rather than white tablets) for Combivir, Epivir tablets, Epivir solution, Trizivir and Retrovir solution which are now registered in more than 50 countries. GSK was the first company to receive a Positive Opinion (for Epivir and Combivir red coloured tablets) from the European Medicines Evaluation Agency (EMEA) via the Article 58 regulatory procedure for medicines intended for use outside of the EU. This should serve to speed up registration of red coloured tablets in developing countries.

Corporate Responsibility Report of 2006

GSK Corporate Responsibility Report 2006

22
A report from the UN-led Accelerating Access Initiative (AAI), suggests that by September 2006 more than 738,000 people living with HIV/AIDS in developing countries were receiving treatment with at least one ARV supplied by the seven pharmaceutical companies in the AAI (compared with 221,000 people on treatment in 2004). This includes 424,000 patients in Africa.

**Extending preferential pricing**

We are considering extending our preferential prices in Africa to a wider range of products. However, a number of commercial factors and the overall market environment must be considered. The findings from our five country pilot study are informing this evaluation.

**VOLUNTARY LICENSING AND PARTNERSHIPS**

GSK wants to play its part in the global response to the HIV/AIDS pandemic. Our preferential pricing arrangements enable us to supply highly discounted, safe and quality products for as long as they are needed. In some situations voluntary licences also help to increase the supply of medicines.

Voluntary licences (VL) enable local manufacturers to produce and sell generic versions of our products. We granted our first VL in 2001 and have now negotiated eight licensing agreements for our ARVs in Africa. This includes a new licence agreed in 2006 with a South Africa company. Some of our VLs cover individual countries or trade blocks whilst others cover all of sub-Saharan Africa. VLs are not a universal solution to HIV/AIDS but a specific response to a particular set of circumstances.

A decision to grant a VL depends on a number of factors including the severity of the HIV/AIDS epidemic in that country, local healthcare provision and the economic and manufacturing environment. Selecting the most appropriate licensee is key. We need to be sure that the manufacturer will be able to provide a long-term supply of good quality medicines and will implement safeguards to prevent the diversion of medicines to wealthier markets.

There has been much discussion about the use of compulsory licences, under which intellectual property rights are taken away from rights holders. Compulsory licenses are one of the flexibilities in the World Trade Organisation’s TRIPs agreement on intellectual property. GSK believes that widespread use of compulsory licences will undermine the intellectual property framework and be counter-productive in the long term. R&D into new treatments, especially where commercial markets exist, such as for HIV/AIDS, depends on protection for intellectual property.

**MIDDLE-INCOME COUNTRIES**

Middle-income countries are more economically developed but often have healthcare demands that outstrip their available resources. These challenges are made worse by a growing AIDS epidemic in many middle-income countries.

We can only afford to supply products at low prices in the world’s poorest countries if we can still make an adequate return on them in wealthier markets. Nevertheless, we recognise that many middle-income countries need assistance.

We negotiate preferential pricing arrangements with middle-income countries on a case-by-case basis. This is done bilaterally through dialogue with governments. We believe this is the best approach since the disease burden, and resources available to address it, vary significantly from country to country and also within countries. These arrangements combine a viable and sustainable commercial return for GSK with improved affordability for the healthcare systems concerned.

For several more developed countries we are also introducing discount cards for senior citizens, see developed world.

**Activity in 2006**

**Russia**

We announced an agreement to supply ARVs to the Russian Government at discounted prices. This is the first direct, federal purchase of anti-retroviral medicines in Russia. During 2006 GSK supplied over 90,000 treatment packs to the Russian Government of its HIV medicines, Combivir, Epivir and Ziagen which were dispensed by hospital centres across the country. This agreement will contribute to the Russian Government’s target of reaching 15,000 patients by the end of 2006. This target has been doubled to 30,000 in 2007.

**China**

In September 2006, we signed a voluntary licence with Simcere, a Chinese manufacturer, granting them the right to manufacture and sell zanamivir (Relenza) containing products in China, Indonesia, Thailand, Vietnam and all LDCs. Relenza is an anti-viral which can help treat influenza. More than half of all human cases of flu caused by the H5N1 virus have occurred in the Asia-Pacific region.
Commitment to Access

DEVELOPED WORLD

Access to medicines is not just an issue for the developing world. Even in developed countries some patients cannot afford the medicines they need. This is a particular problem in the US where many people do not have health insurance. GSK has developed Patient Assistance Programs and a discount savings card in the US to help patients without insurance.

We are also introducing discount savings cards in several middle-income countries to enable qualifying patients to obtain prescription medicines at a discount price.

Programmes in the US

Patient Assistance Programs provide prescription medicines to low-income, uninsured patients free or at minimal cost. GSK operates several programmes, including Commitment to Access which covers cancer treatments and Bridges to Access which covers other medicines for outpatients. Patients are registered through one phone call from a patient advocate and receive medicine at participating pharmacies. A hotline number has been set up to help patients find their nearest pharmacy. In 2006, 200 pharmacies (20 percent of the pharmacies in Lithuania) are registered to participate. In 2006, 202,000 patients received GSK medicines worth $370 million through these programmes, compared with $464 million in 2005. The value of the medicines is calculated using the wholesale acquisition cost (WAC).

GSK believes that the intellectual property protection provisions set out in TRIPS are vital to the development of medicines to meet unmet medical needs around the world. A robust IP system is essential to encourage research-based companies to undertake risky and hugely expensive R&D to discover new and better medicines and vaccines. Most of the generic medicines already on the market in India will not be affected by the introduction of patent protection. They will continue to be available in India and elsewhere in the same way as they are today. We also believe that the public health safeguards in the TRIPS agreement will prevent access problems in the future.

The root cause of developing countries’ inability to address their healthcare problems does not lie with the patenting system but with a lack of funding, a lack of political will and inadequate healthcare infrastructure. None of these factors is affected by intellectual property rights or by full implementation of TRIPS in India or elsewhere.

INTELLECTUAL PROPERTY RIGHTS IN INDIA

India has developed a large generics industry partly as a result of national legislation that did not permit patent protection for pharmaceutical products. In 2005, to comply with the WTO Trade Related Aspects of Intellectual Property Rights (TRIPs) agreement, India introduced legislation that allowed for the patenting of pharmaceutical products. In the context of the access to medicines debate, some argue that this obligation on India will result in an end to the provision of cheap generics and undermine the future availability of affordable innovative products.

This is a significant reduction from last year and reflects the introduction of a new drug benefit as part of the US Medicare programme – known as Medicare Part D. Prior to this, Medicare patients did not have prescription coverage for most medicines. Once a patient had enrolled in a Medicare Part D Plan, they became ineligible for our existing patient assistance programmes (Bridge to Access and Commitment to Access). However we still recognise that, even with this drug coverage, these patients may still need assistance. A new programme GSK Access provides the extra help some low income senior and disabled Medicare Part D patients need in getting their medicines. This programme allows those who spend $600 out of pocket in 2007 for prescription medicines, and whose incomes are between 135 percent to 250 percent, (up to 350 percent for Oncology products) of the Federal Poverty Level to apply and if eligible obtain GSK medicine for free for the remainder of 2007. See www.gsk-access.com for more information. We expect this new programme to increase the number of patients in our assistance programmes during 2007.

In January 2005, GSK and nine other pharmaceutical companies created a discount savings programme to improve access to medicines for uninsured Americans who are not eligible for Medicare. The Together Rx Access card provides savings of 25-40 percent on more than 300 medicines. Approximately 37 million people, around 80 percent of the people in the US without prescription insurance, are eligible to enroll. The participating companies enrolled 469,888 people in 2006, who received 1.6 million 30-day prescriptions saving $24million (based on WAC). Of these, GSK provided discounts of $3.1 million to 98,955 patients through 31,737 30-day prescriptions.

Orange Cards in middle income countries

Our Orange Card in the Ukraine gives all asthma and chronic obstructive pulmonary disease patients who are under 25 or over 50, an average discount of 19 percent on the most popular presentations of GSK’s Seretide asthma medicine. Asthma patients of any age who suffer disabilities or who are affected by the Chernobyl nuclear disaster are also eligible. Eligibility is assessed by the patient’s doctor and patients can receive the medicine at participating pharmacies. A hotline number has been set up to help patients find their nearest pharmacy. In 2006 Orange Card discounts totalled $119,722 (£65,000).

In Lithuania, our Orange Card gives senior citizens and the disabled an average discount of 40 percent on the patient co-payment on all GSK prescription medicines. So far more than 25,000 patients have applied for an Orange Card and over 200 pharmacies (20 percent of the pharmacies in Lithuania) are registered to participate. In 2006, 25,000 patients received discounts worth £150,000.
GSK’s Orange Card in Bulgaria provides low-income patients with a discount on GSK medicines to treat chronic diseases such as asthma, chronic obstructive pulmonary disease and diabetes. We broadened the scope of our Orange Card in 2006 in response to changes in the Bulgarian reimbursement system which meant that 50,000 patients with chronic diseases could no longer access state assistance for their currently prescribed medicines. The Orange Card provides direct benefits (in the form of subsidy) to patients suffering from three important chronic diseases in Bulgaria – asthma, diabetes and benign prostate hyperplasia. The 2006 GSK investment in the Orange Card in Bulgaria is now Euro 4.5 million (£3.1 million).

<table>
<thead>
<tr>
<th>Country</th>
<th>GSK programme</th>
<th>Number of patients</th>
<th>Value of benefit to patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>US</td>
<td>Patient Assistance Programs – Free or minimal cost medicines for low-income, uninsured patients</td>
<td>402,000 received prescriptions</td>
<td>$370 million (£200 million)</td>
</tr>
<tr>
<td>US</td>
<td>Together Rx Access – Discounts for all low-income uninsured patients. Joint industry programme</td>
<td>98,955 received prescriptions</td>
<td>$3.1 million (£1.6 million)</td>
</tr>
<tr>
<td>Bulgaria</td>
<td>Orange Card – Discounts for low-income patients with chronic diseases</td>
<td>50,000 approx</td>
<td>Euro 4.5 million (£3.1 million)</td>
</tr>
<tr>
<td>Lithuania</td>
<td>Orange Card – Discounts for senior citizens and disabled people</td>
<td>25,000</td>
<td>£150,000</td>
</tr>
<tr>
<td>Ukraine</td>
<td>Orange Card – Discounts on asthma and COPD medicine for patients under 25 or over 50</td>
<td>not available</td>
<td>$120,000 (£65,000)</td>
</tr>
</tbody>
</table>
New medicines and vaccines have brought huge benefits to the health and quality of life of millions of people over the last 100 years. But continued R&D remains as important as ever. There are still many serious, debilitating and life-threatening illnesses for which there are no effective treatments or where treatments could be significantly improved.

Our goal is to build the best product pipeline in the industry. In 2006 we invested £3.5 billion ($6.4 billion) and employed over 15,000 people in R&D.

Our research aims to address unmet medical needs. Our pipeline includes compounds with the potential to make a major contribution to healthcare in developing countries, see Access to medicines. Throughout the R&D process we seek the views of patients to inform our research. Focusing on patient needs drives innovation which brings commercial success.

We recognise that biomedical and pharmaceutical research raises ethical concerns – from the use of new technologies to the objective reporting of clinical trial results. We are committed to attaining high ethical and scientific standards in all our R&D work. This section explains our approach to:

• Animal research, and our efforts to reduce, refine and replace animal testing
• The conduct of clinical trials. How we ensure GSK sponsored clinical trials are carried out to the same high ethical standards irrespective of where they are conducted
• Training and auditing for clinical trials. How we train GSK employees involved in clinical trials and how we check that trials are carried out to Good Clinical Practice (GCP) standards
• Clinical trial information and results. How we publicly disclose trial information and results through journal articles, the GSK Clinical Trial Register and other public databases
• Patient safety. How we monitor the safety of our medicines

Background information on our approach to new technologies, including pharmacogenetic research and the use of transgenic animals, is available on our website.

ANIMAL RESEARCH

Animal research and testing is an essential component of understanding disease and evaluating safety and effectiveness of new vaccines and prescription and over-the-counter medicines.

Safety regulations require us to test all new medicines on animals before they are tested in clinical trials using humans. Most vaccines have to be tested on animals each time a new batch is produced.

GSK has 17 animal research laboratories in Europe, Asia and the US. Some animal research is conducted by external contractors on our behalf. This represents an additional 9 percent of animals. We estimate that animal research accounts for around 5 percent of all GSK research expenditure.

Around 99 percent of the animals used by GSK are rodents (such as rats, mice, guinea pigs) and rabbits. The remaining 1 percent includes fish, ferrets, pigs, dogs, cats and primates.

<table>
<thead>
<tr>
<th>Animals used by GSK in 2006</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>mouse</td>
<td>67.7</td>
</tr>
<tr>
<td>rat</td>
<td>25.0</td>
</tr>
<tr>
<td>guinea pig</td>
<td>5.2</td>
</tr>
<tr>
<td>other rodent</td>
<td>0.1</td>
</tr>
<tr>
<td>rabbit</td>
<td>0.8</td>
</tr>
<tr>
<td>other</td>
<td>1.2</td>
</tr>
</tbody>
</table>

Ultimately GSK would like to see the important benefits of research being achieved without the use of experimentation which has the potential to cause pain or distress to animals. We do not believe this can be achieved in the foreseeable future, therefore GSK is committed to the 3Rs – reduction, refinement and replacement of animals in research and to achieving high standards of animal welfare. Our goal is to use animals only when scientifically necessary, use as few as scientifically feasible and to minimise pain and distress.

This approach continues to have an impact. In 2006 there was a small increase in the absolute numbers of animals used from a baseline in 1994, however the growth in R&D activity continues to greatly exceed any increase in animal use.

1 We started estimating our external animal use in 2002, and to 2006 have recorded external animal use as representing 3.3%, 4.5%, 7.1%, 6.7%, 8.9% of the total animal use in our own laboratories. This change may both represent a rise but also improvement in reporting of data from our diverse external collaborations.

2 We use 1994 as a baseline for comparison as this was the first year we were able to collect reliable data. The increased use in 2006 was due to more mice being used, especially for vaccines testing.
Change in R&D activity compared to change in number of animals used in GSK research laboratories*

*These data do not include animal research conducted by external contractors on our behalf. R&D activity combines our R&D budget and our vaccine sales, the two main drivers of animal use. Vaccine sales are included since most vaccines have to be tested on animals each time a new batch is produced.

<table>
<thead>
<tr>
<th>Year</th>
<th>Animals used</th>
<th>R&amp;D activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>1994</td>
<td>100.0%</td>
<td>100.0%</td>
</tr>
<tr>
<td>1995</td>
<td>85.9%</td>
<td>120.4%</td>
</tr>
<tr>
<td>1996</td>
<td>83.1%</td>
<td>128.8%</td>
</tr>
<tr>
<td>1997</td>
<td>86.5%</td>
<td>135.2%</td>
</tr>
<tr>
<td>1998</td>
<td>95.5%</td>
<td>140.7%</td>
</tr>
<tr>
<td>1999</td>
<td>92.5%</td>
<td>154.0%</td>
</tr>
<tr>
<td>2000</td>
<td>92.8%</td>
<td>168.6%</td>
</tr>
<tr>
<td>2001</td>
<td>92.4%</td>
<td>176.2%</td>
</tr>
<tr>
<td>2002</td>
<td>103.3%</td>
<td>191.8%</td>
</tr>
<tr>
<td>2003</td>
<td>105.0%</td>
<td>195.8%</td>
</tr>
<tr>
<td>2004</td>
<td>103.9%</td>
<td>203.0%</td>
</tr>
<tr>
<td>2005</td>
<td>102.3%</td>
<td>227.6%</td>
</tr>
<tr>
<td>2006</td>
<td>109.8%</td>
<td>259.0%</td>
</tr>
</tbody>
</table>
Implementing the 3Rs commits us to:

- replacing animal studies with alternative methods wherever possible
- reducing the number of animals used in each study
- refining studies to minimise pain and maximise the information obtained from each animal

For example, we are currently replacing the use of primates with mice in vaccine batch testing. Beyond this we are looking at ways to use the advances in quality control processes for vaccine production to change testing requirements so that eventually it will not be necessary to test each batch of vaccines on animals.

Training and awareness

We provide training on the 3Rs to all staff who are involved in the care and use of animals and publish quarterly news bulletins on the 3Rs to raise awareness.

Our ethical review committees of GSK scientists, statisticians, senior managers, animal technicians and veterinarians encourages a 3Rs culture at GSK through seminars and ‘Recommended Practice’ guidelines for scientific procedures and animal welfare.

In 2006 we closed a laboratory in Japan, acquired laboratories in Croatia and Canada, and established GSK-managed laboratories in Singapore and the US, giving a current total of 17 GSK laboratories where we use animals.

1 In 2006 we closed a laboratory in Japan, acquired laboratories in Croatia and Canada, and established GSK-managed laboratories in Singapore and the US, giving a current total of 17 GSK laboratories where we use animals.
CONDUCT OF CLINICAL TRIALS
The safety and effectiveness of new medicines and vaccines must be evaluated in human clinical trials before they can be approved for marketing. Regulators will only give approval if trials demonstrate that a product is safe and effective and that its benefits outweigh any risks from potential side effects.

A new product will typically be tested through three stages of clinical trials. These involve both healthy individuals and patients with the relevant disease.

In 2006 there were 159 projects in clinical development.

Standards for clinical trials
All GSK clinical trials, wherever they are carried out, are conducted according to the Good Clinical Practice (GCP) guidelines developed by the International Conference on Harmonisation (ICH) and the principles contained in the World Medical Association Declaration of Helsinki on the 'Ethical Principles for Medical Research Involving Human Subjects (2004)'.

The ICH guidelines provide an internationally accepted ethical and scientific quality standard for designing, conducting, recording and reporting trials. They cover issues such as the selection and training of trial investigators, gaining informed consent from trial participants, monitoring and quality assurance.

Trial protocols (the plan for how a clinical trial will be conducted) are reviewed by external regulatory agencies in the relevant countries when required, and all protocols are considered by the relevant ethical review committees which cover the sites where studies will take place.

An ethics review committee is composed of lay people, medical professionals and scientists. They assess whether a trial is justified and whether it is designed and will be conducted according to appropriate ethical standards. Ethics committees have the power to reject or stop a clinical trial.

Safety data are routinely collected throughout development programmes and are reported to regulators in line with applicable regulations. Data are also reviewed by GSK on an ongoing basis for any safety signals (events not necessarily caused by the treatment that require further exploration). GSK has a Global Safety Board (GSB) led by the Chief Medical Officer and composed of senior physicians and scientists. The GSB oversees the safety of all investigational and marketed compounds, approving the administration of investigational compounds to humans and defining the doses and duration of treatment that are considered safe. The GSK Global Safety Board is responsible both for approval of pivotal protocols (pivotal trials are those whose results provide the primary data on which regulatory approval is based) and internal assessment of any issues related to patient safety that arise during the product development programme or when it is marketed.
We audit clinical trials to ensure they are conducted to the appropriate standards. See Training and Auditing for Clinical Trials.

**Clinical trials outside Western Europe and North America**

Most clinical trials take place in Western Europe and North America but GSK is starting to perform more trials in regions such as Central and Eastern Europe, South Africa, Latin America and parts of Asia.

We seek to conduct clinical trials where:

- The population is relevant to the scientific question and where the results can be generalised to broader populations
- There are qualified investigators capable of carrying out the research
- There are people who qualify for participation in the research
- The research can be carried out as quickly and efficiently as possible

All GSK-sponsored clinical trials are conducted to the same ethical standards irrespective of the location. All studies meet international and national regulatory and legislative requirements and are conducted in accordance with the principles of Good Clinical Practice (GCP) standards, the principles contained in the World Medical Association Declaration of Helsinki on the ‘Ethical Principles for Medical Research Involving Human Subjects’ (2004) and GSK’s own policies.

GSK is committed to investing in R&D for diseases disproportionately affecting developing countries, see *Access to Medicines*. These compounds must usually be tested through clinical trials in developing countries where the disease is prevalent and the medicine is relevant for the local population.

In some of the least-developed countries additional safeguards may be needed. For example, in some cultures, while still complying with normal ethical and legal requirements, additional steps are taken to match the objectives of informed consent to local culture. So for example local leaders and/or family members may need to be involved in the consent process.

You can read our *position on clinical trials in the developing world* in the background section of our website.

**TRAINING AND AUDITING FOR CLINICAL TRIALS**

We provide training to ensure that clinical trials are performed to high ethical and quality standards. We audit the conduct of clinical trials to ensure they are carried out according to the study protocol, GSK Standard Operating Procedures (SOPs), Good Clinical Practice (GCP), current regulatory directives, laws, guidelines and the ethical considerations of the Declaration of Helsinki.

All employees involved in designing, conducting and monitoring GSK-sponsored trials are trained in GCP. Training is mandatory and employees must have completed the required training before starting or changing jobs.

In 2006 there were 14,988 training activities related to GCP. Each ‘training activity’ represents a successful completion of an e-learning module or instructor-led course related to GCP by one of our employees or contractors.

We keep detailed training records which are routinely requested by regulatory authorities when undertaking an inspection to assess the competence of employees undertaking clinical trials.

GSK’s internal audit department audits GSK systems and processes involved in the conduct of trials, as well as auditing external clinical research organisations and investigators performing clinical research on our behalf. A risk management approach is used to determine which trials are audited. Risk factors evaluated include the complexity of the study, the patient population, the location of the study, previous audit history and any unusual findings during the conduct of the study.

In 2006, 213 audits were conducted:

- 132 audits of investigator sites conducting GSK-sponsored trials. This represents approximately 5 percent of investigator sites participating in pivotal clinical trials
- 22 audits of internal GSK systems and processes used in managing clinical trials and data
- 29 audits of clinical research organisations carrying out clinical trials on GSK’s behalf
- 13 audits of GSK local operating companies, including the medical departments managing the clinical research in those countries
- 17 “For Cause” audits were conducted in response to suspected irregularities and six investigators were reported to regulatory agencies

Audit results are reported quarterly to the R&D Risk Management & Compliance Board, and annually to the GSK Audit Committee. Any concerns or issues identified during audits are fully investigated and appropriate action taken. This may include retraining or, in severe cases, dismissal for the individuals concerned as well as development of new training programmes or procedures to prevent a reoccurrence. Trial data may also be re-analysed.
Inspections of investigators, clinical research organisations, Independent Ethics Committees /Institutional Review Boards and sponsors of clinical trials are also carried out by regulatory authorities to ensure the safety of trial participants, the quality of data, and that trials are conducted according to GCP. During 2006 there were more than 30 such inspections of GSK and investigators used by GSK to conduct clinical studies.

**CLINICAL TRIAL INFORMATION AND RESULTS**

We make the results of our clinical trials widely available to healthcare practitioners and others who use or evaluate the use of our medicines. We also publicly disclose information about ongoing trials.

**Ongoing clinical trials**

Publicly available internet-based registration of ongoing clinical trials can provide a stimulus for increased participation in clinical research. It also provides an important reference point so interested parties can track the subsequent disclosure of clinical trial results.

GSK is legally required to post summary protocol information for ongoing studies of treatments for serious or life-threatening diseases conducted under a US Investigational New Drug Application on the National Institutes of Health website [www.ClinicalTrials.gov](http://www.clinicaltrials.gov).

In addition, GSK is posting protocol summaries of all clinical trials, irrespective of the countries involved, to ClinicalTrials.gov.

At the end of 2006 there were 223 protocol summaries of actively recruiting clinical trials on ClinicalTrials.gov. These meet the requirements of such postings as set out by the International Committee of Medical Journal editors. For non-phase III trials, our policy is to delay the posting on the website of certain data elements on an exceptional basis when they are competitively sensitive.

**Clinical trial results**

Pharmaceutical companies are legally required to disclose all relevant data from clinical trials to the appropriate regulatory authorities when seeking approval for a new product.

After approval, sponsors have a continuing obligation to provide regulatory authorities with updated safety information from clinical trials, see patient safety. Safety and efficacy information is provided to doctors through prescribing information which is approved by regulators.

In addition there is a need to use other ways to communicate the results of our clinical trials to healthcare practitioners and others who use or evaluate the use of our medicines.

GSK follows the PhRMA Principles on the Conduct of Clinical Trials and the Communication of Clinical Trial Results and is committed to timely communication of results for all products approved for marketing. Wherever possible we publish our trial results in peer-reviewed scientific and medical journals, or in conference abstracts and proceedings. These are used by research and healthcare communities to obtain the latest information on treatments.

GSK cannot guarantee publication by these methods since this is at the discretion of journal editors and conference organisers. For this reason, we launched the GSK online Clinical Trial Register in 2004, to supplement prescribing information and publications in the scientific literature.

The Register contains results and protocol information from GSK-sponsored trials of marketed medicines. It also provides references to publications that have appeared in medical journals. Anyone can use the internet to access the register.

**Activity in 2006**

At the end of 2006 there were 2,760 clinical trial summaries on the GSK Clinical Trial Register ([http://ctr.gsk.co.uk/welcome.asp](http://ctr.gsk.co.uk/welcome.asp)). This includes all clinical trials of our major marketed products which have been completed since the formation of GSK in 2000, or that were completed before this and are likely to inform medical judgement.

We have continued to populate the register with clinical trials that relate to our other marketed medicines and this was largely completed in 2006.

Our approach to authorship of journal articles

There have been concerns about “ghost writing” of journal articles, where doctors put their names to articles written by pharmaceutical companies. GSK’s policy is that:

- Authorship and acknowledgements for articles must be consistent with journal guidelines and be determined on the level of contribution to study design, data acquisition, analysis and interpretation and writing or revising the manuscript.
- The named senior author for a paper must actively participate in the drafting process, lead the content development, and retain final approval authority for the manuscript.
- Any GSK staff or contractors who contribute to the development of manuscripts for external authors must be named in the article.

*Read our Public Policy on Disclosure of Clinical Trial Information Authorship of Journal Articles.*
PATIENT SAFETY

Ensuring patient safety is extremely important and we take the safety of all our medicines, vaccines and medical devices very seriously.

Safety of medicines

Medicines are a part of modern life. In an ideal world, a medicine would target only the disease or disorder it’s meant to and never do anything else. Unfortunately, despite the best efforts of scientists, such a medicine does not yet exist.

All medicines have potential risks as well as benefits although not everyone who takes a medicine will experience side effects. It is important that we identify, evaluate and minimise safety concerns to ensure that the overall benefits of a medicine outweigh any risks. This is known as pharmacovigilance.

Monitoring the safety of medicines

The pharmaceutical industry has two major roles in managing the safety of medicines:

1. To collect, investigate and proactively evaluate information relating to side effects of medicines for the purpose of protecting patients and advising on drug safety
2. To fulfil its legal obligations to the regulatory authorities by reporting individual adverse events (AEs) on an expedited basis and/or periodically, according to the drug safety regulations of each country

We strive to ensure patient interest is served through the prompt detection of a potential safety issue with one of our drugs so that appropriate communication with regulators occurs. Following evaluation, decisions can then be made and action taken. See collecting and reporting safety data.

How do we monitor safety?

An efficient, fully operational, worldwide system for pharmacovigilance is maintained within our company. We have dedicated teams of scientists and healthcare professionals across the world who monitor, review, evaluate and communicate safety issues with our medicines.

The safety of our products is assessed in clinical trials before a product can be approved for marketing. Sometimes adverse events occur after approval when a product is being used by large numbers of patients. We have policies and a governance framework in place to help us detect and act on any adverse events reasonably associated with our products. See drug safety governance framework.

Adverse events are recorded on our global safety database and clinical trial database and investigated by our clinical and pharmacovigilance teams. This helps us to monitor the balance between benefits and risks. See benefit-risk management.

When appropriate, we respond to safety issues by changing product labelling and communicating with doctors. In most cases these actions are sufficient; in a small number of cases we conduct risk minimisation activities, such as further clinical trials. In certain cases it may also be appropriate to stop clinical trials or to withdraw the medicine from the market. See collecting and reporting safety data.

GSK is investing in a number of areas of emerging science that have the potential to improve patient safety, for example, pharmacogenetic research, see sidebar.

Enhancing the pharmacovigilance system

The science of pharmacovigilance is continually evolving, providing new ways of enhancing the pharmacovigilance framework to the benefit of industry, regulators, healthcare professionals and most importantly patients. To enhance pharmacovigilance GSK recommends that:

- Initiatives are undertaken to increase the quantity and quality of the reporting of possible side effects of medicines by healthcare professionals and patients
- There is a focus on the development of electronic patient records which would permit “real time” access to anonymised data for the detection and evaluation of possible side effects
- Pregnancy registries are established by health care systems to enable the rapid collection and evaluation of data related to possible adverse events, including birth defects
- Research is undertaken to establish the most effective ways to minimise the risks of medicines including effective ways of communicating the benefits and risks of medicines to healthcare professionals and patients
• There is increased harmonisation of pharmacovigilance rules through the rapid and consistent implementation of ICH guidelines by the EU, US and Japan

• An EU Pharmacovigilance Regulation is introduced to streamline and simplify pharmacovigilance reporting requirements in Europe

In order to achieve this it is necessary for the industry and regulators to work together. Safety monitoring is not considered to be a competitive area, since it benefits all parties if carried out to the highest standards. GSK makes new ideas and technology available to other pharmaceutical companies and regulators by presenting at scientific conferences and also by working with third party software suppliers to make new advances accessible to all.
Ethical conduct

GSK is committed to business practices that meet high standards of ethical and legal compliance and to ensuring that our employees behave with honesty and integrity. Getting this right requires a combination of effective systems and an ethical corporate culture, in which it is understood that everyone is required to conduct business with honesty and integrity and in compliance with applicable legal requirements.

Patients, consumers, doctors and governments want to use medicines from companies that they trust. Our reputation with these stakeholders is therefore critical to our business. Meeting high ethical standards enables us to maintain their support and retain our ‘licence to operate’. It also helps us to attract, retain and motivate the best people.

Unethical conduct could have serious legal and financial consequences for the company. So our ethics programmes are also an important element of risk management and good stewardship of corporate assets.

This section explains our approach to business and marketing ethics and our progress in embedding an ethical culture at GSK. It covers:

- GSK’s Code of Conduct and management certification on business ethics
- Marketing ethics, including our codes of practice and policy on direct-to-consumer advertising
- Ethical training and awareness programmes
- Monitoring and compliance systems, including channels for reporting cases of misconduct
- Data on the number of employees dismissed or disciplined for violating company policies

CODE OF CONDUCT

Our Employee Guide to Business Conduct requires all employees to act with integrity, comply with the law, avoid conflicts of interest and report any violations of the law or GSK’s policies or any unethical behaviour. It provides guidance, including specific examples, on what constitutes acceptable or unacceptable behaviour.

Employees learn about our standards during their induction and can access the guide via the company intranet.

Read our Code of Conduct and Employee Guide to Business Conduct.

Management certification on business ethics

Commitment to our Code of Conduct is reinforced by an annual management certification programme that requires managers to confirm that they comply with our ethics policies. The programme covers over 12,000 managers worldwide. Eligible managers from all business units completed the certification in 2006.

Certification is managed electronically and non-certification is tracked and followed up. Non-certification is typically due to extended leave of absence, such as maternity leave or long-term sick leave.

The full certification statement is reproduced in the background section of our website.

Business ethics and our suppliers

We expect our suppliers to operate to the same high ethical standards as our own employees. See Supply chain page 50.

MARKETING ETHICS

GSK markets its medicines to doctors, hospitals and governments. In some countries, such as the US, we also advertise medicines directly to consumers.

Our specialist sales representatives meet regularly with doctors and pharmacists to inform them about our medicines and their approved uses.

We believe that sales representatives play an important role in providing up-to-date information to doctors on our products and their benefits to patients. However, we recognise that the marketing of pharmaceutical products raises some challenging issues.

In particular, some people are concerned that marketing by pharmaceutical companies exerts undue influence on doctors, that sales representatives do not always give doctors full information about potential side effects, or that promotion for unapproved uses may be common despite increased training, monitoring and oversight.

Find out more

In our report:

- Ethical issues in R&D, including our policies on relationships with doctors involved in clinical trials, disclosure of clinical trial results and writing of articles for medical journals
- Our relationships with governments and patient groups
- Supply chain standards
- Our access to medicines policies

On our website:

- More background information on our ethics policies
- Our Code of Conduct
- Our European Marketing Code of Practice

Find out more

In our report:

- Ethical issues in R&D, including our policies on relationships with doctors involved in clinical trials, disclosure of clinical trial results and writing of articles for medical journals
- Our relationships with governments and patient groups
- Supply chain standards
- Our access to medicines policies

On our website:

- More background information on our ethics policies
- Our Code of Conduct
- Our European Marketing Code of Practice

Read our Code of Conduct and Employee Guide to Business Conduct.
The promotion of pharmaceutical products is highly regulated and several governments are extending legislation in this area. For instance, six US states require pharmaceutical companies to restrict or report their interactions with doctors. Requirements vary from prohibiting companies from providing meals to setting annual spending limits or requiring transparent reporting. Similar legislation is being considered in many other states. The American Medical Association now enables doctors to request that their prescribing activity is not shared with pharmaceutical companies.

Our approach to addressing these issues includes the following:

- All GSK employees must comply with our marketing codes of practice – revised and strengthened in 2006 – and our policies governing consumer advertising
- Sales and marketing employees receive training to ensure they have a good understanding of our marketing policies and the legal framework governing their sales activities
- We have programmes to monitor compliance including, in some regions, feedback from doctors on our sales practices

Marketing codes of practice
Our Pharmaceutical Marketing and Promotional Activity policy applies to all employees and agents. It commits us to promotional practices that are ethical, responsible, principled and patient-centred. It prohibits kickbacks, bribery or other inducements to doctors, and any promotion for unapproved uses of our medicines.

This policy is supported by regional marketing practices codes in Europe, our International region, Japan and the US. These codes apply the same ethical standards but reflect differences in market structures, national healthcare systems and regulations. They incorporate the principles of industry codes of practice such as the EFPIA, IFPMA, JPMA, and PhRMA marketing codes.

Our codes are available in many languages and employees can access them via the intranet.

A copy of the GSK European Promotion of Medicines Code of Practice is available on our website.

Progress in 2006
We revised our procedure for making charitable donations to health-related organisations and funding external science and medical programmes in all our regions. Decisions about these grants must now be made by relevant medical and/or compliance personnel and not by sales and marketing departments.

US
We strengthened our policy on Grants for Independent Medical Education. All grants will now be made by the new Center for Medical Education within our Corporate Ethics & Compliance department. Grants to medical education companies (MECs), hospitals, medical associations, and patient groups must not account for more than 25 percent of that organisation’s annual budget. Sales staff are not permitted to deal with MECs or other providers of independent medical education or to recommend speakers for education programmes.

International region
We revised the Marketing Code for our international region to ensure it meets new IFPMA standards and added a comprehensive Q&A to help employees understand our requirements. We provided more guidance to employees on the use of healthcare professionals as consultants and sponsorship of healthcare professionals to attend conferences.

Europe
We updated the GSK European Promotion of Medicines Code of Practice in March 2006 to ensure alignment with the updated EPFIA Code. The major changes include:

- New sections on distributing product information to healthcare professionals via email or the internet
- Prohibiting the use of competitions with prizes to promote our medicines

We established a new procedure on relationships with patient groups and committed to publishing GSK funding for these groups. See patient advocacy on page 13.

R&D
We strengthened our R&D policy on gifts and entertainment. This policy states that the primary purpose of a meeting must be to facilitate substantial discussion of a medical or scientific topic. Meals may be provided during such meetings only if they are incidental to the meeting. The meal must be modest in value and GSK personnel must be present.

Consumer advertising
This section explains our approach to advertising our prescription medicines in the US and our consumer healthcare products in other markets.

Direct-to-consumer advertising
In the US we advertise our prescription medicines to consumers through TV and print advertisements. This is known as direct-to-consumer (DTC) advertising. New Zealand, Bangladesh and Korea also allow limited DTC advertising. DTC advertising of prescription medicines is not permitted in other markets.

Our Marketing Codes of Practice in summary

- Full and accurate information – information can only be provided on approved uses for a medicine. It must be based on valid scientific evidence, and must be accurate, balanced, fair, objective, unambiguous and up-to-date
- Promotional items to healthcare professionals – promotional items must be given only occasionally and must be relevant to the practice of medicine. Their nominal value must be no more than $10 (less than £6). Items cannot be made as an inducement to prescribe any of our medicines or to medical professionals retained as consultants to GSK
- Appropriate hospitality for meetings – no entertainment is permitted. Hospitality (such as travel costs or food) may only be provided for meetings with an educational purpose. The level of hospitality must be appropriate to the occasion and must only be provided for relevant healthcare professionals, not spouses, children, office personnel, or any other guests. Travel costs are not provided in the US
- Decisions about grants for medical education are reviewed by qualified medical or scientific personnel within our compliance function
Supporting industry codes of conduct
GSK supports efforts to strengthen marketing standards across the pharmaceutical industry. In 2006 this included:

Global – We helped revise the International Federation of Pharmaceutical Manufacturers and Association’s (IFPMA) Code of Pharmaceutical Marketing Practices. GSK is a member of the newly formed Code Compliance Network that will support implementation of the IFPMA standards through training and education. GSK helped revise the European Federation of Pharmaceutical Industries Associations (EFPIA) Code of Practice for Promotion of Medicines.

Greece – GSK Greece is leading the local industry body working group set up to improve their local code of practice.

Korea – GSK led efforts to improve the Korean Research-based Pharmaceutical Industry Association’s Code of Conduct and to have this endorsed by the Korea Fair Trade Commission.

Japan – GSK joined the Executive Steering Committee of the Fair Trade Council of the Ethical Pharmaceutical Drug Manufacturing Industry that seeks to strengthen compliance with marketing codes.

Slovakia – GSK’s General Manager in Slovakia helped found the recently formed local industry association and now leads this group.

Sri Lanka – GSK led efforts to create the first marketing code for the Sri Lanka Chamber of the Pharmaceutical Industry based on the IFPMA Code.

In the US, we implemented a policy incorporating the new PhRMA Guiding Principles on DTC advertising for prescription medicines. This states that DTC advertising should:

- Only begin after we have spent an appropriate amount of time educating doctors and healthcare professionals about new medicines
- Be designed to educate consumers about the medicine and the condition for which it is prescribed
- Be accurate and supported by evidence
- Include information on the risks and benefits of treatments
- Provide information on other treatment options (such as diet and lifestyle changes), where these are referenced in the prescribing information for a product.

‘Reminder’ advertisements – short advertisements that mention the pharmaceutical brand name but not the medical condition it is designed to treat – are not permitted.

All DTC television advertisements (including audio and visual components) are submitted to the US Food and Drug Administration (FDA) for review at least 30 days in advance. No problems with GSK DTC advertising were identified by the FDA during 2006.

Members of the public and healthcare professionals can send comments on DTC advertising to PhRMA’s Office of Accountability established in 2006. These are forwarded to the relevant company. The Office of Accountability reports periodically on the comments and the companies’ response to the FDA. In 2006, GSK did not receive any comments from the Office of Accountability regarding its DTC advertising.

In 2006, our employees involved in DTC marketing attended training on our new policy and the PhRMA Principles. We also developed a DTC e-Learning module for future training.

Disease awareness campaigns
We fund disease awareness campaigns which are designed to increase understanding of a specific disease but are not linked to the promotion of GSK products. We revised our policies in 2006 to make clear that disease awareness campaigns must not imply endorsement by a government agency, professional body or patient advocacy group without consent. Campaigns cannot include links to third party websites without permission or to any websites which contain information about uses of our products outside of their licence.

Non-prescription products
We advertise over-the-counter medicines, oral healthcare and nutritional products directly to consumers. This is governed by national regulations or codes of practice for advertising. These are generally less stringent than the requirements for prescription medicines.

We belong to the Consumer Healthcare Products Association in the US and comply with its Code of Advertising Practices for Non-prescription Medicines. This states that advertising should not imply a casual attitude towards using medicines or suggest that an over-the-counter medicine can prevent or cure a serious disease that must be treated by a licensed practitioner. In addition GSK policies require that all claims in advertisements are consistent with product labelling. Advertising that compares a GSK product to a competitor’s must be supported by adequate data.

GSK Consumer Healthcare advertising is reviewed by Copy Review Committees (in our larger markets) or medical and legal personnel (in our smaller markets) before publication to ensure it meets our standards.

Our over-the-counter medicines are also promoted to pharmacists, doctors and dentists by our sales teams. In 2006 a prescription weight loss medicine was promoted in preparation for its approval as an over-the-counter medicine. Our US Consumer Healthcare medical sales team completed online training on our Marketing Codes of Practice prior to promoting this product.

Advertising to children
Our guidelines for advertising to children meet or exceed local laws and codes of practice. They prohibit advertising designed to appeal to, or targeted at, children below the legally mandated minimum age. For example, in the UK we do not buy advertising space in children’s media and we do not supply vending machines to primary schools.

Sports star sponsorship is important to brands such as Lucozade Sport. Our guidelines state that only people who set an appropriate example should be used for sponsorship, and they should have an appeal that is not solely to children below the age of 13.
TRADING AND AWARENESS

Training and awareness programmes help employees understand and comply with our ethics policies.

In our global leadership survey, over 91 percent of managers said they believe that people in their department show commitment to performance with integrity.

Specialised training is provided for employees working in R&D, manufacturing and sales and marketing where there are additional regulatory requirements.

We monitor the success of our training through regular employee surveys. In 2006 we surveyed our US district sales managers (DSMs) who play an important role in helping sales representatives resolve compliance questions. This showed that a substantial majority of DSMs have a good understanding of compliance issues and are confident that they can help representatives resolve ‘grey’ areas. The survey identified opportunities to enhance our training and resource materials. For instance, we will provide managers with additional training and materials to increase their expertise and for providing more effective guidance to their staff.

Ethics training

New employees in the UK and the US complete induction training on our Code of Conduct. This ensures that they understand the importance of ethical conduct from day one, know how to deal with dilemmas and where to seek help.

We ran an Ethical Decision Making workshop for managers as part of our ‘Hot Topics’ training programme. Follow up emails were sent to encourage managers to review the key points with their teams. We piloted three e-Learning modules on ethical leadership within our Corporate HR and Corporate Ethics and Compliance teams before they are rolled out to all managers worldwide during 2007.

Training and awareness for sales and marketing

Employees working in sales and marketing receive extensive training on ethics and our marketing policies. This includes:

- Induction training for new employees on our marketing codes of practice
- Sales employees are required to pass a test on our marketing code before starting their sales role
- Detailed training for sales representatives on the medicines they promote and the diseases they are designed to treat
- Regular refresher courses held at least once a year
- A yearly bulletin on the major types of unethical conduct detected and the actions taken, for employees in the US
- Senior managers within our European region receive a quarterly update on the number and types of disciplinary actions for policy breaches

US

In 2006, all new sales and marketing staff in the US completed training and more than 9,000 existing staff received two hours of annual refresher training.

In the US, compliance is a formal performance objective for sales and marketing employees. They are appraised against the following objective:

“Consistently follow company policies and procedures, take and complete required compliance training in a timely manner, and report compliance issues to manager, Legal or Compliance.”

In addition, managers are evaluated against the following objective:

“Ensure that supervised employees are trained on company policies and procedures and have taken all required training, and provide oversight and direction to supervised employees so that they are in compliance with company policies and procedures.”

We will launch a Compliance University in 2007 for US sales managers. This is a one day programme designed to improve understanding of our policies and the ability of managers to guide staff, reduce the number of breaches of our policies, and increase managers’ expertise in detecting compliance issues so that corrective actions can be taken early.

International

In 2006, all sales and marketing staff continued to receive training in the Pharmaceuticals International Promotion and Marketing Code. This involves initial awareness sessions at induction courses and regular reminders and refreshers, facilitated by medical staff, at sales conferences.

In addition a number of supplemental policies were implemented in 2006 and these have been added to an internal intranet community which supports visibility by all International staff. Training of sales and marketing staff will be delivered in the first half of 2007 regarding the updated International Code.

Europe

All pharmaceuticals sales and marketing staff in Europe were trained in the updated Promotion of Medicines Code of Practice and certified that they understood the revised Code.

Ethics training for R&D

We updated our ‘Performance with Integrity’ face-to-face induction training for R&D employees which was completed by over 11,500 new and existing employees worldwide in 2006. This mandatory course—offered in 12 languages—includes training on the Code of Conduct, conflicts of interest, acceptance of gifts and entertainment by employees and external professional activities.

Our view on direct-to-consumer advertising

Promoting the use of prescription medicines directly to consumers can be controversial. Critics believe that it encourages people to request unnecessary treatment, adding to the burden on healthcare systems.

We believe that responsible pharmaceutical advertising is a useful source of health information for patients. It helps to increase knowledge of conditions and educates patients about treatment options.

In countries such as the US where DTC advertising is common industry practice, we need to ensure that our products are also promoted in this way. If we do not, GSK would be at a disadvantage against our competitors.

Patients must still consult with their physicians about their condition, the appropriateness of a prescription medicine, and obtain his or her consent before receiving such medicines.
We launched additional training for R&D employees on our policies governing:

- Collection, use and storage of protected medical information (information held on clinical trial participants relating to their health status and medical conditions)
- Collection and use of human biological samples, data integrity management of human safety information
- Public disclosure of clinical trial results
- Post-trial treatment for participants in GSK-sponsored clinical trials

**Ethics training in practice**

Ethics training is designed to help employees apply our policies in real life situations and make the right decisions in their work.

For example, employees are encouraged to ask themselves the following questions before making a decision:

- Would I be embarrassed if my friends or family knew what decision I have made?
- How would my decision look to a cynic?
- What could the newspaper headline look like?
- Am I still confident that this is the right decision for GSK?

During training employees explore ethical dilemmas they may face in their work and receive guidance to help them understand the appropriate response. This is one example from a recent training session:

**Scenario:** you are at a trade conference and put your business card in a prize draw. You win the grand prize, which is a set of golf clubs worth £1,000. You enjoy golf and would like a new set of clubs. The draw is sponsored by an exhibitor with whom GSK does business. Should you keep the clubs?

**Guidance:** taking into account the GSK policy, *acceptance of entertainment and gifts by GSK employees*, the clubs must not be accepted and it would be better not to put your business card in the draw.

**Objectives for 2007**

- Translate 20 key policies and the Employee Guide to Business Conduct into 12 languages to improve understanding across the business
- Create company wide compliance training on our Employee Guide to Business Conduct to supplement local training and to reinforce our annual Management Certification in Business Ethics

**MONITORING AND COMPLIANCE**

We recognise that strong policies, codes of practice, and good training do not guarantee that all employees will meet our standards. Our internal compliance systems are designed to identify and address breaches of our codes.

This section covers:

- The role of our Corporate Ethics and Compliance department
- Channels for employees to report concerns or suspected cases of misconduct
- How we address misconduct
- The number of employees dismissed or disciplined for misconduct

**Corporate ethics and compliance function**

Our corporate ethics and compliance department promotes effective compliance programmes, addresses compliance issues, and reports problems and progress to senior management and the Board.

We have a dedicated compliance officer in each of our eight business units – R&D, Manufacturing, Biologicals, Pharma Europe, International Pharma, Consumer Healthcare, Japan Pharma and US Pharma, in addition to the corporate compliance officer, who reports directly to the CEO.

Compliance officers are senior managers with direct access to the leadership teams of GSK functions. They are a source of expertise for anyone with a question on ethics or GSK policies. In our European and International regions they are supported by a network of regional and country compliance officers and local compliance champions. We will further strengthen these networks in 2007, particularly in eastern Europe.

Sales representatives are supervised by their managers who regularly monitor educational events, visits to doctors and expenses. We also have independent monitors to review records in a number of key risk areas in the US. Our internal audit department regularly audits our sales and marketing practices globally.

GSK requires each business or functional unit to identify all significant risks, implement effective controls to manage those risks, periodically review those risks and provide upward communication of any significant issues that arise.

In the US we have four sales and marketing compliance advisers who provide feedback on infractions, conduct customised training and recommend process improvements. They are an important link between our compliance department and commercial units. Our compliance data analysis and reporting function coordinates monitoring, reporting and targeting of our compliance efforts.
In 2006 we set up a Strategic Tracking, Analysis & Reporting (STAR) System. This gives senior managers access to comprehensive compliance information and makes it easier to identify instances of non-compliance in their area and take appropriate action.

**Europe**

The European Code of Marketing Practice includes a quarterly reporting mechanism where the markets confirm whether any breaches of the code of practice have occurred, the severity of any breaches and what actions have been taken to prevent recurrence. These reports are reviewed by senior managers. Expenses and payments to doctors (for example for speaker fees) are monitored locally and a summary report for each market is reviewed by our European compliance officer each quarter.

**International**

We established a monthly review system in our International region. During 2006 senior managers reviewed and resolved a number of compliance issues through this mechanism. Many other minor issues were resolved at a local level.

**Reporting channels**

Employees are encouraged to seek help and to report any concerns or suspected cases of misconduct. They can do this through their line management, a compliance officer, or through our confidential Integrity Helplines or offsite post office box (in the US).

Reporting channels are promoted through the Employee Guide to Business Conduct, on the GSK intranet and during training.

In 2006 there were:

- 5,363 contacts with the compliance functions. This is an increase from 3,644 in 2005, and 2,593 in 2004
- Of these, 81 percent were from employees seeking advice or information; 19 percent were from employees reporting suspected cases of misconduct

The compliance group continues to make efforts to promote high standards of legal compliance and ethical behaviour, as well as the use of the Integrity Helpline as a compliance resource. The year-on-year growth (41 percent in 2005; 47 percent in 2006) seen in the contact figures above may be due to a greater awareness and sensitivity to these standards.

Doctors can raise any concerns or report unethical conduct by GSK sales representatives through our customer response centres, during our market research or via industry associations such as PhRMA and the ABPI. Staff are trained to deal with concerns about marketing practices that might be raised by healthcare professionals, patients or the public. They redirect calls to appropriate senior management or a compliance officer if necessary.

The **Addressing misconduct**

Our Corporate Ethics and Compliance department monitors and tracks allegations and suspected cases of legal, ethical or policy infractions. It ensures that all such allegations are appropriately investigated. Disciplinary action, up to and including dismissal, is taken where necessary.

Our discipline reporting process was changed in 2006 in order to provide GSK with the ability to better identify issues resulting in formal HR disciplinary action. Significant changes include: new category sections; more precise reporting directions; and interactive training sessions conducted with appropriate personnel. Because of these improvements, the information for 2006 policy discipline cases differs from the information reported in previous years. The overall level of dismissals collected is similar to previous years, but is not directly comparable. In future reports, GSK will be using 2006 HR policy discipline numbers as the baseline against which to compare policy discipline trends.

In 2006:

- 1,089 employees were disciplined for policy violations
- Of these, 284 were dismissed or agreed to leave the company voluntarily (known as separation)
- Other disciplinary actions included documented warnings (805 instances) and financial penalties
- Employees staying with the company received retraining and increased monitoring

The 1,089 disciplinary actions included 381 cases of employees breaching sales and marketing codes. These 381 cases resulted in 49 dismissals or separations from the company. All the other 332 cases resulted in documented warnings.

We will use these data to analyse compliance trends and regional differences, and to identify appropriate corrective actions.
Employment practices

Our goal ‘to be the best place for the best people to do their best work’ is central to our business strategy and underpins our success. Our people are our greatest source of competitive advantage. Their skills and intellect are essential to GSK discovering and delivering the best new medicines and vaccines, and successfully marketing and selling our prescription and consumer healthcare products.

GSK employs over 100,000 people in 116 countries. Our goal is to be a company where talented people apply their energy and passion to make a difference in the world. Competitive reward is important but not the only factor that influences our ability to recruit and retain talented employees.

This section explains our approach to employment and our performance in 2006 including:

- Initiatives to increase diversity and inclusion
- Training, development and talent management
- Internal communication – how we communicate with employees and get their feedback
- Flexible working arrangements, wellbeing and resilience programmes that support a healthy workforce

Breakdown of global employment by business (end December 2006):

<table>
<thead>
<tr>
<th>Business or function</th>
<th>Number of employees</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manufacturing</td>
<td>33,235</td>
</tr>
<tr>
<td>Selling</td>
<td>44,484</td>
</tr>
<tr>
<td>R&amp;D</td>
<td>15,952</td>
</tr>
<tr>
<td>Administration</td>
<td>9,024</td>
</tr>
<tr>
<td>Total</td>
<td>102,695</td>
</tr>
</tbody>
</table>

GSK SPIRIT

We expect employees to meet high standards in the way they carry out their work for GSK. The GSK Spirit defines our culture and the principles we expect employees to work by. These include:

- Performance with integrity
- Innovation and entrepreneurial spirit
- Accountability for achievement
- Passion and a sense of urgency
- Continuous learning and development

Regular performance appraisals assess whether employees have upheld these principles and the requirements of our Code of Conduct in their work (see Ethical Conduct for more on our Code). The results affect bonuses and career progression.

EMPLOYEE SURVEYS

Regular employee surveys help us to monitor GSK’s culture, gauge employee satisfaction and assess the effectiveness of our employment policies.

Our Global Leadership Survey (GLS) is sent to GSK managers every two years and is available in nine languages. In 2006, over 10,000 managers took part, a 78 percent response rate. The survey tracked their views against our previous two surveys and against findings from other global companies through a cross-company database. This database includes 42 top-ranked companies from several industries including pharmaceuticals, automotive, banking, energy and IT. The normative database has responses from around three million employees in 139 countries.
Key survey findings
The survey showed that managers in GSK are more satisfied with their company than managers in the other companies that took part. GSK participants were also more satisfied than they were in 2004, with overall responses on average 4 percent higher.

Improvement plans
Survey results are reviewed by our corporate executive team which has identified two key areas of focus
- Reducing unnecessary bureaucracy within and across our businesses
- Leadership visibility, defined as the drive for managers to spend more time with their teams and to be more visible in their respective businesses

Each business unit and function has developed an action plan to address these and other areas for improvement.

DIVERSITY AND INCLUSION
We aim to create an inclusive working environment at GSK where employees from diverse backgrounds can flourish.

Diversity benefits our business. A workforce with diverse backgrounds, cultures and outlooks helps us to better understand the needs of different patients and customers. Only by delivering genuine equality of opportunity can we be sure that we have the best people in the right jobs.

We reinforce our commitment to diversity and inclusion (D&I) through:
- Our corporate executive team which endorses a global policy for D&I and support activities and initiatives such as the annual Multicultural Marketing and Diversity Awards
- Our company-wide D&I policy and practices are available to view by employees through our intranet
- Monitoring and reporting data on gender diversity by management grade worldwide and on ethnicity in the US and UK
• Reinforcing the GSK Spirit which states that we will value and draw on the differing knowledge, perspectives, experiences and styles resident in our global community
• D&I steering teams in the UK and US that run awareness campaigns and training for employees
• Diversity champions in each business unit and among our field staff
• Employee networks that provide insight and support for diversity objectives

More background information on our approach to D&I is available on our [website](#).

In the US we conduct an annual survey of 1,000 employees selected at random to gauge progress on inclusion and resilience. In the 2006 survey where we achieved a 41 percent response rate, 76 percent agreed that ‘my workgroup has a climate in which diverse perspectives are valued’ and 79 percent agreed that ‘my manager demonstrates the ability to manage a diverse workforce.’

**Gender diversity**

<table>
<thead>
<tr>
<th>Gender diversity in management 2006 (worldwide)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Women in management grades</strong></td>
<td>2006</td>
</tr>
<tr>
<td>A&amp;B Bands*</td>
<td>22%</td>
</tr>
<tr>
<td>C01 – C03**</td>
<td>34%</td>
</tr>
<tr>
<td>C04 – C05***</td>
<td>39%</td>
</tr>
<tr>
<td>Total for all management grades</td>
<td>36%</td>
</tr>
</tbody>
</table>

* Corporate Executive Team, Senior Vice Presidents, Vice Presidents
** Director grade
*** Manager grade

This positive trend of increased female representation in management positions reflects the impact of GSK’s D&I strategy across the businesses and the effect of our flexible working policies in attracting and retaining women. This is further supported by the 2006 US D&I survey where 79 percent of employees agreed that ‘my manager enables flexible and innovative solutions for managing work and personal life’.

For more than 12 years, the annual Women in Science event in the US has fostered positive, mentoring relationships between GSK female scientists and female students aspiring to enter science fields. It also exposes students to hands-on, real-life laboratory and research environments and further enhances GSK’s ability to attract and retain women in the fields of science.

**Ethnic diversity**

In the US, minorities (defined as Blacks, Hispanics, Asians, Pacific Islanders, American Indians and Alaskan natives) made up 19.8 percent of our workforce, compared with 19.6 percent in 2005 and 19.5 percent in 2004. This is above the average in our closest comparator, the US chemical industry.

In the UK, ethnic minorities, as defined by the UK Commission for Racial Equality (CRE), accounted for 18.3 percent of employees (compared with 16.8 percent in 2005 and 15.5 percent in 2004). The CRE defines ethnic minorities as anyone not identifying themselves as ‘White British’. Figures from the 2001 census show that 12.5 percent of the population of England and Wales were from an ethnic minority.

An alternative measure of diversity is the number of employees who define themselves as ‘non-white’. In 2006 11.6 percent of GSK UK employees defined themselves as non-white (compared to 11.0 percent in 2005 and 10.4 percent in 2004).

**Age**

In advance of new age discrimination regulations in the UK, we carried out a comprehensive review of our policies and practices and consulted our UK Information and Consultation Forum. As a result a number of policies were amended and updated. Extensive training was provided for HR professionals and the changes were communicated to managers and employees to ensure they understand the implications of the new law.
Disability
We are committed to offering people with disabilities access to the full range of recruitment and career opportunities at GSK. In the UK we were awarded the two ticks symbol from Jobcentre Plus and we partner with the Employers Forum on Disability and other interest groups to ensure we are a Disability Confident organisation.

Multicultural Marketing and Diversity Awards
Our annual Multi-Cultural Marketing and Diversity Awards (now in their fifth year) inspire staff to find creative ways to reach a wider audience of employees, customers and communities.
Awards are given in several categories including Employee Attraction, Development or Retention, Multicultural Marketing and Sales, Community Outreach and Diversity Ambassador. There have been 289 entries to the awards since 2001 and 21 employees have received the GSK Diversity Ambassador Award for leading diversity efforts with passion, innovation, and impact.

Employee networks
Employee networks are an integral part of our D&I programme. Networks support professional growth for participating employees and provide a forum for employees with similar backgrounds to meet and discuss issues of shared concern.
Several networks have a particular diversity focus, including our networks for Asian, African American, Hispanic, Gay, Lesbian, Bisexual or Transgender employees. As well as benefiting the participants, the networks act as a source of expertise on diversity issues for other people at GSK.
Each employee network has an executive sponsor who helps in setting and achieving goals, obtaining resources, and promoting network objectives among senior management. GSK-sponsored networks, regardless of affiliation, are open to all GSK employees.

EMPLOYEE DEVELOPMENT AND TALENT MANAGEMENT
GSK invests in training and development to enable all employees to perform to the best of their ability and to support their career progression. We work hard to attract and retain the best and the brightest people at GSK and to help them develop their potential.

Training
We provide job-related training courses for all employees and leadership training for managers.
Employees can enrol in training programmes through our myLearning intranet site available in the UK, US and other countries. During 2006, we registered on the system over 638,000 course completions.

Leadership training in 2006 included:

- 108 managers attended four Leadership Edge programmes
- 77 managers attended six Inspirational Leadership Workshops that focused on inspiring and motivating people to high performance
- 407 managers attended new manager / experienced manager training
- 692 managers attended ‘Hot Topics – Harnessing the Power of Real Conversations’
- 678 managers attended ‘Hot Topics – The Art of Self Leadership’

Development
Regular performance appraisals reward strong performance, identify training needs and help employees set objectives that are aligned with our business priorities. More than two-thirds of GSK employees receive an annual performance appraisal through our Performance and Development Planning (PDP) programmes.
PDP includes an assessment of how well employees have implemented the GSK Spirit – the principles we use to define our culture. It can have an impact on bonus payments and affect future career development.

Employee turnover
We have a number of teams that focus on issues affecting employee retention, for example the management of people in different age groups and development and promotion for female and minority employees.

Rewarding strong performance
Performance related pay and share ownership schemes help us attract and retain the best people and generate a culture of ownership among employees. In countries where employee share ownership schemes exist the level of participation is high.

Talent management
Our talent management processes help us identify and develop leadership candidates. We identify the highest performing employees in each business and function through our annual talent management cycle. Talented individuals take part in our leadership programmes and are exposed to top management through programmes such as the Chief Executive Forum.
INTERNAL COMMUNICATIONS

Good internal communication is important in achieving our business objectives as well as creating an open and inclusive work environment. We have a range of communications channels to keep employees up to date with company news and enable them to give feedback.

These include:

- myGSK, our global intranet site, provides news and updates and a Q&A section where employees can put questions directly to the CEO and senior executives. In 2006 JP Garnier, GSK’s Chief Executive, answered 341 questions from employees. Behind the News, a section of the GSK intranet, gives the company’s position on important issues linked to press stories about GSK.

- Web-broadcasts from GSK senior management, including 16 during 2006 from executive team members, for employees at our major sites.

- Spirit, our internal magazine, reaches around 34,000 employees throughout the company four times a year. Many sites also produce local newsletters.

- Confidential feedback mechanisms enable employees to raise concerns. These include our Integrity Helpline. See Ethical conduct.

- Regular employee surveys, see page 40.

- 44 ‘townhall’ sessions during 2006 for employees at all levels of the company were hosted by senior management. Employees have the opportunity to discuss the progress of the business, raise questions and give feedback.

We track the effectiveness of communications through employee surveys. We monitor the questions employees put to senior managers through the Q&A pages on myGSK to ensure we pick up potential areas of concern. We also track readership of news stories on myGSK to help improve the relevance and interest of the content.

Employee consultation

We consult employees on changes that affect them. In Europe we discuss business developments through our European Employee Consultation Forum (EECF). In 2006 the EECF received updates from GSK’s global business leaders and reviewed proposals and progress reports on a number of European initiatives in IT, distribution and medical.

We also have national consultation forums and in 2006 we established a UK Information and Consultation Forum to provide information about the company’s progress and plans and to help stimulate constructive dialogue with employee representatives within the UK. The Forum is made up of 15 elected employee representatives and seven managers. It meets three times a year and, to date, has reviewed areas such as employment policy changes, UK pension arrangements and preparations for supporting employees in the event of a flu pandemic.

We have similar forums in other countries where this is national practice.

Communicating corporate responsibility

It is through our employees that we put our responsible business policies into practice and communicate this to the outside world. Employees are also important stakeholders in their own right and want to know about our progress on responsibility issues.

We keep employees informed about corporate responsibility through regular news articles on the GSK intranet, through articles in Spirit magazine and by presentations to departmental groups. During 2006, a summary of our CR report was distributed to 34,000 employees.

EMPLOYEE HEALTH

Protection and promotion of the wellbeing of our employees is an ethical obligation and an important contributor to our goal to be an employer of choice. This philosophy also supports our business strategy because a healthy and resilient workforce drives positive business performance by increasing employee productivity and attendance. Healthy workers also reduce health care and insurance costs.

Healthy High Performance

Healthy Culture

We consider four dimensions of health to be vitally important to high performance: physical, emotional, mental and spiritual. People need to be physically energised, emotionally connected, mentally focused and ‘spiritually aligned’ (meaning they have a sense of purpose). Linked to these four dimensions are 16 factors that enable high performance. The factors range from fitness and nutrition to self-awareness and time management. We deliver programmes such as the Corporate Athlete and the Health Risk Assessment (HRA) that are directed at improving these 16 factors and measuring our risk reduction and health impacts.

Driving a healthy culture through all of GSK starts with the leadership. We want the company’s leaders to be committed to the continuous development of their physical and psychological well being so that they can be effective leaders and role models to their employees.

Resilience

We use the term ‘resilience’ to describe the skills and behaviours needed to be successful in a highly pressured environment. It is the same set of skills that helps to prevent work-related mental illness, which is a leading cause of ill-health leading to time away from work. Resilient employees can manage work and home demands effectively and minimise the adverse health affects of stress.
We identify and manage the challenges to employee resilience and mental well being, in accordance with GSK’s Global Resilience and Mental Well Being Standard. The majority of GSK sites have programmes to reduce workplace pressures and help employees achieve a good work-life balance, such as time management training, flexible working options and health awareness. Since 2002, work-related mental ill-health is down by 57 percent.

Our Team Resilience programme is now available in 11 languages. It helps GSK teams to take control of their work and avoid excessive pressure which can lead to stress. The first step is to assess seven sources of pressure that can impact performance and health, and identify the extent of pressure the team is facing. Team members then consider the issues that are creating excessive pressures and how they can be managed more effectively. The objective is not to avoid any pressure – which can help to achieve high performance – but to avoid becoming strained or overwhelmed due to excessive work demands.

By the end of 2006 more than 12,000 people from over 1,000 teams had gone through the programme. The results show significant improvements. In the first two years of the programme:

- Reported pressure due to worklife conflicts fell by 25 percent
- Participating staff satisfaction increased by 21 percent
- 14 percent increase in willingness among staff to experiment with new work practices
- Teams that have taken the profile for a second time are showing improvement in the seven sources of pressure of between 30 percent and 70 percent

We also provide a training programme to support personal development and help individuals become more resilient. Pre- and post-assessments in a pilot of 500 employees found improvement in 55 of 58 elements measured, with the greatest improvement in employees’ sense of being relaxed and engaged. After two months the number of people who felt less pressured rose by almost a fifth.

**Personal health**

Our programmes aim to improve the health of employees and their families, which benefits the business through increased employee commitment and productivity and reduced costs of ill-health.

Support includes on-site health and fitness centres, flexible working arrangements and family support services. Healthcare benefits focus on prevention and access to innovative and proven treatments. For example, in the US employees receive free immunisations, cancer screening, help with smoking cessation and regular check-ups. We assist employees suffering from chronic diseases with their medical plans so they can continue with treatments.

We have developed a new global management role focused on improving the health of employees around the world by developing health and well-being resources and sharing best practice. In 2006, we:

- developed a Health Risk Appraisal tool that can be used at all our sites
- worked with the World Heart Federation on a joint project at two of our sites in India. This ground breaking three-year study will look at two different interventions aimed at reducing the effects of chronic disease, identifying the most effective interventions that are sustainable and transferable to other companies and community programmes
- began global health education webinars (web-based seminars)

**Ergonomics**

The reduction of musculoskeletal illness and injury continues to be a key area of focus, because it is one of the leading causes of time away from work. We have set a target to reduce the number of these illnesses and injuries by 5 percent each year through to 2010. Better workplace and job design, a science called ‘ergonomics’, will prevent musculoskeletal injuries and illnesses as well as increase efficiency and productivity.

Ergonomics improvement teams include cross-functional team members who impact how work and the work environment is designed and implemented. We now have established ergonomics improvement teams at manufacturing sites around the world. In 2006, ergonomics workshops were provided to regions in the US, UK, France, India and Malaysia to increase in-house ergonomics knowledge and expertise.

Sites share good practices for work, ranging from commercial operations to laboratory research to manufacturing, via an intranet site called The Global Ergonomics Community. This intranet site provides access to the latest information on ergonomics, good practices and validated tools for practitioners, including our online computer ergonomics risk assessment tool. The online assessment is used by 144 GSK sites globally. Over 17,800 employees worldwide have used the tool during the past two years to assess their computer work and to take steps needed to improve their workstations.

Ergonomic principles are integrated into designs including major engineering projects, and furniture procurement takes ergonomics into consideration to ensure that appropriate furniture and equipment are selected.

**HIV**

We provide anti-retroviral treatment to all HIV positive GSK employees (full and part-time) and their families in countries where treatment is not available adequately or consistently through the local healthcare system. (For more background information see employee access to anti-retroviral drugs.)
We have developed awareness-raising material for use by peer educators, in a project funded by Positive Action and delivered by the National AIDS Trust. GSK and other employers use these materials to deliver training in ways that address the problems of HIV and AIDS-related stigma.

The materials are based on the experience of GSK Kenya and adapted versions have now been used in India and Central America. A French version has been promoted by the GSK Foundation across francophone Africa.

**Flu Pandemic Preparedness**

GSK is committed to supporting governments and health authorities around the world, as well as our own employees, in minimising the impact of a global influenza pandemic.

GSK will play a vital role in providing potentially life-saving medicines and vaccines for flu, as well as continuing to produce our other critical medicines. We have invested more than $2 billion in expanding seasonal flu vaccine capacity, developing an avian flu vaccine, and increasing production capacity for the anti-viral flu treatment Relenza. See our Contribution to Society.

We have also been developing plans to ensure the continuity of critical business operations and processes, and to safeguard the health of the GSK employees, their dependents and key contractors on our sites. Every GSK market is developing a comprehensive country plan which covers all local business units. The plans include annual seasonal flu vaccine and travel health programmes, measures to reduce infection risk at work, management of sickness absence, and provision of a treatment course of anti-virals (and possibly vaccine) to all employees and immediate family members worldwide. All markets are expected to have completed plans by the third quarter of 2007.

**HEALTH AND SAFETY AT WORK**

The health and safety of employees and contractors is an absolute priority for GSK. We have programmes to systematically assess the risks associated with our operations. We monitor performance, aiming to learn from the causes of incidents and take action to protect employees and others in the workplace.

Our ultimate aim is to eliminate all work-related injuries and illnesses (I&I). We are now focusing on ‘reportable’ incidents. These are more serious than first aid but do not necessarily result in time off work (lost time) which was the main measure of performance we used in the past. We believe that addressing causes of these minor events will help to eliminate risks and hazards, which should lead to fewer reportable cases as well as lost-time I&I cases.

Our new target (from 2007) is to reduce reportable I&I by 5 percent a year. We will still monitor and report ‘lost time’ incidents but we no longer have a target for this measure.

Our programmes cover a wide range of health and safety (H&S) aspects, from providing safety training for sales employees to working with all employees to improve their general health. This section reports on specific health and safety issues. See the Environment section on page 52 for more information on how we manage environmental and broader EHS issues.

**HEALTH AND SAFETY MANAGEMENT**

We manage health and safety through an integrated environment, health and safety (EHS) management system. The system incorporates our EHS and Employee Health Policies, EHS Vision and 64 Global EHS Standards. Our EHS Plan for Excellence sets out our strategy for improving EHS performance. We renewed the Plan in 2006 and extended it to 2015. See more on our EHS Management System in our background pages.

**OHSAS 18001 certification**

In 2006, one additional site achieved certification to the international health and safety standard OHSAS 18001. This brings the total number of manufacturing sites certified to 21 out of 80 pharmaceutical and consumer manufacturing sites. The certified sites are in Argentina, China, Egypt, France, Germany, India, Japan, Kenya, Mexico, Poland, Saudi Arabia, Turkey, USA and the UK. The voluntary certification process is being replaced with a plan to require all manufacturing sites to be certified by 2010.

**Training and awareness**

Training is targeted to match employee responsibilities. Employees with responsibility for H&S issues receive regular training about initiatives in areas such as ergonomics, chemical exposures and driver safety. This is handled through regional meetings of H&S staff. They in turn train employees in manufacturing, research, sales and other divisions. Corporate EHS and Employee Health staff arrange annual meetings to determine training issues and provide training materials.

We also want employees to be aware of health and safety in their personal lives. Employee bulletins, announcements on the myEHS website, the CEO’s EHS Excellence awards programme and Health and Safety Week activities aim to raise employee awareness of issues such as wearing seat belts, being careful with electricity and using ladders appropriately.

We conduct a Health and Safety Week every October to coincide with the European Health and Safety week and Fire Safety Awareness Month in the United States. Information kits are sent to all sites to help them develop ideas and plan activities.

In 2006, over 20,000 employees from 63 sites in 38 countries took part in the Health and Safety Week. Activities included safe driving education, training in fire evacuation, ergonomics, first aid, awareness-raising on noise, healthy eating and lifestyles.
Ergonomics – training in ergonomic risk assessment during Network Meetings as well as regional training.

Resilience – rollout of the tool for assessing team resilience, training during EHS Network Meetings.

Chemical agents – monitoring to determine exposure and ensure adequacy of respiratory protective equipment that may be required at unit operations until engineering and other controls can be implemented.

Risk assessment – the Guideline was revised and aligned with the risk assessment requirement in the Quality group.

Self audit – training and workshop on self-auditing conducted at EHS Network Meetings.

Management system elements – agreement of Global Manufacturing and Supply to target OHSAS 18001 certification (along with ISO 14001 certification) for all pharmaceutical and consumer manufacturing sites.

EHS AUDITS

We aim to conduct EHS audits at each operational site at least once every four years. We carry out more frequent visits at selected sites, depending on an assessment of risk and the issues raised by previous audits.

Auditors signal ‘critical’ findings if they conclude that there is a high probability of incidents with potentially serious consequences. They made five such findings in 2006. These involved serious deficiencies in:

- Controlling exposures to high hazard chemical agents
- Managing dust explosion risks (related to a dust collector)
- Managing fire or explosion risks from flammable liquids
- Preventing falls from elevated locations

Site actions are monitored to ensure that appropriate actions have been taken to mitigate risks and ensure ongoing compliance. None of the critical findings have become ‘delinquent’ (greater than 90 days overdue).

We actively track audit findings and identify improvements with follow-up audits. For sites scoring less than 50 percent, we also provide increased support from the audit team, including follow-up visits to ensure progress, and discussions with senior business management about increased site resources. Many sites require several years to put adequate systems and programmes in place in these areas.

We introduced or continued specific work in the following areas in 2006 to achieve improvements:

- Chemical agents – monitoring to determine exposure and ensure adequacy of respiratory protective equipment that may be required at unit operations until engineering and other controls can be implemented
- Resilience – rollout of the tool for assessing team resilience, training during EHS Network Meetings
- Ergonomics – training in ergonomic risk assessment during Network Meetings as well as regional training

INJURY AND ILLNESS RATES AND CAUSES

Our main measure of injury and illness is the number of reportable cases which we require sites to report. We express this as a rate per 100,000 hours worked.

Our target is to reduce this reportable injury and illness rate by 5 percent each year to the end of 2010.

We also measure the number of days lost from injuries and illnesses. This provides an indication of the severity of the incidents, although it is only a rough guide. For example, an illness could lead to permanent hearing loss or other disability without resulting in significant lost time.

The main data cover GSK employees and contract workers who we directly supervise. Separately, we report data for contractors who work on GSK sites but supervise their own staff. (Contractors’ data are not covered by the SGS verification). The data are collected from all our 80 pharmaceutical and consumer manufacturing sites, 12 of our 13 Biologics manufacturing sites, all 22 pharmaceutical and consumer research and development sites, all 8 major office locations and 59 smaller offices.

Causes of injuries and illnesses

Injuries with and without lost time arise mainly from slips, trips or falls, over-exertions or strains and motor vehicle accidents.

Lost-time illness stems mainly from mental ill-health and musculoskeletal problems (primarily repetitive strain injury). Musculoskeletal illness is the main cause of reportable illness which does not lead to days off work, accounting for about a third of the total.

2006 highlights

At 76 sites in 38 countries, there were no lost-time injuries or illnesses during the year. In addition:

- one site in India achieved 4 million hours worked without a lost-time injury or illness
- one site in India achieved 3 million hours worked without a lost-time injury or illness
- one site in the US achieved 2 million hours worked without a lost-time injury or illness

Employee health management

UK – resilience policy

Employee Health Management developed a wide-ranging resilience policy that successfully addresses work-life balance and pressure issues, to the benefit of GSK and our employees. We define resilience as the ability to be successful, personally and professionally, in a high-pressure, fast-paced and continuously changing environment. The policy encompasses the team resilience process and personal resilience workshops, which focus on work and home balance and fulfillment.

This project has global application, although the focus in the first year was the UK and US. In the second and third year of the programme the project has been offered globally and is currently active in India, Japan, China, Brazil, Argentina, Finland, Czech Republic, Nigeria and Israel. It has reached more than 7000 employees.

This project won first place in the EHS Initiative health & safety category of the CEO’s EHS Excellence Awards.
Performance
In 2006 we recorded 995 injuries and 376 illnesses (total of 1371 incidents), compared to 984 and 344 respectively in 2005. Employees lost working days in 646 (47 percent) of these incidents (624 in 2005).

GSK’s injury and illness performance placed us in the third quartile of a benchmark industry group in 2005 which means we need to improve.

Working time was lost in 552 injuries and 94 illnesses, a rate of 0.33 lost time injuries and illnesses per 100,000 hours worked.

There were 443 injuries and 282 illnesses without lost time, a rate of 0.37 injuries and illnesses without lost time per 100,000 hours worked.

There were 11,281 lost calendar days from injuries and 4,386 calendar days lost from illnesses, a rate of 8 calendar days lost per 100,000 hours worked.

See data table on page 74 for more details.

Fifteen sites in Argentina, Canada, India, Philippines, Singapore, Spain, Sri Lanka, UK and the US achieved 1 million hours worked without a lost-time injury or illness.

SERIOUS INCIDENTS AND FATALITIES

Fatalities
In November 2006, two employees of contractors died as a result of injuries suffered in an explosion and fire caused by a ruptured butane cylinder used for cooking in the canteen of the Agbara, Nigeria Consumer Healthcare factory. A thorough investigation was conducted by the global audit team and improvements identified. Progress in implementing the improvements will be monitored by the audit team and learnings from the incident will be shared across GSK.

In April, one sales employee in India died as a result of head injuries suffered when his motorbike collided with another motorbike.

Irvine – explosion
A serious explosion occurred at the Irvine, UK site in February 2006, involving a ‘placebo’ batch used to test plant conditions and controls. Two operators were injured. The event has been thoroughly investigated, learnings shared and improvements made. The UK Regulator, HSE, is considering its course of action, with prosecution a possibility.

Amputations
In 2006, there were three incidents involving GSK employees that resulted in partial finger amputations caused by work equipment.

Five year trend in employee fatalities:

<table>
<thead>
<tr>
<th>Year</th>
<th>Fatalities</th>
</tr>
</thead>
<tbody>
<tr>
<td>2002</td>
<td>3</td>
</tr>
<tr>
<td>2003</td>
<td>5</td>
</tr>
<tr>
<td>2004</td>
<td>2</td>
</tr>
<tr>
<td>2005</td>
<td>1</td>
</tr>
<tr>
<td>2006</td>
<td>3</td>
</tr>
</tbody>
</table>

We investigate the circumstances of all fatalities and other serious incidents and assess what can be learned to reduce the risks. We also issue global alerts (posted on our intranet site) to communicate information that could help prevent similar incidents at other sites.

SAFETY PROGRAMMES

We systematically assess risks to anticipate potential accidents, and put programmes in place to minimise them. We learn from investigating the causes of accidents and make improvements accordingly. In this section we cover four key areas: driver safety, process safety, material hazard information and chemical exposure.

Driver safety
Our sales representatives drive long distances every year and are therefore particularly at risk of being involved in work-related road traffic incidents. In 2006, there were 184 driving accidents, 1 resulting in a fatality and 116 resulting in lost time. These accounted for 21 percent of lost-time injuries.

Our compliance tool for drivers, called ‘EHS Essentials’, includes instructions and guidelines on driver training, vehicle selection, risk assessment and accident reporting as well as other information. We continue to use it as we implement our driver safety programme around the world.

Around two thirds of GSK’s commercial businesses have extensive driver safety programmes in place. They include driving licence checks, guidance on the use of mobile phones in vehicles, driver safety training, tracking and reporting incidents. We are working to ensure all sites have the same high standards in place. In 2006 we have been concentrating on improving areas such as accident and injury reporting and driver training.

In a few countries we provide motorbikes or scooters for employees and have produced a GSK motorbike rider safety manual. This has been translated and distributed to employees in countries such as Bangladesh, India, Indonesia, Pakistan and Vietnam. These countries have now also fully implemented the GSK requirement for every driver of a motorbike to wear a helmet. We will continue to follow up and monitor the implementation of the motorbike safety programme.
Process safety

Our process safety programme ensures that safety is built into all manufacturing, research and development processes. The programme is based on hazard identification, control and risk assessment.

We launched a major review of our process safety strategy in 2006, following the explosion at our Irvine factory. This encompassed:

- consistency of design standards
- evidence for the Basis of Safety, including any gaps in documentation and installation checks
- skills and competencies in process safety
- control of change and non-routine operations
- culture issues – awareness, attitudes and behaviour

Material hazard information

In 2006 we focused on preparation for new legislation that will have a significant impact on how we assess and communicate material hazard information. We continue to publish EHS information on our key products in safety data sheets. Some 600 of these for pharmaceutical and consumer healthcare products that are sold in the US or Europe are available on our website – see safety data sheets for more information.

We are using more alternatives to animal testing in our occupational toxicology programme. For example, in 2006 we assessed 23 chemicals for potential to cause skin and/or eye irritation in our workforce. All of these assessments were conducted without the use of laboratory animals by using information about chemical structures and novel human tissue tests. Our occupational toxicologists used this and other information to establish workplace exposure limits for 35 unique GSK materials.

To support our commitment to ensure that our products do not adversely affect the environment (see pharmaceuticals in the environment) we have enhanced our environmental hazard testing programme to include a number of new studies aimed at assessing long term effects in aquatic organisms. In addition, due to new EU technical guidelines we are conducting more extensive environmental testing of new drug substances.

Occupational hygiene and control of chemical exposure

In 2006, exposure to chemicals resulted in 7 respiratory or skin-related lost-time incidents and 98 cases which did not result in lost time. Together, they accounted for 28 percent of work-related illnesses.

In 2004 we developed a strategy to control chemical exposure up to 2010. This sets out a plan to achieve ‘respirator free’ status – having validated control at the source for 80 percent of unit operations handling high hazard compounds, so that employees do not need to wear protective equipment.

There has been substantial progress during 2006:

- we have recruited a number of regional hygienists to deliver an improved occupational hygiene service to businesses around the world
- we are establishing our baseline performance and have developed and deployed across the business a tracking tool to monitor progress towards ‘respirator free’ and completion of Chemical Risk assessments
- we have enhanced collaboration between engineers and occupational hygienists at all levels to ensure that control solutions are implemented
- we have revised and updated guidelines to the business on control measures
- we have begun to build our occupational hygiene network by bringing specialists together, and held the first network meeting for occupational hygienists to ensure a common approach and understanding across the businesses
- we have engaged with new product introduction teams to ensure that new installations meet ‘respirator free’ standards.

See more on our approach to Occupational hygiene and control of chemical exposures on our background pages.
Supply chain

Our supply chain is complex, with over 75,000 suppliers worldwide. It ranges from major strategic relationships with suppliers that manufacture active pharmaceutical ingredients, intermediates, raw materials and packaging for GSK medicines through to local contracts for goods or services such as office equipment, cleaning and security.

We endeavour to ensure that all our suppliers follow the same high standards as GSK with regards to the environment, health and safety (EHS), loss prevention and human rights. Given the size and global scope of our supply chain this is a challenge and we recognise that some suppliers do not meet these standards (see supplier performance below).

We work with suppliers on these issues. Our approach includes:

- pre-assessments before we start working with a new supplier
- inclusion of human rights and EHS requirements in supplier contracts
- review of EHS and human rights in routine supplier engagements
- EHS supplier audits

Our supply base is large and complex so it is not possible to engage directly with all our suppliers on these issues. We focus on critical suppliers.

Critical suppliers are contract manufacturers and those suppliers that present the greatest risk to GSK on one or more of the following issues:

- threats to continuity of supply
- hazards associated with manufacturing processes and materials
- environmental impacts
- regulatory requirements
- relevance to the supply of essential medicines

These suppliers are based primarily in Europe, North America, and Asia and account for approximately 30 percent of our total supplier spend.

We expect critical suppliers to work to high standards and produce an uninterrupted supply of materials and services to GSK. If they do not, the safety, effectiveness or availability of our medicines could be affected. For these reasons, it is important that we forge long-term relationships and undertake regular monitoring to assess progress and to allow intervention where necessary.

Supplier selection

Critical suppliers must pass detailed assessments before they can be selected. As well as looking at quality, we assess their policies and procedures for health and safety, human rights, and environmental issues. This includes the use of questionnaires, on-site reviews, quality audits and EHS audits of facilities which will directly supply GSK.

All contract manufacturers must also be approved by the applicable regulatory authority before they can start manufacturing GSK medicines.

SUPPLIER CONTRACTS

EHS

Our supplier contracts contain requirements based on our Global EHS Standards.

Human rights

Our supplier contracts contain human rights clauses based on international workplace norms in the International Labour Organisation conventions and the UN’s Universal Declaration of Human Rights. You can read the human rights clauses in the background section of our website.

All new local and central supplier contracts worldwide include human rights clauses and these are added to contracts with existing suppliers as they are renewed. Most contracts are renewed on a three-year cycle so the vast majority of our contracts now include the clauses.

Engagement and auditing

We provide contract manufacturers with information on the EHS risks associated with the GSK materials they are producing or handling.

We inform suppliers about our ethical requirements and policies. Our supplier booklet on working with GSK includes our ethics policies and explains that GSK employees are prohibited from accepting gifts and entertainment. Suppliers are asked to respect this position and to apply the same standards in their business and interactions with GSK. In some countries we send out letters to all suppliers during the local festival season making them aware of our policies and asking them to refrain from sending gifts and providing entertainment.
We consider EHS and human rights issues during our routine interactions with critical suppliers. These interactions include ongoing supplier reviews as well as follow-up visits by procurement, quality and EHS staff. We also hold global and regional supplier review meetings where senior GSK managers address and interact with suppliers on key issues.

During 2006 we started a pilot project to assess the risk of human rights issues occurring among suppliers of services. We decided to focus in the following two areas:

**Suppliers of outsourced business processes**

We are starting to work with more suppliers in India. This includes providers of outsourced services, for example our accounts payable department is now managed by an Indian supplier, as well as providers of technology and professional services. Since this is a growing and important area we are focusing on ensuring that we select the right suppliers with strong reputations for their Employee Satisfaction. Our research shows that the suppliers we work with typically lead the way in surveys on best Indian business process outsourcing employers.

**Suppliers of promotional gift items**

Many of our gift items sourced from our Indian business, are sourced from within India in an industry with a higher risk of the use of child labour. We have implemented a process of unannounced spot checks for these suppliers, often during the night. As a result of these spot checks we have agreed corrective actions with some suppliers to improve their standards in this area.

**EHS audits**

We conduct regular environment health and safety audits of critical suppliers and contract manufacturers of pharmaceutical and consumer healthcare products. Priority for undertaking audits is based on business and EHS risks, including factors related to continuity of supply, hazards presented by processes and materials, regulatory regimes and essential medicines. We focus on the 150 higher risk suppliers.

A quantitative evaluation is made of sites against EHS standards and protocols. Acceptance criteria are in place and sites will not be used for supply unless minimum performance levels are met. Recommendations are made following audits and progress is monitored with particular focus on poorly performing suppliers. Performance reviews are undertaken to check progress and to help drive continuing improvements. For some sites this means, at the least, an annual visit.

**Supplier performance**

In 2006, 28 assessments were conducted of suppliers of active pharmaceutical ingredients and intermediate materials for the global pharmaceutical supply chain. Of these, ten were in the UK and Europe and 18 were in the Asia region. Six sites supplying other products and materials were audited in the UK, EU and US, one in Asia and one in South Africa.

The EHS acceptability criterion for key suppliers and contract manufacturers is scoring at least 50 percent in the EHS Quantitative Audit scheme. Where EHS performance is identified as unacceptable (less than 50 percent) progress is required before EHS risks and impacts can be considered to be managed robustly and sites considered as acceptable suppliers or contract manufacturers.

A wide range of performance was noted for the sites audited. The range of audit scores for these suppliers was 23 percent to 90 percent. Eleven of these suppliers failed to meet the 50 percent EHS acceptability criterion, and the companies were either not progressed for supply or work is underway to ensure improvements are made.

During these EHS audits no human rights issues of significant concern were noted.

**Training for GSK procurement teams**

It is important that our employees understand our standards. We provide training for procurement staff as part of our Sourcing Group Management programme. This explains how we develop sourcing strategies and our criteria for supplier selection, including human rights and EHS. The training is compulsory for all new procurement staff.

In 2006, we launched new training on Effective Contracting. This explains our requirement for human rights clauses to be included in all supplier contracts. It will be compulsory for all procurement staff and we expect everyone to have completed the training by the end of 2007.

**Reporting suppliers’ EHS performance**

We have tried to collect EHS data from key suppliers over the past five years but have had only limited success. Suppliers either do not collect the data and use it to manage their EHS programmes or they cannot identify the impacts specific to manufacture of GSK products. Data that we have received from suppliers is often not reliable.

In 2007, we will conduct a survey of suppliers, at the request of both the Corporate Responsibility Committee and the Audit Committee of the Board, to determine why the suppliers have not provided us with this information. We want to understand suppliers’ impacts as well to measure the total EHS footprint of all of the processes that generate our products, ie both GSK and supplier facilities.

We are working with our Ribena suppliers and the Wildlife Trust to improve biodiversity on blackcurrant farms and to understand the overall environmental impacts of these operations. See the case study section on our website for more details.
Environmental management

Our vision is to achieve sustainable competitive business advantage and environmental sustainability through leadership and excellence. We aim to reduce our environmental impacts and address broader sustainability issues such as climate change, product stewardship and material and energy efficiency.

Q&A

James Hagan
Vice President, Corporate Environment, Health and Safety

What is the top environmental priority for GSK?

The priority is to manage all the issues properly, looking at people, plant and processes, in the context of a long-term strategic plan.

We have been working on that since GSK was formed. In 2001 and 2002 I asked all operations worldwide to contribute to the creation of a self-regulating framework of programmes (i.e. policies, standards, guidance, audits, etc.) that defines how we believe we should operate, with legal compliance as the basic foundation. In 2003, we identified the key risks to GSK as employee chemical exposure, process safety, ergonomics, and driver safety, which we will continue to work on for some years to come.

In 2004, in discussions with our external stakeholders about EHS issues, they said that climate change and energy conservation, pharmaceuticals in the environment and the use of hazardous/toxic chemicals were our key external challenges. In 2005, we worked to complete core programmes and EHS management systems and achieve our improvement targets. Now it’s time to move to the next stage.

Q&A continues on next page

We discover, develop, manufacture and sell pharmaceutical and consumer products. This requires significant resources, so we need to understand, address and report on environmental impacts. They include issues common to all manufacturers, such as the use of energy and water, and waste handling. We also need to consider potential impacts of certain chemicals which can release volatile organic compounds (VOCs) and the chemicals in our inhalers which can damage the ozone layer and contribute to climate change. And our industry can have specific impacts through the release of pharmaceuticals into the environment after use by patients.

A systematic approach to management of these issues is crucial because control needs to be consistent over the long term. This is important as we move away from controlling emissions from our processes to developing and implementing new processes that are more efficient and therefore use less raw material and produce less waste. This is one of the first steps toward environmental sustainability which is our long term goal.

Overall responsibility for environmental issues rests with the Corporate Executive Team and the Board. The Board champion for Environment, Health and Safety (EHS) is JP Garnier, the Chief Executive Officer. Rupert Bondy, General Counsel, is the operational champion of EHS on the corporate executive team. We have a Corporate Responsibility Committee and Corporate EHS department.

Environmental issues are managed together with health and safety through an integrated EHS system that aims to ensure issues and risks are identified, standards are established and adhered to, training is provided, targets set and audits conducted.

Our EHS Policy, Vision and 64 Global EHS Standards set the overall framework. We provide sites with an EHS management toolkit which contains instructions and descriptions of appropriate procedures to help them comply with the standards.

Further background information on our approach to managing environmental issues is available in the Environment, Health and Safety section of our website.

THE PLAN FOR EXCELLENCE

We launched an EHS Plan for Excellence in 2001 which set out a strategy to improve EHS performance over a ten-year period. In 2006 we reviewed the first five years’ performance, renewed the Plan for the second stage and extended it to 2015.

We began our review of the Plan for Excellence with an extensive consultation with key internal and external stakeholders, who encouraged us to adopt higher aspirations and align EHS objectives more closely with the business strategy.

The first five years of the plan established fundamental programmes that protect employees, our communities and the environment. The renewed plan includes a commitment to stakeholder engagement and strengthens the focus on sustainable environmental practices through operational efficiency. This requires a new approach to manufacturing processes and means we will move to incorporating environmental performance in process design, moving from compliance and risk management to adding value and creating new opportunities. For example, we want to move from having to treat a hazardous waste stream to choosing processes that do not produce hazardous waste.

The renewed plan is designed to complement the business strategies and contains three EHS Aspirations for GSK by 2015:

- **EHS fundamentals embedded in the business** – we believe that to produce and sustain high EHS performance we need to combine structured EHS systems with the attitudes and values that create a positive EHS culture. To achieve this we need to embed EHS awareness and systems in all GSK activities

- **Environmental sustainability** – we believe we need to embrace environmental sustainability as a driver for competitive advantage. To do this we have to define the principles of environmental sustainability and progressively integrate them into the business, translating them into practical action in line with advancing knowledge
• Open and transparent EHS external relations – we believe that external stakeholders who have a legitimate interest in the company's EHS affairs should have ready access to relevant information and the opportunity for dialogue about issues that concern them. We also believe that building open relationships and partnerships can lead to business opportunities, while failure to engage may damage our reputation.

Each of these aspirations is supported by strategic objectives with performance targets in some areas.

Progress and targets
Our EHS Plan for Excellence initially set out targets in 10 areas, with interim targets for 2005.

See 2005 report for progress against these targets.

The plan for the next 10 years is aligned with the GSK business drivers and with our desire to move towards environmental sustainability. We have introduced these new targets:

• Material efficiency – by targeting efficiency we simultaneously target resource consumption, air emissions, water pollution, waste disposal and safety concerns

• EHS audit scores – these are a measure of the success of our management systems approach

These are the improvement targets across the company up to 2010, with 2006 as the new baseline:

<table>
<thead>
<tr>
<th>Annual reductions per £ of sales</th>
</tr>
</thead>
<tbody>
<tr>
<td>Energy</td>
</tr>
<tr>
<td>Solid waste</td>
</tr>
<tr>
<td>Water</td>
</tr>
<tr>
<td>Air emissions (volatile organic emissions)</td>
</tr>
<tr>
<td>Wastewater (chemical oxygen demand)</td>
</tr>
</tbody>
</table>

Material efficiency
Achieve average 2% material efficiency of manufacturing processes for new products introduced between 2006 and 2010.

<table>
<thead>
<tr>
<th>Cumulative targets for 2010</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ozone depletion</td>
</tr>
<tr>
<td>EHS audit scores</td>
</tr>
<tr>
<td>– Minimum 70%</td>
</tr>
</tbody>
</table>

We no longer have targets in these areas:

• global warming potential – we have replaced this with a target on energy efficiency

• hazardous waste – we are now addressing hazardous waste through the new material efficiency target

Each business sector will develop its own objectives to support the corporate targets and will develop specific short and medium-term plans to achieve them. Individual sites may also set local targets to contribute to the business target.

We use annual action plans to focus our efforts on selected priority issues. The theme for 2006 was ‘Embedding EHS in the Business’ following the initial focus on fundamentals in the first 5 years of the Plan.

The theme for 2007 is ‘EHS Stewardship’, which means caring for the present and thinking to the future when we make decisions, building excellence over time and maintaining the highest possible standards in everything we do. Each business sector will encourage a culture that accepts this responsibility by incorporating EHS into their planning and business processes.

Corporate EHS will work with businesses to:

• determine which elements of environmental sustainability we need to focus on and begin to promote environmental sustainability principles throughout the business

• continue the pilot programme of developing and distributing product stewardship guides for marketed products

• expand our programme of discussions with EHS external stakeholders beyond the UK to the rest of Europe and into the US.

See more in the Product Stewardship section and our background web pages.

STAKEHOLDER ENGAGEMENT

Stakeholder engagement plays an important role in how we manage EHS. This section reports engagement specifically on EHS issues. See engagement with stakeholders in the Managing CR section for details of engagement on other corporate responsibility issues.

In addition to inclusion in the Dow Jones Sustainability Index and the UK FTSE4Good, GlaxoSmithKline is rated by Business in the Environment (BiE), in the ‘premier league’ in a field of 145 participating companies. This rating indicates the extent to which we interpret environmental responsibility into the way we manage our business and in our environmental performance.

We have frequently engaged through ad hoc meetings with a range of external stakeholders to help us understand their views and identify emerging issues. In 2005 we stepped up our internal and external engagement on EHS issues and created a formal stakeholder panel in the UK to provide a perspective on our EHS performance. The panel is facilitated by The Environment Council, an independent charity, and the 10 members represent our customers, suppliers, regulators, public interest groups and investors, plus four senior EHS representatives from GSK.

The next step is to expand our focus by improving our use of natural resources as a step towards sustainability. That’s complex.

We are working on material efficiency in our production (see page 57). Energy is also a critical component and in 2006 GSK adopted a life cycle approach to investing in energy efficiency and renewable energy. (see page 60). In fact our CEO has requested a further review in 2007 of energy saving measures and use of renewable energy. Product stewardship is another aspect of sustainability and we will need to focus on the issue of pharmaceuticals in the environment (see page 59).

What is the highlight of 2006?
Approval of the second stage of our Plan for Excellence, up to 2015 (see page 52). In the first stage of the plan, since 2001, we focused on the fundamentals and improved our performance in many areas, but we need to do more. In the second stage of the plan, we will keep a keen focus on maintaining improvements, based on that foundation and on new annual improvement targets. In 2006, we established improvement targets for manufacturing new medicines which will move us toward our goal of sustainability.

From a tangible standpoint, our manufacturing function (GMS) has accepted the challenge from the Board of Directors to be ISO 14001/ OHSAS 18001 certified, which will embed management systems into the business. We have also created new EHS Director positions in GMS and Biologicals who sit on the executive teams and will help EHS to be integral to all business decisions.

Q&A continues on next page
It provides an opportunity for EHS experts from across GSK’s businesses to meet stakeholders and discuss emerging EHS issues. Feedback has been used in developing the EHS Plan for Excellence.

The panel meets every six months. In 2006 discussions covered:

• our engagement strategy
• the need for public position papers on climate change/energy management, the management of hazardous chemicals, and pharmaceuticals in the environment (the final versions, approved by GSK management, are published on gsk.com)
• a serious process safety incident at our Irvine site (see the Health and Safety section)
• the strategic plan for EHS
• EHS performance in 2005
• how EHS aligns with GSK’s business direction

Stakeholders have repeatedly highlighted their view that it is important for GSK to address broader issues such as climate change and sustainable development. We are beginning to address broader aspects of sustainability, for example in our work on material efficiency.

We plan to extend our stakeholder engagement activities to the US, Europe, and beyond over the next few years, beginning in the US in 2007. (See Stakeholder engagement background pages.)

Local engagement

Many of our sites also engage with stakeholders locally, through activities such as open days, newsletters and community projects. For example, our Dresden site conducted intensive communications with the local community ahead of doubling the manufacturing capacity for its flu vaccines. The construction activity was particularly sensitive because the site is in a residential area. This work won third place in our CEO’s EHS Excellence Awards for community projects.

In 2006, we conducted a survey of EHS stakeholder engagement at 52 GSK sites around the world. This found that our sites engage most frequently with local government, the emergency services, neighbours/resident associations, local environmental and advocacy groups, and local business partners. Our sites reported that open dialogue with communities helps to build strong relationships and to dispel preconceptions. In particular they reported that it is beneficial to involve local communities in environmental risk assessments and the development of emergency response plans and site waste management plans.

Internal engagement

We engage with our GSK staff throughout the business in several ways. This includes discussions with business leaders to debate and agree the way forward for EHS at GSK, especially to agree the annual action plan and position papers on specific issues such as energy.

Engagement with EHS professionals helps us to work out details of programmes such as energy initiatives.

In 2006, we surveyed staff who are involved in EHS to assess the success of our communications and to identify areas for improvement. We also completed an internal review of Corporate Environment Health and Safety (CEHS) communications.

The EHS Framework documents received high marks for usefulness as a source of information, as did the EHS Community webpage. But the web page needs to be more user-friendly and we will relaunch the site in 2007.

We found that there was high awareness of the EHS Plan for Excellence, of EHS programmes on chemical agents and process safety, of EHS reward and recognition programmes, and of the theme of sustainability. But people said we needed to be clearer about our messages, especially priorities and their relationships to the overall mission of the corporate EHS department and GSK. We will address this in 2007.

In 2006, we also took feedback from company wide GSK employees to develop the 2006-2015 EHS Strategic Plan.

Engagement with regulators

GSK is keen to see proper measures in place to protect the environment and safeguard the development and launch of new medicines. At the same time, regulations need to be workable for industry to avoid unnecessary cost and bureaucracy. We collaborate with regulators to help them develop effective controls.

In 2006 we engaged with regulators in the UK on the government’s work to improve regulation of business. We submitted comments on 14 EHS regulations which we consider should be reviewed for practicability, and hosted a visit from the Better Regulation Commission to one of our pilot plants to demonstrate some of the issues. We also participated in the House of Commons Select Committee Inquiry into the work of the Environment Agency.

We worked with trade associations, including the British, European and US pharmaceutical industry EHS groups.

We engaged in the consultation process for the European Union’s Regulation on the Registration Evaluation and Authorisation of Chemicals (REACH) and the Globally Harmonised System (GHS) for the classification and labelling of chemicals. GSK supports the aims of both these initiatives to protect human health and the environment. We are pleased by the outcomes and by the efforts made by all parties to achieve workable regulation. We continue to play our part in the development of supporting guidance for REACH.
We welcome the introduction of formal guidelines for the conduct of environmental risk assessment established under the EU's New Medicines Legislation. GSK has lobbied for the environmental impacts of pharmaceuticals to be regulated solely through the European Agency for the Evaluation of Medical Products, and not also through the proposed REACH framework which would lead to duplication of effort and place an unnecessary burden on the pharmaceutical industry.

For more details on Public Policy see the Managing CR section, see page 7.

TRAINING AND AWARENESS
Raising employees' awareness of environment, health and safety issues and improving their skills through training are key parts of our EHS programme. This is critical to embedding our framework and building an EHS culture throughout the business. Employees at all levels need to understand the EHS issues in their working environment. For example, employees need to understand the properties, hazards and necessary precautions associated with the chemicals they handle. Those who handle waste need to know its properties, the regulations that govern its disposal, and which materials can be recycled.

We help employees deal with these issues through meetings, bulletins and information on our intranet site, as well as specific training events. We have an EHS standard on training.

The intranet site, myEHS Community, contains links to a range of programmes, including the EHS Manager information system which contains policies, standards, guidelines, tools, training materials, examples of best practice and news. It also provides customised management reports on EHS performance by site.

Training
Training takes place at site level and programmes are routinely included in induction training for new employees. EHS training is also accessible through myLearning, GSK's online training service.

In 2006 we carried out additional EHS management training for our Consumer Healthcare and Regional Pharma Supply organisations. We made site visits for one-on-one training on the use of the EHS Manager software system.

EHS managers are encouraged to attend conferences and training programmes sponsored by local environmental organisations and academic institutions.

Awareness
We raise the profile of environmental issues through a variety of means, including the EHS framework, the Plan for Excellence and the Chief Executive Officer's EHS Excellence Awards scheme. (See side bars on the next two pages for the 2006 first place winners.)

We also run an Earthweek every June (to coincide with the World Environment Day) and send information kits to all sites to help them develop ideas and plan activities. In 2006, 74 sites from 34 countries celebrated Earthweek with activities involving over 80,000 employees.

Examples of activities in 2006 are:
- The GSK site in Mississauga, Canada celebrated Earthweek by planting 2,000 seedlings or small trees which are indigenous to the local area, involving 350 employees
- 160 GSK employees from the Civac Consumer Healthcare site in Mexico raised the environmental awareness of a group of local school children by showing them how to separate household waste for recycling.

We cover EHS issues regularly through EHS bulletins, and articles in GSK's internal magazines (GSK Spirit, e-Spirit). We encourage employees to consider environmental issues outside the workplace, such as minimising household waste, saving energy and water.

For more information see EHS Communication on the background pages.

How is GSK planning to move beyond basic environmental protection to address sustainability more broadly?
As I mentioned before, our first step toward sustainability concerns the efficiency with which we use materials and energy in manufacturing processes. We have a new target to double the efficiency for manufacturing new products introduced up to 2010. After that date we hope we will be starting to use raw materials from renewable resources rather than petrochemicals. And in the more distant future we will want to be using biological transformations rather than chemical synthesis. All of this needs to happen with inherent safety built in to all that we do.
EHS EXCELLENCE AWARDS

The CEO’s EHS Excellence Awards recognise and reward GSK sites that show leadership in EHS. In 2006 the programme was expanded to include aspects of sustainability. The awards recognise people who have done exceptional work in promoting and implementing EHS projects. They highlight innovation and examples of good practice in EHS management to share with other sites. Each winner receives a trophy and selects a charity to receive a donation from GSK.

The winners of our 2006 Excellence Awards demonstrate once again that many projects which improve environmental performance also save money.

In 2006 – the fifth year of the awards – there were 95 entries from 25 countries. There were applications from all GSK’s business sectors: R&D, manufacturing and commercial, and from facilities management teams.

The winners were chosen by a panel that included experts from academia, government and public interest groups. In 2006, 12 projects representing Europe, North America, Central America, the Middle East and Asia received top honours.

Three of the 2006 first place award winners are featured on these pages. See further details on the CEO’s EHS Excellence Award background pages.

AUDITS AND COMPLIANCE

At the request of the Audit Committee of the Board of Directors, GSK has embarked on a programme to achieve ISO 14001 and OHSAS 18001 certification.

In 2006, the leadership of GSK’s manufacturing division (GMS) approved a four-year programme to certify all remaining GMS sites to ISO 14001/OHSAS 18001. This programme began early in 2007 and will be completed in 2010. Some sites had already achieved certification and in 2006, one additional site was certified to ISO14001 and OHSAS 18001, bringing the total of dual certified sites to 21. This means that 27 of our 80 pharmaceutical and consumer manufacturing sites are now certified (6 sites are certified to ISO 14001 only).

We carry out regular EHS audits of GSK operations, contract manufacturers and key suppliers. The aim is to assess how well they control risks and comply with key legislation, and the extent to which management systems and standards are being implemented to improve performance and maintain compliance. See supply chain page 50 for more information, including human rights audits.

Our audit programme requires all manufacturing and R&D sites to undergo EHS audits by our internal audit team. Audits occur every one to four years, depending on our assessment of risks. Sites are required to develop plans to address any weaknesses identified in the audit and auditors monitor sites’ progress in implementing the plans. Internal auditors are certified as lead auditors against the international environment, health and safety management standards: ISO 14001 and OHSAS18001. Sites are also expected to conduct routine self audits of their EHS programmes.

In 2006 the majority of audits were conducted using a new risk-based process that focused on significant operational EHS risks and environmental impacts, rather than the full range of applicable EHS Standards. The audit frequency was determined by considering key site risks and the demonstrated performance in managing them effectively.

We conducted corporate audits of 32 sites, including 2 office locations. The average score was 74 percent (compared to 77 percent in 2005). No site achieved a score below 50 percent, which we regard as unacceptable. We aim to correct unacceptable performance and continue to pursue further improvements to achieve best practice.

A good level of performance was found at most sites, especially in areas covered by GSK environmental standards. But several aspects were identified for improvement, especially safety issues, see Health and Safety page 46.

In 2006, two sites achieved ‘leadership’ scores above 90 percent (two in 2005), while a further 10 achieved scores over 80 percent (seven in 2005).

The best performance on environmental issues was in:

- management of solid wastes
- air emissions
- emergency planning

Sites were generally weakest on:

- self auditing and inspection
- risk assessment processes
- biodiversity

Compliance

As a minimum, our policy is to comply with all legal requirements. There were no fines or penalties reported in 2006. We regret that in 2006 we were in breach of regulations in three cases, prompting the US Federal Aviation Administration to issue warning letters without penalties regarding non-compliance with shipping regulations. Deficiencies were:

- Non-compliance with marking, labelling and documentation of a shipment of inhalation aerosols
- Inoperative emergency number for hazard information
- Undeclared dangerous goods (flammable liquid) shipped via inter-office mail
MATERIAL EFFICIENCY

We aim to improve the efficiency with which we convert raw materials to finished product, as part of our drive for environmental sustainability. It will help us to reduce our consumption of resources, the waste we generate and the cost of production.

We have set a target to double the average material efficiency of manufacturing processes for new products introduced between 2006 and 2010. This will achieve material efficiencies of 2 percent for these new processes i.e. two tonnes of active pharmaceutical ingredient (API) for every 100 tonnes of input chemicals.

Pharmaceutical processes are typically very complex, often requiring large amounts of solvent. Typically, the industry uses about 100 tonnes of material for every tonne of API produced. That 1 percent material efficiency compares to about 20 percent for fine chemicals and 50 percent for bulk chemicals. It represents a waste of valuable resources, with financial as well as environmental consequences.

Our approach to addressing EHS issues already includes minimising the amount of material used – for example, through the eco-design toolkit (see page 58). We are now placing a higher priority on improving our use of materials and are bringing together R&D and manufacturing teams to increase material efficiency in the product development stage, as well as for selected existing products.

Our key measure of material efficiency is ‘mass productivity’. This is the mass of all materials (except water but including solvents) used in the process compared to the mass of product produced. Our new 2 percent target applies to this measure.

We are already making improvements to material efficiency. For example, a research and development team at our Stevenage, UK R&D site, worked with our Cork, Ireland site to achieve substantial environmental benefits by developing a simplified process for manufacturing dutasteride, a treatment for benign prostate hyperplasia. The project will continue to deliver benefits to at least 2015.

This work won third place in the Green Chemistry category of the Chief Executive Officer’s EHS Excellence Awards in 2006.

The new process:

- vastly reduces the use of solvent and therefore waste – a 70 percent reduction in the mass of waste, which avoids up to 80 tonnes of waste per annum
- is more robust than the previous process, resulting in less waste through failed batches
- reduces exposure of employees to hazardous materials.

The chart shows the extent to which we are improving material efficiency as compounds move through development stages. These data relate to compounds in development in 2006.

In early development almost all compounds have a mass productivity less than 1 percent. But the proportion with this low level efficiency falls in each stage. By the last stage of development, before transfer to manufacturing, the majority achieved productivity of more than 2 percent and some are above 3 percent, with one process achieving productivity of 4.9 percent.

Stevenage, UK

Our R&D site in Stevenage reduced the environmental impacts of manufacturing a compound which was in the development stage.

The original process for manufacturing the drug involved the use of seven different solvents and a number of hazardous chemicals. It produced low yields and high waste volumes.

The team at Stevenage developed a new technique that tripled material efficiency from 0.7 percent to 2.0 percent, which will reduce waste by 68 percent, using less organic solvent and hazardous chemicals. It also required less energy and the majority of waste could be handled on site.

This project won first place in the Green Chemistry/Technology category.
PRODUCT STEWARDSHIP

We address environmental issues associated with our products throughout their life cycle. This begins with product design and continues through manufacturing to eventual disposal. We refer to this as product stewardship.

This section covers product design (including packaging) and the impacts of pharmaceuticals in the environment. The research and development section of this report covers our approach to animal testing. Read more about environmental issues associated with our products on our background pages.

Product design

Environment and health and safety staff work with product development teams to incorporate EHS considerations into the design of products and sourcing materials, and to identify residual EHS risks as products move from R&D to manufacturing.

Eco-design toolkit

We have developed an eco-design toolkit which scientists and engineers use to identify process improvements and address EHS issues early in the development process. The toolkit is available on the GSK intranet and consists of five modules:

- a Green Chemistry/Technology Guide, which helps GSK scientists and engineers apply Green Chemistry concepts to achieve more efficient use of resources, reduce EHS impacts and minimise costs
- Materials Guides, containing information on a range of materials used within GSK operations, including solvents that should be avoided. One guide covers solvent selection while a second deals with chemical base selection
- a Green Packaging Guide – an assessment tool which includes guidance and a business process for evaluating and selecting packaging options (see Packaging next)
- FLASC (Fast Lifecycle Assessment for Synthetic Chemistry) – a web-based tool and process that allows bench chemists to perform a streamlined life cycle evaluation of the environmental impacts of new or existing processes based on the materials used. FLASC helps scientists and managers to rapidly identify the ‘greenest’ materials option by comparing and benchmarking processes. It identifies the materials that have the most significant life cycle environmental impacts and provides guidance on how to reduce those impacts
- The Chemicals Legislation Guide (CLG) identifies legislation in various parts of the world aimed at phasing out hazardous substances from routine use. The CLG provides risk-based guidance, about a variety of chemicals of concern, in an easily accessible form.

Each module was designed to ensure that all EHS impacts of materials, processes and services are considered, from the manufacture of the raw materials through to the ultimate fate of products and wastes in the environment.

See more on the toolkit and our approach to product design in the background pages.

PACKAGING

We are working to improve the environmental performance of our packaging across several areas.

Our Green Packaging Guide provides guidance and a business process for evaluating and selecting packaging options. It includes an interactive “wizard” known as WRAP – Wizard for the Rapid Assessment of Packaging – which helps packaging designers and managers to benchmark new and existing packaging designs, considering five metrics over the product life cycle:

- manufacture of the material
- mass of the material
- biodegradability
- PVC content
- resource depletion

The example of bottles for consumer products such as Lucozade illustrates the range of work on packaging:

- reducing the amount of packaging – we moved from glass to a plastic bottle, making a huge saving in weight, energy and transport costs. Then we progressively reduced the weight of the plastic bottle by 14 percent
- increasing the use of recycled material – bottles currently contain between 20-30 percent of recycled material and we intend to increase this to 100 percent as soon as we can develop a reliable supply
- improving design to facilitate recycling of our bottles – recycling is easiest from clear bottles with no contaminating residues. We have changed from coloured to clear bottles and have developed shrink sleeves which do not need adhesive and can easily be separated
- promoting recycling in the community – we are active members of Recoup, which is a charitable organisation promoting plastics recycling in the UK (www.recoup.org). Through Recoup, GSK was a key contributor to a study on ‘Design for recycling of plastic containers’ and we are funding another project to promote recycling of plastic containers by providing ‘reverse vending machines’ in public places.
investigating biodegradable plastics – we are following developments of materials such as polylactic acid (PLA) made from corn starch but currently believe return and recycling of conventional (PET) bottles is the best environmental option

using other packaging types – we aim to use the best type of container for each product. For example, we use cartons from Tetra Pak™ for Ribena, which minimises weight and improves distribution efficiency, although recycling systems are still under development

other packaging impacts – we have invested in a distribution centre that is closer to the bottle supply company, which means we can maximise the efficiency of lorry movements

PHARMACEUTICALS IN THE ENVIRONMENT

Medicines work through active pharmaceutical ingredients (APIs) that are absorbed in the patient’s body. These materials – including anything that is not absorbed – are eventually excreted through the body’s normal mechanisms and enter the sewage system. Wastewater treatment plants remove most pharmaceutical residues, but small concentrations do end up in rivers or in the sea. In areas without wastewater treatment, higher concentrations enter the environment.

GSK has developed business processes to ensure that we carry out appropriate environmental tests. Environmental risk assessments are part of the approval process for new medicines in the EU and US, so we provide regulatory agencies with assessments to evaluate and allow for mitigation of any potential environmental impacts. In 2006 we were part of industry groups that met with regulatory agencies on this issue, including the Food and Drug Administration and Environmental Protection Agency in the US and the Environment Agency of England and Wales.

Risk assessments indicate that our products do not appear to pose an appreciable risk for humans or the environment based on current methods for ascertaining safe levels. But we continue to monitor the latest scientific studies and findings to improve our risk assessments in this area.

We also engage in joint projects in the pharmaceutical industry through the Pharmaceutical Research and Manufacturers of America (PhRMA). In 2006:

- a GSK model was used to upgrade the Pharmaceutical Assessment and Transport Evaluation (PhATE™) model so it can be used to estimate the potential environmental impact of sewage sludge applied to the land. PhATE™ is used to make risk assessments based on specific local stream flows and population patterns
- we contributed to developing a database of scientific literature on the impacts of pharmaceuticals on aquatic life
- we contributed to an analysis of the impact of unused medicines on the environment, a report which is being shared with regulatory agencies and will be developed into a paper for publication in the scientific literature

We also continue our own work in this area. In 2006 we:

- conducted chronic ecotoxicity testing on selected APIs based on new EU guidelines. We now use these guidelines as an integral part of our environmental risk assessment strategy
- continued comprehensive environmental risk assessments for about 40 APIs. We developed ‘Allowable Daily Intake’ levels for human consumption through drinking water and fish consumption, as well as ‘No-Effects Levels’ for aquatic organisms. We make quantitative risk assessments by comparing these levels with predicted environmental concentrations. We presented data on selected sets of these compounds at scientific meetings
- provided data and risk assessments on more than 20 GSK APIs to the Swedish Association of the Pharmaceutical Industry (LIF) as part of a voluntary programme to provide data to physicians. GSK is also part of the technical team that developed the LIF Guide document ‘Guidance for Pharmaceutical Companies’.

See more on our approach to pharmaceuticals in the environment on our background pages.
Environmental performance

In 2006, we continued to improve our use of energy and reduce emissions to the atmosphere. We used slightly more water than in 2005 and generated more waste but succeeded in keeping the percentage increase below the percentage rise in sales.

Scope of the data

We manufacture pharmaceutical and consumer products using processes that involve chemicals, so we need to understand, address and report on environmental impacts. They include issues common to all manufacturers, such as the use of energy and water, and waste handling. In common with some other sectors, we also need to consider potential impacts of certain chemicals which can release volatile organic compounds (VOCs). Our manufacture of asthma inhalers also means we use chemicals which can damage the ozone layer.

In 2006 we reviewed our reporting to consider the materiality of environmental impacts, in the light of pharmaceutical industry practice and the Global Reporting Initiative, as well as inputs from stakeholders.

Stakeholders have told us they want simplicity in reporting, but they also need an appropriate level of detail, and we have tried to balance these sometimes conflicting requirements. For example, we have reduced and simplified the graphs and charts in this report, concentrating on areas with targets. We include a full data table for completeness at the back of the environment section on page 72.

We concentrate our reporting on:

- issues with potential financial benefit or impact for GSK such as material efficiency and energy efficiency
- issues directly related to the use of chemicals such as volatile organic compounds, chemical oxygen demand of wastewater and hazardous waste

This is the seventh year that we have reported on GSK’s environmental performance (and the legacy companies reported for several years before the creation of GSK). Copies of these reports are available on the Corporate Register.

Verification

The data in this Environment section and in the health and safety pages of the employment section of this report are externally verified by SGS UK Ltd. Details can be found in the verification statement on page 70.

ENERGY EFFICIENCY

We need energy to discover, develop, manufacture and distribute medicines. Most of our energy use is in our facilities, especially manufacturing, but also R&D and office sites. Global Manufacturing and Supply (GMS) and Research and Development (R&D) accounted for 58 percent and 25 percent respectively, of our consumption in 2006 and this is where we are concentrating efforts to increase energy efficiency. Transport is the main source of our remaining energy use.

Improving energy efficiency will help to reduce our global warming impact. It is now widely accepted that the activity of humans is changing our planet’s climate. There is a scientific consensus that ‘greenhouse gases’ (GHGs) such as carbon dioxide and methane are causing the ‘greenhouse effect’ – trapping heat within the earth’s atmosphere, causing a global increase in temperatures. Burning fossil fuels has greatly increased the presence of these gases in the atmosphere. Most experts now agree that this increase in GHGs is causing the earth to warm, a process which could bring about disastrous changes to our climate.

We will continue working to minimise energy use and emissions, despite expected growth in new products which will require additional energy. We expect to continue finding opportunities for greater efficiencies in new and existing facilities and operations. As a result, our new target is to reduce energy consumption by 1 percent per unit of sales each year until 2010.

In 2006 we finalised a position paper on our future use of energy, following extensive internal and external consultation. The position paper sets out a strategy for energy efficiency, renewable energy and emissions trading. It commits GSK to:

- reduce our reliance on fossil fuels whenever it is technically and economically possible
- support effective market-based mechanisms such as emissions trading, but seek to reduce our own emissions first
- evaluate the use of renewable energy
- evaluate energy investments over their lifetime rather than over the normal payback period used by GSK
- encourage suppliers, contractors and employees to improve their energy consumption
- report transparently our energy consumption using internationally recognised protocols
Renewable energy

We have started to invest in renewable energy projects. For example, Barnard Castle has installed two wind turbines and other sites are using solar energy to heat water. Some sites purchased some of their electricity from renewable resources. In the future we will report the amount of electricity from renewable sources.

Emissions trading

A number of UK sites participate in the government’s emissions trading scheme (ETS), helping us to gain experience in carbon trading. The UK ETS is a voluntary scheme which rewards companies with lower energy taxes if they improve energy efficiency. Sites that keep emissions below an agreed target can ‘bank’ the spare credits to help comply with limits in subsequent years, or they can sell the credits to other participants in the scheme.

In 2006 all GSK sites complied with their Climate Change Agreements.

The European Union trading scheme came into force at the start of 2005 for an initial three-year period. Sites with more than 20 megawatts of installed combustion capacity are required to participate and 16 GSK sites are covered. On balance GSK had surplus carbon credits. Any proceeds from the sale of carbon credits are invested in energy efficiency projects.

Energy investments

We have adopted an approach to energy investments which reflects the long-term nature of the projects and the importance of energy supply to the business. Instead of applying our normal investment criteria we will assess the return on the investment over the project’s lifetime.

We expect that this will result in approving energy efficiency and renewable energy projects which would not qualify under our normal investment criteria.

The first project to be approved was for solar water heating at our site at Slough, UK.
Transport
We estimate that transport accounts for 340 million kilograms of CO₂, about 20 percent of our global warming impact from energy in 2006.

Business air travel accounts for almost half (44 percent) of our travel-related CO₂ emissions. In 2006, employees travelled a total of almost 900 million kilometres by plane resulting in 106 million kg of CO₂ emissions. Air travel does not include group travel originating outside the UK. Our global sales fleet drove a total of over 1 billion kilometres on business travel – resulting in 136 million kg of CO₂.

In addition to business travel, we also transport products from our manufacturing plants to distributors. In 2006, GSK products were transported a total of 227 million kilometres – the majority (81 percent) by air freight. We estimate that the air freight resulted in 87 million kg of CO₂ while ocean and road freight resulted in an additional 11 million kg of CO₂.

This year we used the Greenhouse Gas Protocol for all of our calculations of CO₂ emissions. We are also now able to obtain more details about freight shipments. With these details we can be more precise in our calculations of CO₂ emissions from freight transport. Because of these changes we are unable to compare CO₂ emissions from transport with previous years. We are still working on obtaining the same level of detail from our passenger air travel.

We have launched a number of initiatives to reduce the impact of transporting products. They include consolidating freight shipments so pharmaceutical and consumer products are transported together, consolidating shipping points, and making more use of round tripping (managing inbound freight trucks so they do not return empty). We also switch from air to sea transport where possible.

We have ‘green travel plans’ at a number of sites to encourage employees to reduce the environmental impact of their travel to work. For example, at GSK House in Brentford, UK, privileged parking spaces are given to car-sharers and drivers of fuel efficient cars, buses powered by biodiesel run to and from the local train station, while changing rooms and showers are provided for cyclists as well as discounts for bicycle equipment and repairs. We are beginning to use hybrid-engine cars for our chauffeur service.

We encourage employees to use video and teleconferencing where possible to reduce air travel. Virtual meeting software is available to employees for making presentations and collaborative working. In 2006, GSK employees conducted over 5,000 video meetings, over 464,000 teleconferences and over 5,000 web conferences.
WATER USE

GSK uses water in manufacturing (for processes, products, cooling and cleaning) and for general site uses including drinking, food services and sanitation. Primary supply sites – those that manufacture active pharmaceutical ingredients – are typically heavy users of water, as are sites that manufacture vaccines or produce drinks. Those involved in research and development and commercial activities typically use less.

Water is a valuable natural resource that needs to be conserved – especially in areas where there are shortages – and protected from pollution. The GSK water standard requires sites to minimise water use, re-use water whenever feasible and ensure that all wastewater is treated and discharged in a way that minimises adverse environmental impacts.

Our target is to reduce water consumption by 2 percent per annum per £ of sales.

Water performance

In 2006, we used 22 million cubic metres of water, 1.5 percent more than in 2005. In spite of the small increase in water consumption, with the rise in sales, water consumption per £ sales was 5.3 percent lower than in 2005. Our consumption is about average for the industry, based on benchmarking with other major pharmaceutical companies.

Water usage has gone up mainly due to increased activity at biologics sites, especially higher vaccines production at Biologicals Belgium. Higher production at manufacturing plants in Ireland and the UK also required more water. These increases were partly offset by partial closing of one site and small improvements at several sites as a result of water conservation measures.
Wastewater performance

We generated 10 million cubic metres of wastewater in 2006. The total volume was 6.4 percent less than 2005.

This reduction was partly due to changes at several sites including a new specialised wastewater treatment facility at a primary manufacturing plant which removes solvent from the wastewater, closure of some manufacturing operations in another plant and other changes to wastewater treatment and product mix.

Total chemical oxygen demand (COD) discharged after on-site treatment was 15 million kilograms which was 15 percent less than in 2005. The reduction in COD per £ sales was 21 percent.

<table>
<thead>
<tr>
<th>Year</th>
<th>kg per £ million (sales)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2001</td>
<td>1223.7</td>
</tr>
<tr>
<td>2005</td>
<td>802.5</td>
</tr>
<tr>
<td>2006</td>
<td>632.8</td>
</tr>
</tbody>
</table>

WASTEWATER

Most sites discharge wastewater to municipal treatment facilities. Some large sites, especially primary manufacturing, have their own on-site wastewater treatment systems. Some sites are permitted to discharge wastewater direct to the sea.

We assess the quality of wastewater by measuring the chemical oxygen demand (COD) – the oxygen required to chemically oxidise compounds in the water. The lower the COD, the cleaner the water.

Our target from 2006 is to improve COD discharge by 3 percent a year per £ of sales.

We have changed COD measurement to concentrate on wastewater from manufacturing processes and exclude sites whose waste is mainly from ‘domestic’ activity (such as washrooms and canteens). The vast majority of COD comes from manufacturing and the contribution from these other activities is not sufficiently significant to warrant the time and effort required to collect the data. This change may result in a decrease in reported COD of up to 5.7 percent. We have recalculated prior years’ data so that it is comparable.
WASTE

Our research, production and commercial activities all produce waste, which we aim to manage safely and responsibly from when it is generated to its final disposal. We want to eliminate waste where we can, reduce it where we cannot, re-use materials if possible, recycle other waste and dispose of any remaining material sensitively.

We generate different kinds of waste in different parts of the business:

- production – hazardous wastes such as solvents and other chemicals
- R&D and quality laboratories – small amounts of chemicals including products and intermediates, as well as broken glassware and plastics
- offices – paper and other standard commercial waste
- renovations take place in production, office and lab space which produce non-routine waste such as obsolete equipment, office furniture and structural materials

Most of the active ingredients in our pharmaceutical products are manufactured using chemical processes. This means that a significant proportion of our waste is classified as hazardous because it contains solvents and chemicals used in these processes. We classify waste as hazardous, non-hazardous, and non-routine (for waste such as construction and demolition rubble).

Most production facilities segregate their wastes, re-use what they can, send what they can for recycling, and incinerate or landfill anything else. Incineration is usually the preferred choice for dealing with solvents that can’t be reused or recycled. Where practicable, sites use waste management companies which use incinerators that recover energy from burning the materials.

We require disposal contractors to comply with our EHS requirements and local regulations. Sites audit their waste contractors or hire consultants to carry out the audits.

We continue to work on reducing waste, especially hazardous waste. Improving material efficiency will reduce waste, especially the number and volume of solvents. We have set a target to increase material efficiency of new products going from R&D to manufacturing to 2 percent.

In the past, some waste and chemicals handling practices contaminated land and groundwater. These practices are no longer followed, however we are continuing to clean up these sites to deal with health and environmental hazards.

GSK and its heritage companies have spent more than £100m cleaning up more than 50 sites in the US over the last 20 years. We are continuing to clean up 25 of these sites. Most of them are waste disposal sites where GSK is one of several responsible parties. These figures are not included in the data verification.

Non-hazardous waste

Most non-hazardous waste is general material such as office waste paper, kitchen waste and non-hazardous substances used in manufacturing. A very small part is biological waste that has been treated so it is not hazardous. We do not include construction and demolition rubble and similar material not related to day-to-day operations, which we describe separately as non-routine waste.

We continue to look for ways to reduce waste and have undertaken waste management reviews at many sites. Our new target is to reduce non-hazardous waste per £ of sales by 1 percent per annum.

Hazardous waste

More than 93 percent of our hazardous waste consists of solvents that are used in production processes. We also dispose of some lubricants and fluorescent lights, while research waste includes animal carcasses.

Regulations vary widely around the world, but our first choice for solvents is to re-use or recycle material. When this is not possible the main disposal option for solvents is incineration. We aim to recover energy from incineration wherever possible.

<table>
<thead>
<tr>
<th>Year</th>
<th>Hazardous waste disposed (kg per £ million (sales))</th>
</tr>
</thead>
<tbody>
<tr>
<td>2001</td>
<td>2850.1</td>
</tr>
<tr>
<td>2005</td>
<td>2917.3</td>
</tr>
<tr>
<td>2006</td>
<td>2871.1</td>
</tr>
</tbody>
</table>

Most hazardous waste comes from primary production activity, and this is where we concentrate our efforts. We have stopped collecting hazardous waste data from consumer manufacturing plants, laboratories, offices and most secondary manufacturing sites. These sites produced about 3 percent of our hazardous waste in the past.

We have not set a target for reduction of hazardous waste. Our target to improve material efficiency is geared to accomplish reductions in hazardous waste.
Recycling

We recycle hazardous and non-hazardous waste, aiming to minimise environmental impacts as well as the cost of materials and waste.

The largest waste component is solvent which has been used in the manufacturing process. Some solvent is purified on our sites and reused in the original manufacturing process. Sometimes we sell the solvent to commercial reprocessing companies, which we also include in the recycling statistics. Solvent which is not recycled in this way is usually incinerated.

Recycling non-hazardous waste such as paper, cardboard, glass, plastic or aluminium, usually means sending it for reprocessing so it can be reused to make new products.

Two sites in India have stopped land filling their coal ash generated on site; instead they sell it as raw material for the production of construction material.

In addition, three nutritional-drink manufacturing sites send some of their process wastes (barley husk) for animal food while others recycle canteen waste or effluent treatment plant sludge by converting it into bio-compost.

The data table on page 72 includes additional details about waste such as amounts of hazardous and non-hazardous waste that go to recycling, landfill and incineration and the amount of non-routine waste.

<table>
<thead>
<tr>
<th>Year</th>
<th>Non-hazardous waste disposed (kg per £ million (sales))</th>
</tr>
</thead>
<tbody>
<tr>
<td>2001</td>
<td>2610.7</td>
</tr>
<tr>
<td>2005</td>
<td>1901.8</td>
</tr>
<tr>
<td>2006</td>
<td>1620.0</td>
</tr>
</tbody>
</table>

GSK Corporate Responsibility Report 2006
The chart refers to ODS lost from production activities and equipment leakage. See data table on page 72 for information about patient use of inhalers.

We are installing new equipment which will help us meet our target of eliminating CFCs from equipment and product use by 2010, apart from halon fixed fire protection systems and equipment containing under one kilogram of CFC.

In 2006, 186 thousand kilograms of CFC propellant were released when patients used our products. A much smaller amount – 22.8 thousand kilograms – were released during production of inhalers and we estimate that 645 kilograms CFC 11 equivalent were emitted from equipment.

CFC 11 and CFC 12 are contained in 163 pieces of equipment, amounting to 16,137 kilograms of CFC. Over 4 thousand items of equipment contain other ozone depleting substances with the ODP of 7,315 kilograms of CFC 11 equivalent. We estimate that 2.75 percent or 645 kilograms CFC 11 equivalent were released from the equipment (using an estimation factor from the British Refrigeration Association).
Equipment and production
ODSs – mainly HCFCs – are sealed inside cooling systems and are only released in the event of a leak or during maintenance.

The only way to eliminate emissions is to eliminate CFC and HCFC from cooling systems and that is our new strategy.

In 2006 we carried out an inventory of all CFC and HCFC containing equipment and will repeat the exercise in the first quarter of 2007 and annually so we can monitor the decrease in the CFC content. In 2007 we will also collect data on HFCs.

We recognise that there is also a risk of catastrophic failure of equipment and larger releases, until we eliminate these chemicals. We are focusing attention on the larger pieces of equipment to remove them from service before the end of 2010.

We do not intend to replace equipment containing 1 kilogram or less because these are typically hermetically sealed and less likely to leak.

We no longer collect data on losses from equipment as we are concentrating on eliminating the equipment rather than controlling the releases. For comparison to prior years we have estimated that 2.75 percent of the total amount of CFC and HCFC is lost from the remaining equipment. The ODP chart shows the emissions from producing inhalers and the estimated emissions from equipment. Last year we reported 2985 kg released based on losses during equipment failures and replacements.

Metered dose inhalers
Metered dose inhalers (MDIs) are commonly used to deliver the main forms of treatment for asthma sufferers. They are pressurised, hand-held devices that use propellants to deliver doses of medication to patients’ lungs. They were first introduced in the 1950s and CFCs were traditionally used as the propellant because they are non-toxic, non-reactive, non-flammable, and do not have any odour or taste.

When a patient uses the MDI, the propellant is released into the atmosphere. The Montreal Protocol bans the production of CFCs but it exempts a number of ‘essential uses’ which include MDIs. Nevertheless we plan to eliminate the use of CFCs from our worldwide product portfolio by 2010.

We have stopped using CFCs in the US and the European Union. We now offer a selection of alternatives to ODS-containing inhalers in most countries. The main alternative propellant we use is HFC 134a, which does not affect ozone but does have high global warming potential, although it is less than CFCs. We have also invested heavily in dry powder delivery systems that do not use CFCs or HFCs.

We will continue to manufacture CFC MDIs in India, China and Pakistan and will use subcontractors to produce CFC devices for the Bangladesh and Latin America market until 2010. Our target is to eliminate all CFCs by then.

Ozone depletion potential from patient use of metered dose inhalers was 32 percent lower than in 2005. In previous years we only had this information from the US and EU. We now have data from India, Pakistan and China and have calculated the decrease from all CFC inhalers that we produce.

As production of CFC-containing MDIs decreases, the amount of CFC lost during production also declines. Total ozone depletion potential from production was 55 percent lower than 2005.
VOLATILE ORGANIC COMPOUNDS

We use volatile organic compounds (VOCs) mainly as solvents in our primary manufacturing operations and R&D pilot plants. Solvents are also used to coat some tablets and in cleaning for sterile operations. We also use small quantities in laboratories but do not measure emissions from this use.

VOCs react with nitrogen oxides in the presence of sunlight, creating ozone in the lower atmosphere. This results in smog, which is a factor in human respiratory illness. Workplace exposure to certain VOCs can also pose a health risk.

In 2006, we released 4.2 million kilograms of VOCs to the atmosphere. This was 16 percent lower than in 2005. Emissions per £ of sales were 22 percent lower than in 2005.

Our target from 2006 is to reduce VOCs by 2 percent per annum per £ of sales. Improvements in VOC emissions in 2006 were due to several projects at primary manufacturing sites to capture fugitive emissions, changes in production and changes in the way VOC emissions are calculated in alignment with local regulations. Photochemical ozone creation potential was 19.8 percent lower than in 2005.

We have changed the way we measure VOCs to exclude the small quantities from laboratories, estimated to be 3 percent of total VOC emissions in prior years. We have recalculated VOC emissions in prior years to make them comparable.

Control of volatile organic compound emissions at the GSK Cork site

VOCs arise from many of the processes at Cork, where we use solvents such as dichloromethane, ethyl acetate and ethanol.

The introduction of the UK Air Pollution Act in 1987 led to a focus on control and elimination of solvent emissions and we carried out a complete review of all points of emission.

All solvent emissions from reactions, vacuum pump discharges, centrifuges, pressure filters and tanks are collected through a site-wide system and passed into two high temperature incinerators. They operate at 1100°C and destroy all organic vapours with an efficiency greater than 99.99 percent.

Emissions from the incinerator stacks are continuously monitored for VOC residues, carbon monoxide, sulphur oxides, nitrogen oxides and for hydrogen halides.

This incineration operation is regarded as the best available technology for efficient destruction of VOCs and prevention of emissions of these substances to atmosphere.

Control of VOC at Ulverston

The manufacture of two intermediate stages in the antibiotic, cefuroxime axetil uses solvents including dichloromethane (DCM) and tetrahydrofuran (THF).

In 2006, GSK approved a project to install a carbon adsorption unit to remove VOCs from these process stages. Carbon adsorption technology was selected as the methodology to reduce VOC emissions because the technology offers a robust, industry standard abatement solution and represents best available technology.

Existing vents to air will be redirected to the carbon adsorption Unit where they will be adsorbed on an activated carbon bed. The system operates continuously and uses steam regeneration to remove adsorbed solvents which will be recovered at the site by an existing solvent recovery unit for re-use in the process.

This project will remove 30 to 40 tonnes per annum of DCM releases to air and 130 to 150 tonnes per annum of THF. The site will also save an estimated £100k per annum from the recovery and re-use of these solvents.
Nature and Scope of the Verification/Assurance
SGS United Kingdom Ltd was commissioned by GlaxoSmithKline to conduct an independent assurance of their 2006 EHS Report. The scope of the assurance, based on the SGS Sustainability Report Assurance methodology, included 2006 Environment and Health & Safety performance data and graphs, contained in pages 46 to 49 and 52 to 69 of this report and in the accompanying table on pages 72 to 74. Data relating to contaminated land pages 65 and health and safety data relating to non-GSK employees (page 47) were not included in this assurance process. Financial data drawn directly from independently audited financial accounts has not been checked back to source as part of this assurance process.

The information in the EHS Report of GlaxoSmithKline and its presentation are the responsibility of the directors and the management of GlaxoSmithKline. SGS United Kingdom Ltd has not been involved in the preparation of any of the material included in the EHS Report. Our responsibility is to express an opinion on the data, graphs and relevant statements within the scope of verification.

The SGS Group has developed a set of protocols for the Assurance of Sustainability Reports based on current best practice guidance provided in the Global Reporting Initiative Sustainability Reporting Guidelines (2002) and the AA1000 Assurance Standard (2003). The data in this report has been assured using our protocol for content veracity. The assurance comprised a combination of interviews with relevant employees; evaluation of data collection and submission methodologies, documentation and record review and validation with external bodies and/or stakeholders where relevant. Six sites were visited (in UK, USA, Belgium, Italy and Singapore) and a further eight sites were contacted by telephone (in UK, USA, Ireland, India and Australia). The sites selected included those submitting high proportions of key data and included all parts of the GSK business. Additionally visits were made to the Corporate Head Quarters and web-conferencing with key individuals was utilised in order to complete our verification activities.

Statement of Independence and Competence
The SGS Group of companies is the world leader in inspection, testing and verification, operating in more than 140 countries and providing services including management systems and service certification; quality, environmental, social and ethical auditing and training; environmental, social and sustainability report assurance. SGS United Kingdom Ltd affirm our independence from GlaxoSmithKline, being free from bias and conflicts of interest with the organisation, its subsidiaries and stakeholders.

The assurance team was assembled based on their knowledge, experience and qualifications for this assignment, and comprised auditors registered with IRCA, IEMA and EMAS Verifiers.

Verification/Assurance Opinion
On the basis of the methodology described and the verification work performed, we are satisfied that the data contained within the GlaxoSmithKline 2006 EHS Report is reliable and provides a fair and balanced representation of GlaxoSmithKline’s EHS activities in 2006.

We believe that GlaxoSmithKline has chosen an appropriate level of assurance for this stage in their reporting.
Key areas for improvement to data collection, submission and manipulation were identified as follows:

- Definitions for data to be submitted were not always fully understood or adhered to consistently at site level;
- Estimations are used to calculate certain data and further guidance could be provided to sites to ensure that such calculations are approached consistently;
- Establish a more rigorous process to check entered data for anomalies, such as data entered in error, or missed data;
- Consider incorporation of an internal audit of data and data management systems alongside corporate EHS audits;
- Ensure training is undertaken when key individuals are replaced to ensure consistency and full understanding of systems and requirements;
- Ensure that, when sites submit data, comments are included to explain estimations, calculations and any significant changes;
- Ensure that the process used to extract data from electronic systems is used consistently and appropriately to enable the correct values to be obtained by all individuals utilising the system.

Key areas for improvement in data verification process were identified as follows:

- Ensure that all relevant data is available and internally checked in advance of external verification process.

For and on behalf of SGS United Kingdom Ltd

Pauline Earl
Business Manager
Systems and Services Certification

27 February 2007
Global warming potential

1. Global warming potential (GWP) from energy sources is calculated as CO₂ or CO₂ equivalent using the Greenhouse Gas (GHG) Protocol developed by the World Resources Institute and the World Business Council for Sustainable Development.

2. GWP from air, land and sea transport is calculated using the GHG protocol from distance travelled, not directly from fuel used.

In years before 2006, we did not collect all categories of freight transport or employee business travel.

In 2006 we are missing group air travel that originated outside of UK. Motor vehicle travel conversion assumes medium vehicles for sales employees and heavy diesel vehicles for freight transport.

3. GWP from refrigerants released from equipment is calculated using factors from the Kyoto protocol.

We have changed from collecting data on releases of refrigerants to collecting data on the amount of refrigerant contained in the equipment and calculating the releases using a factor from British Refrigeration Association for probable leakage. We calculate releases only from refrigeration equipment holding greater than one kilogram refrigerant.

4. GWP from ozone depleting substances in inhalers uses factors from the Kyoto protocol. We did not have enough information to calculate GWP from inhaler use in previous years.

5. Water from other sources includes recycled sources.

### Energy use

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Energy for operations</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(million gigajoules)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Natural gas</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9.00</td>
<td>8.66</td>
<td>8.68</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fuels</td>
<td>1.08</td>
<td>1.53</td>
<td>1.33</td>
<td>1.43</td>
<td>1.07</td>
<td>1.42</td>
</tr>
<tr>
<td>Coal</td>
<td>0.47</td>
<td>0.63</td>
<td>0.56</td>
<td>0.64</td>
<td>0.95</td>
<td>1.04</td>
</tr>
<tr>
<td>Steam imported</td>
<td>0.22</td>
<td>0.19</td>
<td>0.17</td>
<td>0.17</td>
<td>0.06</td>
<td>0.28</td>
</tr>
<tr>
<td>Electricity imported</td>
<td>8.19</td>
<td>8.21</td>
<td>7.98</td>
<td>8.31</td>
<td>8.27</td>
<td>8.10</td>
</tr>
</tbody>
</table>

### Global Warming Potential (CO₂ equivalent)

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>GWP from operations¹</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>energy (million kilograms)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Natural gas</td>
<td>453.0</td>
<td>435.9</td>
<td>437.1</td>
<td>475.4</td>
<td>488.6</td>
<td>496.5</td>
</tr>
<tr>
<td>Fuels</td>
<td>81.1</td>
<td>114.0</td>
<td>113.0</td>
<td>104.0</td>
<td>76.9</td>
<td>102.0</td>
</tr>
<tr>
<td>Coal</td>
<td>22.0</td>
<td>29.3</td>
<td>25.9</td>
<td>29.8</td>
<td>44.1</td>
<td>48.3</td>
</tr>
<tr>
<td>Steam imported</td>
<td>15.0</td>
<td>14.3</td>
<td>11.5</td>
<td>11.6</td>
<td>9.4</td>
<td>38.7</td>
</tr>
<tr>
<td>Electricity imported</td>
<td>1095.1</td>
<td>1099.5</td>
<td>1078.0</td>
<td>1128.9</td>
<td>1114.5</td>
<td>1138.5</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>GWP from transport² (million kilograms)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sales force</td>
<td>136.1</td>
<td>102.0</td>
<td>78.0</td>
<td>70.0</td>
<td>75.0</td>
<td>33.0</td>
</tr>
<tr>
<td>Air travel</td>
<td>105.5</td>
<td>112.0</td>
<td>114.0</td>
<td>95.0</td>
<td>92.0</td>
<td>71.0</td>
</tr>
<tr>
<td>Product logistics</td>
<td>98.3</td>
<td>19.0</td>
<td>14.0</td>
<td>13.0</td>
<td>13.0</td>
<td>19.0</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>GWP from other production activities (million kilograms)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inhaler production losses</td>
<td>283.4</td>
<td>420.3</td>
<td>491.9</td>
<td>539.1</td>
<td>857.4</td>
<td>1219.0</td>
</tr>
<tr>
<td>Equipment containing greater than 1 kg refrigerant³</td>
<td>6.99</td>
<td>46.82</td>
<td>46.66</td>
<td>50.20</td>
<td>64.38</td>
<td>58.43</td>
</tr>
<tr>
<td>CO₂, Methane and Nitrous Oxide</td>
<td>26.29</td>
<td>48.42</td>
<td>54.64</td>
<td>54.90</td>
<td>71.50</td>
<td>57.13</td>
</tr>
<tr>
<td>Waste treatment</td>
<td>46.40</td>
<td>76.40</td>
<td>56.86</td>
<td>52.56</td>
<td>44.86</td>
<td>47.06</td>
</tr>
<tr>
<td>Other sources</td>
<td>27.32</td>
<td>15.86</td>
<td>15.09</td>
<td>26.76</td>
<td>44.61</td>
<td>3.58</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>GWP from use of inhalers by patients (million kilograms)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CFC 11 inhalers</td>
<td>197</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>CFC 12 inhalers</td>
<td>1,083</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>HFC 134a inhalers</td>
<td>3,055</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

### Water use and discharge

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Water (million cubic metres)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Municipal</td>
<td>12.73</td>
<td>12.77</td>
<td>12.72</td>
<td>13.03</td>
<td>14.23</td>
<td>15.12</td>
</tr>
<tr>
<td>Wells or boreholes</td>
<td>8.95</td>
<td>8.59</td>
<td>7.96</td>
<td>9.88</td>
<td>9.98</td>
<td>11.60</td>
</tr>
<tr>
<td>Other Water⁴</td>
<td>0.302</td>
<td>0.289</td>
<td>0.137</td>
<td>0.072</td>
<td>0.014</td>
<td>0.037</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Wastewater volume⁵ (million cubic metres)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WW to recycling</td>
<td>0.58</td>
<td>0.43</td>
<td>0.91</td>
<td>0.42</td>
<td>0.42</td>
<td>0.20</td>
</tr>
<tr>
<td>WW to municipal sewer</td>
<td>3.74</td>
<td>3.85</td>
<td>3.86</td>
<td>3.74</td>
<td>3.65</td>
<td>3.76</td>
</tr>
<tr>
<td>WW to water bodies</td>
<td>5.88</td>
<td>6.63</td>
<td>6.62</td>
<td>7.35</td>
<td>7.88</td>
<td>9.17</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>COD after on-site treatment⁶ (million kilograms)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>COD in recycled water</td>
<td>&lt;0.01</td>
<td>&lt;0.01</td>
<td>&lt;0.01</td>
<td>0.90</td>
<td>1.98</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>COD to sewer</td>
<td>2.93</td>
<td>3.60</td>
<td>4.45</td>
<td>4.77</td>
<td>4.42</td>
<td>3.91</td>
</tr>
<tr>
<td>COD to water bodies</td>
<td>11.77</td>
<td>13.80</td>
<td>14.50</td>
<td>16.01</td>
<td>15.94</td>
<td>21.17</td>
</tr>
</tbody>
</table>

---

1. Global warming potential (GWP) from energy sources is calculated as CO₂ or CO₂ equivalent using the Greenhouse Gas (GHG) Protocol developed by the World Resources Institute and the World Business Council for Sustainable Development.

2. GWP from air, land and sea transport is calculated using the GHG protocol from distance travelled, not directly from fuel used.

In years before 2006, we did not collect all categories of freight transport or employee business travel.

In 2006 we are missing group air travel that originated outside of UK. Motor vehicle travel conversion assumes medium vehicles for sales employees and heavy diesel vehicles for freight transport.

3. GWP from refrigerants released from equipment is calculated using factors from the Kyoto protocol.

We have changed from collecting data on releases of refrigerants to collecting data on the amount of refrigerant contained in the equipment and calculating the releases using a factor from British Refrigeration Association for probable leakage. We calculate releases only from refrigeration equipment holding greater than one kilogram refrigerant.

4. GWP from ozone depleting substances in inhalers uses factors from the Kyoto protocol. We did not have enough information to calculate GWP from inhaler use in previous years.

5. Water from other sources includes recycled sources.
### Corporate Responsibility Report of 2006

#### Volatile organic compound emissions

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Volatile organic compound emissions</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(million kilograms)</td>
<td>4.2</td>
<td>5.0</td>
<td>5.3</td>
<td>6.2</td>
<td>6.4</td>
<td>6.6</td>
</tr>
<tr>
<td>POCP from total VOC emissions</td>
<td>1.29</td>
<td>1.60</td>
<td>1.74</td>
<td>2.11</td>
<td>2.14</td>
<td>2.10</td>
</tr>
</tbody>
</table>

#### Top five solvents released (million kilograms)

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Acetone</td>
<td>1.02</td>
<td>1.15</td>
<td>1.11</td>
<td>1.30</td>
<td>1.46</td>
<td>1.23</td>
</tr>
<tr>
<td>Dichloromethane</td>
<td>0.84</td>
<td>0.88</td>
<td>0.95</td>
<td>1.13</td>
<td>1.25</td>
<td>1.72</td>
</tr>
<tr>
<td>Methanol</td>
<td>0.44</td>
<td>0.71</td>
<td>0.66</td>
<td>0.92</td>
<td>0.76</td>
<td>0.73</td>
</tr>
<tr>
<td>Ethanol</td>
<td>0.42</td>
<td>0.44</td>
<td>0.51</td>
<td>0.32</td>
<td>0.28</td>
<td>0.26</td>
</tr>
<tr>
<td>Isopropanol</td>
<td>0.25</td>
<td>0.18</td>
<td>0.23</td>
<td>0.26</td>
<td>0.22</td>
<td>0.35</td>
</tr>
</tbody>
</table>

#### Ozone depleting substances

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>ODS Releases from production (thousand kilograms)</td>
<td>22.8</td>
<td>51.0</td>
<td>59.0</td>
<td>71.5</td>
<td>120.8</td>
<td>183.5</td>
</tr>
<tr>
<td>CFC11 releases from production</td>
<td>6.9</td>
<td>14.1</td>
<td>12.6</td>
<td>27.0</td>
<td>52.4</td>
<td>88.5</td>
</tr>
<tr>
<td>CFC12 releases from production</td>
<td>15.9</td>
<td>36.9</td>
<td>46.3</td>
<td>44.5</td>
<td>68.3</td>
<td>94.9</td>
</tr>
<tr>
<td>ODS Releases from equipment (thousand kilograms)</td>
<td>0.65</td>
<td>2.99</td>
<td>2.66</td>
<td>2.59</td>
<td>6.81</td>
<td>4.32</td>
</tr>
<tr>
<td>CFC11 releases from equipment</td>
<td>0.42</td>
<td>1.62</td>
<td>0.93</td>
<td>0.30</td>
<td>2.70</td>
<td>0.56</td>
</tr>
<tr>
<td>CFC12 releases from equipment</td>
<td>0.02</td>
<td>0.21</td>
<td>0.31</td>
<td>0.32</td>
<td>0.40</td>
<td>0.33</td>
</tr>
<tr>
<td>Other ODS from ancillary equipment</td>
<td>0.20</td>
<td>1.15</td>
<td>1.41</td>
<td>1.97</td>
<td>3.71</td>
<td>3.42</td>
</tr>
<tr>
<td>ODS Releases from patient use of inhalers (thousand kilograms)</td>
<td>185.6</td>
<td>272.5</td>
<td>237.8</td>
<td>222.4</td>
<td>275.3</td>
<td>301.6</td>
</tr>
<tr>
<td>CFC11 from patient use</td>
<td>51.85</td>
<td>76.15</td>
<td>67.55</td>
<td>77.75</td>
<td>102.3</td>
<td>143.8</td>
</tr>
<tr>
<td>CFC12 from patient use</td>
<td>133.7</td>
<td>196.38</td>
<td>166.35</td>
<td>144.75</td>
<td>172.9</td>
<td>258.2</td>
</tr>
<tr>
<td>ODS contained in equipment (thousand kilograms)</td>
<td>23.4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Waste generated and disposed

| Hazardous waste generated (million kilograms) | 234.3 | 253.4 | 251.6 | 291.0 | 312.8 | 345.9 |
| Hazardous waste recycled                    | 167.65| 190.23| 182.19| 234.86| 255.09| 287.5 |
| Hazardous waste disposed                    | 66.68 | 63.19 | 69.40 | 56.13 | 57.74 | 58.40 |
| Hazardous waste incinerated with energy recovery | 28.06 | 28.78 | 35.47 | 25.83 | 27.66 | 27.76 |
| Hazardous waste incinerated with no energy recovery | 38.18 | 33.41 | 32.54 | 28.81 | 28.06 | 27.82 |
| Hazardous waste to landfill                 | 0.44  | 1.00  | 1.38  | 1.50  | 1.93  | 2.82  |
| Non-hazardous waste generated (million kilograms) | 113.7 | 125.0 | 149.3 | 134.6 | 135.3 | 132.8 |
| Non-hazardous waste recycled                | 76.06 | 83.82 | 103.99| 90.63 | 85.61 | 79.34 |
| Non-hazardous waste disposed                | 37.63 | 41.19 | 45.29 | 43.97 | 49.66 | 53.49 |
| Non-hazardous waste incinerated with energy recovery | 8.90  | 9.18  | 7.76  | 8.34  | 8.43  | 5.92  |
| Non-hazardous waste incinerated with no energy recovery | 7.09  | 8.28  | 10.07 | 6.23  | 9.40  | 12.05 |
| Non-hazardous waste to landfill             | 21.64 | 23.73 | 27.45 | 29.40 | 31.83 | 35.52 |

**Wastewater**

6. In 2006 we changed the wastewater calculations to include wastewater and chemical oxygen demand only from the major contributors; primary operations, pilot plants, and coating and sterile operations. We recalculated data for previous years so they can be compared.

7. Chemical oxygen demand (COD), a measure of water pollution, from manufacturing processes is measured when the wastewater leaves our sites, following any on-site treatment.

**Volatile organic compounds**

8. In 2006 we changed calculation to include VOC only from the major contributors; primary operations, pilot plants, and coating and sterile operations. We recalculated data for previous years so they can be compared.

9. In addition to kilometers of VOC emitted, we calculate photochemical ozone creation potential (POCP) in kilometers ethylene equivalents. Conversion to ethylene equivalents is based on the European Chemical Industry Council (CEFIC) “Responsible Care HSE Reporting Guidelines” for VOCs (1998).

**Ozone depleting substances**

10. Ozone depletion potential (ODP) from ozone depleting substances is calculated using factors from the Kyoto protocol.

11. In previous years we did not have information about inhalers produced in Asia for emissions from patients’ use.

12. In the previous years we did not have information on the ODS amount contained in equipment.

**Waste**

13. We consider a waste to be hazardous if it is radioactive, bioengineered or biohazardous, or it has any of the properties defined by the 1989 Basel Convention. This includes flammability, explosivity, water or air reactivity, corrosivity, oxidising potential, acute or chronic toxicity, ecotoxicity or infection. Biological waste rendered non-hazardous after treatment is considered a non-hazardous waste.
14. In 2006 we changed calculation to include hazardous waste only from the major contributors: primary operations, pilot plants, and coating and sterile operations. We recalcualted data for previous years so they can be compared.

15. Incineration with energy recovery means burning the material and using the resulting energy.

16. Non-routine waste includes construction and demolition rubble and is not included in hazardous or non-hazardous waste calculation.

**Injury & Illness**

17. The health and safety data cover both our employees and contract workers who are directly supervised by GSK employees. We report a snapshot of the injury and illness performance for the year. Cases may be added later but we do not correct prior years.

18. Lost time injuries and illnesses are work-related injuries and illnesses that are serious enough to result in one or more days away from work.

19. Lost calendar days are the calendar days that employees could not work because of work-related injuries and illnesses, including weekends. This helps to provide a measure of the severity of injuries and illnesses.

20. Reportable injuries and illnesses without lost time are reported incidents that did not result in time away from work (lost time). They are more serious than first aid but generally less serious than lost time.

### Metric

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-routine waste generated(^1) (million kilograms)</td>
<td>34.9</td>
<td>77.5</td>
<td>34.9</td>
<td>26.1</td>
<td>29.8</td>
<td>25.1</td>
</tr>
<tr>
<td>Non-routine waste disposed</td>
<td>18.02</td>
<td>37.54</td>
<td>6.68</td>
<td>23.49</td>
<td>15.66</td>
<td>18.02</td>
</tr>
<tr>
<td>Non-routine waste incinerated with energy recovery</td>
<td>2.55</td>
<td>7.46</td>
<td>0.14</td>
<td>0.17</td>
<td>0.03</td>
<td>2.55</td>
</tr>
<tr>
<td>Non-routine waste incinerated with no energy recovery</td>
<td>0.66</td>
<td>0.37</td>
<td>0.08</td>
<td>1.88</td>
<td>0.15</td>
<td>0.66</td>
</tr>
<tr>
<td>Non-routine waste to landfill</td>
<td>14.81</td>
<td>29.71</td>
<td>6.46</td>
<td>21.45</td>
<td>15.49</td>
<td>14.81</td>
</tr>
</tbody>
</table>

### Estimated costs and investments

| Operations and maintenance cost (million £)                          | 33.6 | 39.1 | 43.0 | 39.0 | 47.3 | 41.4 |
| Capital investment (million £)                                       | 9.7  | 12.1 | 9.4  | 11.0 | 18.5 | 24.4 |

### Injury and illness – GSK employees\(^7\)

| Hours worked (millions)                                             | 194.7| 196.6| 195.0| 201.8| 203.7| 191.1|
| Fatalities                                                          | 3    | 1    | 2    | 5    | 3    | 5    |
| Number of injuries with lost time\(^14\)                           | 552  | 547  | 519  | 567  | 638  | 751  |
| Calendar days lost – injuries\(^9\)                                | 11,281| 11,080| 12,748| 12,344| 14,077| 16,268|
| Number of illnesses with lost time\(^15\)                          | 94   | 77   | 91   | 95   | 116  | 133  |
| Calendar days lost – illnesses\(^6\)                               | 4386 | 2518 | 2959 | 1377 | 5342 | 5304 |
| Number of injuries without lost time\(^10\)                         | 443  | 437  | 430  | 784  | 955  | 1079 |
| Number of illnesses without lost time\(^10\)                        | 282  | 267  | 354  | 529  | 378  | 315  |

### Injury and illness – non GSK employees (not verified by SGS)

| Hours worked (millions)                                             | 22.8 | 22.8 | 20.6 | 19.8 | 20.5 | 17.0 |
| Fatalities                                                          | 0    | 2    | 1    | 4    | 1    | 0    |
| Number of injuries and illnesses with lost time                     | 114  | 100  | 84   | 63   | 71   | 69   |
| Calendar days lost                                                  | 965  | 1575 | 1369 | 883  | 1069 | 754  |
| Number of injuries and illnesses without lost time                  | 373  | 275  | 293  | 199  | 238  | 1    |
Our work with communities

We believe that using some of our profits to benefit under-served communities is part of being a responsible company. It also supports our business by:

• demonstrating our commitment to tackling healthcare and education challenges
• making our employees feel proud to work for GSK
• improving our reputation with stakeholders

Community investment is not linked to short term business benefits and is not intended to create commercial markets for GSK.

Donations are made at group level to support disease prevention and increase healthcare capacity in developing countries, and by individual GSK sites to support local communities.

In 2006, our total community investment was valued at £302 million ($558 million), equivalent to 3.9 percent of pre-tax profits.

Our objective is to ensure that projects are sustainable in the long term and will continue once our funding comes to an end. Most of our community investment is made through non-profit organisations that are experts in the field of healthcare and education. This helps ensure our giving is targeted effectively at the communities that need it most.

VALUE OF COMMUNITY INVESTMENT

In 2006, GSK donations were valued at £302 million ($558 million) compared to £380 million ($691 million) in 2005. This is equivalent to 3.9 percent of pre-tax profits compared to 5.6 percent in 2005.

The introduction of a new Medicare prescription drug benefit in the US in 2006 meant fewer patients requested help through our Patient Assistance Programs. As a result we donated medicines worth £200 million ($370 million) to low-income patients in the US compared to £225 million ($464 million) in 2005. In addition we made £22 million ($41 million) of humanitarian product donations for under-served communities around the world and donated albendazole tablets valued at £16 million ($29 million) for the lymphatic filariasis elimination programme.

Our total community investment also includes £46 million ($86 million) in cash grants and £15 million ($28 million) in management costs.

GSK is a member of the UK’s Percent Club for companies which donate at least 1 percent of their pre-tax profits to charitable causes. In 2006 GSK was listed sixth in the UK’s Guardian Giving List which listed FTSE 100 companies by the percentage of pre-tax profits contributed to charitable causes during 2005. For the fifth year in a row we were the biggest overall giver in the value of our donations.

We belong to the UK’s London Benchmarking Group (LBG) and the Committee Encouraging Corporate Philanthropy (CECP) in the US. We report our donations in line with CECP guidelines which value our medicines at wholesale acquisition cost, as with other pharmaceutical companies. Wholesale acquisition cost is the wholesale list price, not including discounts.

Awards in 2006
During 2006, we received:

• A World Business Award from the International Chamber of Commerce, the United Nations Development Programme and the Prince of Wales International Business Leaders Forum for our lymphatic filariasis elimination programme
• The Excellence in Corporate Philanthropy Award from the US based Committee Encouraging Corporate Philanthropy (CECP)
• The Frost and Sullivan 2006 Global Excellence Award in Malaria Prevention and Treatment
• The Star Business Commitment to Education Award from the Philadelphia Education Fund
• A Global Health Award for Leadership and Scientific Excellence from the New York Academy of Sciences
• A ‘Platinum Ounce’ Award from the Russian pharmaceutical industry for GSK Russia leadership in Multi-Coloured Lives project
INVESTMENT IN GLOBAL PUBLIC HEALTH INITIATIVES

The greatest contribution we can make to healthcare in developing countries is through research into new treatments and vaccines and preferential pricing that makes life-saving medicines more affordable.

However, we can also help to address barriers to access to medicines through our investment in community health programmes.

We donate money, medicines and expertise to support initiatives to improve healthcare and to raise awareness about disease prevention in developing countries.

We focus on five major programmes in the developing world:

- We are a founding member of the Global Alliance to eliminate lymphatic filariasis (LF or elephantiasis)
- Positive Action is our programme to reduce stigma and improve capacity for HIV and AIDS prevention and treatment
- Our African Malaria Partnership is supporting Mobilising for Malaria, an advocacy initiative to generate political commitment and funding to combat malaria, in addition to behaviour change initiatives
- PHASE is our education programme to prevent diarrhoea-related disease through hand washing
- We also donate essential antibiotics and other products in response to humanitarian disasters and to support basic healthcare provision in impoverished communities

These initiatives are all delivered in partnership with non-profit organisations, in 2006 we made the following progress.

Eliminating lymphatic filariasis (LF)

We are donating our medicine albendazole for the global programme to eliminate LF (www.filariasis.org). LF is a disfiguring disease prevalent in tropical countries, which is transmitted by mosquitoes. It can lead to severe swelling of the arms, legs, breasts and genitals and thickening of the skin. LF is one of the world's leading causes of permanent disability with more than one billion people in 80 countries (over 15 percent of the world’s population) at risk of infection.

The global programme led by the World Health Organization (WHO) and the governments of the endemic countries aims to eliminate LF by 2020 by treating the one billion people at risk. We have committed to donate free of charge as many doses of albendazole, our anti-parasitic drug used to prevent transmission of LF, as are needed to do this. We expect this to require billions of tablets. A team of GSK employees helps the Global Alliance in its advocacy, research, community mobilisation and education initiatives.

In 2006, we donated 155 million albendazole treatments (2005: 136 million), worth £16 million ($29 million) valued at wholesale prices, to 34 countries. We have donated almost 600 million treatments since 1998. Two new countries joined the programme in 2006.

In 2006, we also gave £1.0 million ($1.9 million) in grants to support the Global Alliance to Eliminate LF.

Several countries are starting to integrate the LF programme with other neglected tropical disease prevention initiatives, extending the benefits for public health. Zanzibar, for example, is taking an integrated approach by distributing treatments for two other parasitic diseases schistosomiasis (bilharzia) and onchocerciasis (river blindness) alongside LF treatments.

Each country aiming to eliminate LF must treat all at-risk people with two drugs (albendazole and diethylcarbamazine or Mectizan®) once a year for at least five years. So far, Egypt, several Pacific Island countries, Sri Lanka, Zanzibar and Togo have completed five annual mass drug administrations.

Now these countries will monitor their populations and evaluate the impact of the programme on the disease. In 2006, the Bill and Melinda Gates Foundation donated $11.7 million for operational research to help them do this evaluation. An assessment conducted in Egypt showed that LF has been eliminated in most areas of the country.

In 2006, GSK and the Global Alliance received a World Business Award from the International Chamber of Commerce for the LF programme.

(Mectizan is a registered trademark of Merck & Co.)

Future challenges

Sub-Saharan Africa presents a significant challenge as many countries have yet to commence LF elimination programmes due to lack of funding and health infrastructure. Those countries that have started LF programmes need additional resources to enable them to scale up to reach their full at-risk populations. An additional challenge will be the integration of LF programmes with interventions for other neglected tropical diseases which may involve co-administration of albendazole with other medicines.

Positive Action on HIV and AIDS

Our Positive Action programme, set up in 1992, supports the communities most affected by HIV and AIDS. It aims to strengthen the capacity of community organisations providing HIV and AIDS prevention, education and healthcare services. A key area of focus is to reduce stigma and discrimination (a major barrier to controlling HIV and AIDS) and to increase the number of people coming forward for testing and treatment. It recognises that involving people affected by HIV and AIDS is key to controlling the HIV pandemic.

During 2006 we supported 19 Positive Action programmes running in 17 countries.
Activities in 2006 included:

**Asia**

Asia is at tipping point – research suggests there may be a catastrophic HIV and AIDS epidemic in the region if disease prevention and treatment efforts do not improve. Access to HIV therapies and knowledge about how to use them correctly is critical to effective treatment. In partnership with the American Foundation for AIDS Research (amfAR), Positive Action is supporting TREAT Asia, a network of clinics, hospitals, research institutions and patient support organisations helping communities prepare for new treatment programmes being launched in the region. This includes community projects in China, Cambodia, Thailand and Vietnam and the creation of a regional advocacy network.

India has surpassed South Africa as the country with the most HIV infections in the world. Positive Action is supporting Freedom from Hunger’s Reach India project which aims to tackle cultural and social factors that expose women in rural India to HIV. Reach India is using self help groups (an established and respected means for women to access information and support) to educate women about HIV and AIDS. It will reach 500,000 women and their three million family members over three years, and train local organisations in delivering education projects.

**Mexico**

2006 was the second year of our project with the International HIV and AIDS Alliance and Colectivo Sol in Mexico, to reduce stigma and discrimination associated with HIV and AIDS. Thirteen community organisations which help people living with HIV and AIDS (including gay men, sex workers and drug users) have joined the project. Colectivo Sol is helping them to identify the impact of stigma on HIV transmission and access to services, then work to address this through advocacy with the media, local police and health services and government.

**Africa**

We have committed £1 million ($1.9 million) over three years to strengthen and integrate HIV and AIDS treatment into general healthcare clinics in Kenya. This will enable patients to avoid the stigma of visiting a dedicated HIV clinic and will help doctors to provide ongoing services to people diagnosed with HIV. Positive Action is now working with 70 clinics (over a third of the sites currently offering ARV treatment in Kenya) to identify the most successful approaches to improving take-up of ARV treatment.

**Global**

We sponsored the Global Village – the community exhibition and workshop area – at the International AIDS 2006 conference held in Toronto, Canada. This highlighted key issues for affected communities and stimulated dialogue and networking among the global community. Around 20,000 people attended.

We are also supporting a project with the International Council of AIDS Service Organizations (ICASO) to boost community-based advocacy which will scale up national HIV prevention efforts. This is operating in ten countries, with high HIV prevalence – Ukraine, Russia, China, India, Kenya, Nigeria, Botswana, Rwanda, Belize and Jamaica.

For information on our preferential pricing arrangements for HIV and AIDS medicines, see page 22.

**GSK’s African Malaria Partnership**

Our African Malaria Partnership has supported education and behaviour change initiatives in eight African countries, through partnerships with NGOs such as Freedom from Hunger, the African Medical and Research Foundation (AMREF) and Plan International. Since 2003, we have invested £0.9 million ($1.7 million) targeting approximately two million people. We have fostered effective prevention and prompt treatment, particularly among young children and pregnant women, who are the most vulnerable to malaria. Our funding for these initiatives has now come to an end, but our support will have a long-term positive impact in the target communities.

However the scale of the malaria problem requires a significantly bigger response. We have given a £0.9 million ($1.7 million) grant, over three years, to support Mobilising for Malaria, an advocacy initiative to generate greater awareness, political commitment and sustained funding to combat the disease. In 2006, national Coalitions Against Malaria were launched in the UK, Belgium, France, Ethiopia and Cameroon bringing together advocates and activists from the public sector, NGOs, the media, the private sector and the political, academic and scientific communities.

GSK won the Frost and Sullivan 2006 Global Excellence Award in Malaria Prevention and Treatment. The judges noted that GSK ‘has made facing the challenge of malaria a key corporate responsibility issue, using its core business skills and resources, as well as philanthropic community programs, to contribute to global efforts to tackle this disease’.

**Personal Hygiene And Sanitation Education (PHASE)**

Every year more than two million people die of diarrhoea-related disease, mostly children in developing countries. These deaths can often be easily prevented through better hand washing and sanitation.

PHASE is helping to reduce diarrhoea-related disease by encouraging school children to wash their hands. We established PHASE in 1998 and since then we have invested over £1.7 million ($3.1 million) into the programme.

PHASE is run in partnership with AMREF, Plan International and Save the Children – as well as Ministries of Health and Education in each of the countries.
Our approach to donations medicines
GSK follows the World Health Organization Interagency Guidelines for Drug Donations. These state that donations should be:

- made in response to an expressed need
- sent with prior consent
- labelled correctly
- have a minimum one-year shelf life

We do not donate medicines for diseases which require a continuous, assured supply.

We are an active member of the Partnership for Quality Medical Donations (PQMD), an alliance of pharmaceutical companies and charities that encourages best practice in the donation and delivery of medicines.

Multi-Coloured Lives in Russia
We support Multi-Coloured Lives in Russia to help improve the quality of life of disabled children in Russia. The programme brings together the Regional Charity Community Foundation, the Government of Moscow and GSK Russia. Six thousand children aged 9 to 12 years old with limited health capabilities are taking part.

Multi-Coloured Lives is using community-based communications such as TV, magazines, workshops, schools liaison and exhibitions to educate and gradually change individuals’ perceptions of disabled people.

GSK Russia received a ‘Platinum Ounce’ Award for its leadership in Multi-Coloured Lives from the Russian pharmaceutical industry.

The programme has had impressive results. For example, evaluation data from a sample of PHASE schools in Nicaragua over a four year period show that the frequency of hand washing after using the toilet among pupils in participating schools increased five-fold, and the proportion of children reporting diarrhoea in a two week period fell from over 40 percent to just 13 percent.

In Bangladesh, which joined in 2005, PHASE has been implemented in 64 schools reaching 38,000 children so far. It has been integrated into the School Health and Nutrition Programme of Save the Children (our PHASE partner in Bangladesh).

PHASE was extended to Mexico and Tajikistan during 2006 and now operates in eight countries. The total number of children reached by PHASE is now estimated to be 375,000.

Future challenges
We plan to launch PHASE in Kibera, Kenya – Africa’s largest slum. This will be the first time PHASE has operated in an informal settlement, creating a model for improving children’s health in one of the hardest urban communities.

Humanitarian relief
GSK donates essential products, such as antibiotics, to help relief efforts in disaster areas and support basic healthcare provision in impoverished communities.

Donations are made at the request of governments and major charitable organisations and may be manufactured specifically for these partners. This enables charities to hold a range of medicines in stock so they can respond promptly in an emergency. We work in partnership with several relief charities including AmeriCares, Direct Relief, InterChurch Medical Assistance, MAP International and Project HOPE.

Activity during 2006
During 2006 we donated life-saving medicines worth £22 million ($41 million) valued at wholesale prices, to support relief efforts and community healthcare in 99 countries.

Requests for our medicines are sometimes made to help people affected by conflict. This can be controversial and requires careful management. We seek to ensure equitable treatment in our approach, directing our commitment to support health needs and the provision of long term support, and to work with our partners to get essential drugs to doctors, patients, clinics and hospitals.

For example, in 2006 we made four shipments of our medicines to support people displaced by the conflict in Lebanon. This was in response to specific requests by our humanitarian aid partners. We provided supplies of Augmentin, Amoxil, Zinacef, Zantac and Lanoxin valued at over £216,000 ($400,000), with the products being handled by our partners, AmeriCares, IMA and Direct Relief.

Our investment into local programmes
We support a wide range of health and education initiatives in the communities where we operate. Donations are made centrally and by our sites in response to local needs.

Below are just a few examples of the many community partnerships we supported in our major regions in 2006:

Supporting Health Europe
In addition to our long-term support for the ‘Hole in the Wall’ children’s camps in Barretstown, Ireland and L’Envol, France we are giving £300,000 ($555,000) each to programmes in five European countries to improve children’s healthcare.

The other major country programmes are:

- Italy – Reading for Growing, a reading aloud programme for children with neuro-functional disabilities
- Romania – Beacon of Hope, a palliative care programme for children
- Slovakia – Change in Advance, a disease prevention programme for children on urban housing estates
- Spain – Children’s Shelters, providing healthcare for homeless and abandoned children
- Russia – Multi-Coloured Lives. See sidebar.

International
We support major public health initiatives to tackle HIV and AIDS, lymphatic filariasis, malaria and diarrhoea-related diseases in developing countries.

In addition we are funding country-specific programmes, each with a grant of £200,000 ($370,000), over three years.

Our other country programmes in our international region include:

- Brazil – Attituda Positiva, uses drama in schools to educate teenagers about HIV and good reproductive health
- Philippines – Pinoy Health Pass, Family Health and Well Being that provides health education for families on low incomes

UK
In 2006 GSK supported over 100 charitable organisations in the UK. This included over £580,000 ($1.1 million) to support medical research by Asthma UK, the British Retinitis Pigmentosa Society, Deafness Research UK and the Muscular Dystrophy Campaign.
Other donations to support health charities included:

- The Princess Royal Trust for Carers ‘Out of Hospital’ initiative – a donation of £209,000 ($387,000) over 3 years to develop guidelines and support for GPs and hospitals working with carers
- Myasthenia Gravis Association – a donation of £524,000 ($969,000) over three years to provide specialist nurses for people suffering from Myasthenia Gravis, a chronic auto-immune neuromuscular disorder
- The Down’s Syndrome Association ‘Shifting Perspectives’ – £100,000 ($185,000) to support a photographic exhibition showing that people with Down’s Syndrome can lead full, rewarding and semi-independent lives

Our IMPACT Awards recognise community organisations whose work has significantly improved health. Each year we award £275,000 ($509,000) to a range of healthcare charities, selected by a panel of judges. In 2006 Hartlepool Families First was judged the overall winner for its work in bringing health services to deprived areas of Hartlepool in a refitted double-decker bus.

**US**

We are increasing our support for the Zone Health School Obesity programme run by the North Carolina Prevention Partners, following a pilot programme that successfully reached 8,000 children.

The programme provides elementary, middle and high schools in North Carolina and Philadelphia with a learning model to encourage healthy weight through nutrition, education and exercise. A new component of the programme will include distance learning.

The other programmes we support in the US include:

- The Children’s Health Fund’s Referral Management Initiative (RMI) which helps high-risk and homeless children receive the specialist medical care they need
- We recognise excellence in community healthcare in the Philadelphia area through our US GlaxoSmithKline IMPACT Awards. Each year up to ten non-profit organisations receive £22,000 ($40,000) each to help them continue their work

**Foundations**

GSK does not operate a single charitable foundation for its community investment programmes, but has country-based foundations in Canada, Czech Republic, France, Italy, Romania, Spain and North Carolina in the US. Our local foundations support a wide range of charities and healthcare initiatives.

Since 1998 the GSK France Foundation has supported 77 programmes in 13 countries. These focus on people living with HIV and AIDS in developing countries and aim to improve healthcare through prevention, education and training. During 2006, 23 new programmes were implemented in six countries with grants of £469,000 ($868,000).

The GSK Foundation Canada focuses on hospice care, helping terminally ill patients and their families. The Foundation also supports community programmes in Africa, including AIDS Orphans Uganda, a three-year programme building community support for vulnerable children in the Luweero District, working with African Medical Research Foundation (AMREF).

The North Carolina GSK Foundation in the USA is an endowed, self-funding organisation. It supports initiatives in the areas of mathematics, science and health education in North Carolina. In 2006, this Foundation awarded grants totalling £1.4 million ($2.5 million).

**SUPPORTING EDUCATION**

GSK supports education in the UK and US with a particular emphasis on making science more relevant to young people and supporting professional development for science teachers.

Our education programmes help to increase the pool of potential future employees by encouraging young people to pursue science careers.

**Science education in the UK**

**Puppets: Talking Science** Engaging Science is a new initiative launched in 2006 and sponsored by GSK, which uses puppets to increase children’s understanding of science.

Research by the Nuffield Foundation found that when teachers used puppets in science lessons the children treated them as if they were real characters. The puppets engaged the pupils in helping them to solve science problems. As a result the children talked more about science which increased their understanding of the subject. This was particularly noticeable among low achieving children and those who did not normally speak in lessons. Typical remarks included ‘It’s like talking to a group of friends not a teacher’ and ‘I understand much better with the puppets’.

We have invested over £480,000 ($888,000) to train 9,000 teachers in 4,500 UK primary schools to use the puppets effectively in science lessons. Schools will also receive a book of science based stories, an animated CD and two hand held puppets. In each story the two puppets are faced with a problem with a science theme, and ask the children to help them solve it.

**Vietnam midwives**

Since 2004, we have been supporting a unique training programme based in Tu Du Hospital, Ho Chi Minh City, Vietnam. The project is training 500 birth attendants to provide maternal healthcare services in rural villages. The project aims to reduce childbirth complications and decrease newborn fatality from the unacceptably high level of 6 percent.

Supported by Tu Du medical and nursing staff, and housed within a residential training centre built by GSK, the trainees spend four months gaining practical knowledge of maternal and child healthcare. Over 350 midwives have now graduated with a government-recognised qualification. Each midwife has been equipped with a medical pack and some are provided with a motor scooter to assist access to remote areas.

**Crisis Open Christmas**

Crisis Open Christmas offers much needed support for 1,500 homeless people across London during the festive season. In 2006, we supported Crisis in the following ways:

- Donations of food and clothing from GSK employees
- A donation to the Christmas card challenge campaign, instead of sending corporate Christmas cards
- A donation of £24,000 to cover the operating costs of their mobile medical service that visits the Crisis centres
In 2006 we announced funding for the CREST investigators education project. This programme will be run in partnership with the British Association for the Advancement of Science to provide science activities and awards for after school clubs in primary schools. By 2010, we aim for 5,000 schools and 55,000 children to be taking part.

Our support for INSPIRE (INnovative Scheme for Post-doctoral researchers In Research and Education), enables post-doctoral researchers to spend half their time in specialist science schools and to gain a Post-Graduate Certificate in Education (PGCE).

**Education in the US**

We are a founding partner of the Institute for a Competitive Workforce, a business coalition run by the US Chamber of Commerce to improve educational standards through partnerships between business and education providers.

We are working with the National Board of Professional Teaching Standards (NBPTS) by providing scholarships and an endowment of £541,000 ($1.0 million) to increase the number of science teachers who are National Board Certified. So far we have focussed on North Carolina and Philadelphia but will now be expanded to all 50 states.

We support a range of local education initiatives in the US to help engage young students in science.

Examples include:

- **Science in the Summer**, a free programme in Philadelphia, giving children the chance to participate in hands-on experiments and science courses
- We have been a major sponsor of the University of North Carolina’s travelling science laboratory, Destiny, since its inception in 1999. Destiny serves approximately 100 under-served secondary schools and reaches 4,000 students per year

**EMPLOYEE INVOLVEMENT**

We encourage employees to contribute to their local communities as volunteers. This benefits the community and our employees who gain new experiences and skills.

Hundreds of employees give their time to good causes through our Days of Caring in the US, and to support school science education through our UK Science and Engineering Ambassador Scheme and US Partnership for Educational Discovery.

In the UK and US we make cash donations to charities where employees have done voluntary work. In 2006:

- The GSK Investment in Volunteer Excellence (GIVE) programme gave £183,000 ($339,000) to 365 charities in the US where employees or their partners volunteered at least 50 hours
- Our Making a Difference programme provided grants of £225,000 ($416,000) to over 380 charities where employees volunteered

In many countries we encourage employees to donate money to charity by matching the money they give or by providing tax-efficient ways for them to make a donation, in accordance with local taxation guidelines.

In 2006 in the US, GSK matched donations by employees and retirees at a value of £2.7 million ($5 million). In addition, GSK gave £703,000 ($1.3 million) to match donations by GSK employees through the annual GSK and United Way campaign.
## Data summary

### Access to medicines

<table>
<thead>
<tr>
<th>Year</th>
<th>Number of countries supplied with preferentially priced ARVs</th>
<th>Number of preferentially priced Combivir and Epivir tablets shipped (millions)</th>
<th>Number of generic ARVs supplied by GSK licencees (millions)</th>
<th>GSK Combivir not-for-profit price ($ per day)</th>
<th>Voluntary licences granted to generic manufacturers for GSK ARVs (cumulative total)</th>
<th>Value of products donated through GSK Patient Assistance Program in the US (£ millions)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2002</td>
<td>50</td>
<td>7.9</td>
<td>--</td>
<td>1.7</td>
<td>6</td>
<td>112</td>
</tr>
<tr>
<td>2003</td>
<td>56</td>
<td>15.9</td>
<td>--</td>
<td>0.65</td>
<td>7</td>
<td>125</td>
</tr>
<tr>
<td>2004</td>
<td>57</td>
<td>67.1</td>
<td>--</td>
<td>0.65</td>
<td>6</td>
<td>203</td>
</tr>
<tr>
<td>2005</td>
<td>56</td>
<td>126.3</td>
<td>--</td>
<td>0.65</td>
<td>7</td>
<td>255</td>
</tr>
<tr>
<td>2006</td>
<td>51</td>
<td>86.3</td>
<td>--</td>
<td>0.65</td>
<td>8</td>
<td>200</td>
</tr>
</tbody>
</table>

1. Includes ARVs sold at not-for-profit and discounted prices. We are unable to collect data for the number of patients treated.

### Research and development

<table>
<thead>
<tr>
<th>Year</th>
<th>Expenditure on R&amp;D (£ billions)</th>
<th>Number of trials published on the GSK Clinical Trial Register (cumulative total)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2002</td>
<td>2.9</td>
<td>--</td>
</tr>
<tr>
<td>2003</td>
<td>2.8</td>
<td>143</td>
</tr>
<tr>
<td>2004</td>
<td>2.9</td>
<td>2,125</td>
</tr>
<tr>
<td>2005</td>
<td>3.1</td>
<td>2,760</td>
</tr>
<tr>
<td>2006</td>
<td>3.5</td>
<td></td>
</tr>
</tbody>
</table>

### Ethical conduct

<table>
<thead>
<tr>
<th>Year</th>
<th>Number of managers completing certification to the GSK Code of Conduct</th>
<th>Number of contacts through our ethics compliance channels</th>
</tr>
</thead>
<tbody>
<tr>
<td>2002</td>
<td>700</td>
<td>2,580</td>
</tr>
<tr>
<td>2003</td>
<td>9,000</td>
<td>3,644</td>
</tr>
<tr>
<td>2004</td>
<td>9,600</td>
<td>5,363</td>
</tr>
<tr>
<td>2005</td>
<td>&gt;12,000</td>
<td></td>
</tr>
<tr>
<td>2006</td>
<td>&gt;12,000</td>
<td></td>
</tr>
</tbody>
</table>

### Employment

<table>
<thead>
<tr>
<th>Year</th>
<th>Women in management grades (%)</th>
<th>Ethnic diversity – minorities (US, %)</th>
<th>Ethnic diversity – ethnic minorities (UK, %)</th>
<th>Lost time injury and illness rate (cases per 100,000 hours worked)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2002</td>
<td>32</td>
<td>19</td>
<td>--</td>
<td>0.34</td>
</tr>
<tr>
<td>2003</td>
<td>34</td>
<td>19.5</td>
<td>--</td>
<td>0.30</td>
</tr>
<tr>
<td>2004</td>
<td>35</td>
<td>19.5</td>
<td>--</td>
<td>0.30</td>
</tr>
<tr>
<td>2005</td>
<td>35</td>
<td>19.6</td>
<td>--</td>
<td>0.30</td>
</tr>
<tr>
<td>2006</td>
<td>36</td>
<td>19.8</td>
<td>--</td>
<td>0.33</td>
</tr>
</tbody>
</table>

### Environment

<table>
<thead>
<tr>
<th>Year</th>
<th>Number of contract manufacturers audited</th>
<th>Energy consumption (million gigajoules)</th>
<th>Water consumption (million cubic metres)</th>
<th>Ozone depletion potential from production (tonnes CFC-11 equivalent)</th>
<th>Ozone depletion potential from refrigeration and other ancillary uses</th>
<th>Volatile organic compound emissions (thousand tonnes)</th>
<th>Global warming potential from energy sources (thousand tonnes CO2 equivalent)</th>
<th>Hazardous waste disposed (thousand tonnes)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2002</td>
<td>16</td>
<td>20</td>
<td>24</td>
<td>1,500</td>
<td>72</td>
<td>6</td>
<td>1,734</td>
<td>58</td>
</tr>
<tr>
<td>2003</td>
<td>28</td>
<td>20</td>
<td>23</td>
<td>782</td>
<td>21</td>
<td>6</td>
<td>1,750</td>
<td>56</td>
</tr>
<tr>
<td>2004</td>
<td>35</td>
<td>19</td>
<td>21</td>
<td>464</td>
<td>21</td>
<td>5</td>
<td>1,666</td>
<td>56</td>
</tr>
<tr>
<td>2005</td>
<td>41</td>
<td>19</td>
<td>21</td>
<td>273</td>
<td>3</td>
<td>5</td>
<td>1,693</td>
<td>69</td>
</tr>
<tr>
<td>2006</td>
<td>36</td>
<td>19</td>
<td>21</td>
<td>186</td>
<td>3</td>
<td>4</td>
<td>1,666</td>
<td>63</td>
</tr>
</tbody>
</table>

### Community investment

<table>
<thead>
<tr>
<th>Year</th>
<th>Total community investment expenditure (£ millions)</th>
<th>Value of humanitarian product donations, including albendazole (£ millions)</th>
<th>Number of albendazole tablets donated for prevention of lymphatic filariasis (millions)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2002</td>
<td>239</td>
<td>24</td>
<td>66</td>
</tr>
<tr>
<td>2003</td>
<td>338</td>
<td>116</td>
<td>94</td>
</tr>
<tr>
<td>2004</td>
<td>328</td>
<td>57</td>
<td>67</td>
</tr>
<tr>
<td>2005</td>
<td>380</td>
<td>41</td>
<td>136</td>
</tr>
<tr>
<td>2006</td>
<td>302</td>
<td>38</td>
<td>155</td>
</tr>
</tbody>
</table>

1. Includes ARVs sold at not-for-profit and discounted prices. We are unable to collect data for the number of patients treated.

2. Includes delivery costs. The Médecins Sans Frontières pricing report lists the average cost of generic equivalents.

3. This covers 91% of animals used in GSK facilities. In 2005 we had 14 animal research laboratories. In 2006 we closed a laboratory in Japan, aquired laboratories in Croatia and Canada, and established contracts to use laboratories in Singapore and the US, making a current total of 17 GSK laboratories where we use animals.

4. 98% of trials completed since the merger which created GSK.

5. Includes contacts with line managers, compliance officers, our confidential Integrity Helplines or offsite post office box (in the US).

6. 2002 to 2004 data do not include inhalers made in Asia.

7. We have changed the way we calculate these data and the previous years’ data reflect this change. See full environmental report for details.

---

**Trademarks**

Brand names appearing in italics throughout this publication are trademarks either owned by and/or licensed to GSK or associated companies.